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Summary  
The Darlington Retrospective Outpatient Study (DROPSY) was carried out at the 
Darlington Memorial Hospital Darlington. From Jan 2002 to Dec 2007, 1041 patients 
were seen in the heart failure (HF) clinic. Of these 270 (26%) were diagnosed as 
having left ventricular systolic dysfunction (LVSD). Of the 771 patients who did not 
have systolic dysfunction, we identified 243 patients who fulfilled the study criteria for 
heart failure with preserved ejection fraction (HFpEF). The remaining 528 patients 
formed the non heart failure (Other) group. 
Patients with HFpEF were older and more likely to have hypertension and diabetes 
than the other two groups. The LVSD group had more men plus ischemic heart 
disease patients while the third group of non HF also had more females and a high 
number with COPD.  
Over the mean follow up of 7 years, the number of admissions to hospital per patient 
was similar in both the LVSD and HFpEF groups, but HFpEF patients had a 
significantly longer length of stay. In the HFpEF group, the use of beta blockers, ACE 
inhibitors, and a lower median resting HR of < 78 / min predicted better survival. All 
cause mortality was high in both LVSD and HFpEF groups, with strikingly different 
cause of death. Patients with LVSD had more cardiovascular deaths whereas HFpEF 
patients were more likely to die of non-cardiovascular causes. Patients in the third 
group diagnosed as not having HF (Other group) also had high five year mortality.  
Conclusion 
Patients with LVSD and HFpEF have high mortality but different causes of death. The 
use of beta blockers, ACE inhibitors, and a lower resting heart rate in the HFpEF 
group was associated with better survival. Patients who were reassured as not having 
HF do badly as well. 
3 
 
Declaration 
The research contained in this thesis was carried out by the author whilst a 
postgraduate student in the School of Medicine and Health at Durham University. 
None of the work in this thesis has been submitted in candidature for any other 
degree. 
Statement of copyright 
The copyright of the thesis remains with the author. No quotation from it should be 
published without the prior consent and information derived from it should be 
acknowledged. 
 
 
Dr Rajender Singh 
 
 
 
 
 
 
 
 
4 
 
Acknowledgement  
This thesis work would not have been possible without the patience, guidance, 
enthusiastic encouragement and useful critiques by my supervisors Professor J.J 
Murphy and Professor A.P.S Hungin. They demanded a high standard and a work 
ethic that elevated my abilities; gave me the academic freedom to pursue new ideas 
and provided valuable support and guidance to make this research possible. 
I am also much obliged to Professor D.W Wilson, who has guided me through the 
maze of statistical formulas and SPSS software used for analysing reams of data.  
I wish to thank Prof A Fuat, for his valuable and constructive suggestions during the 
planning and development of this research, and help with data collection from the one 
stop heart failure clinic.  
I am deeply grateful to Gill Brennan, for her support with daily issues of data collection 
and her valuable help for accessing clinical records and performing the double data 
entry.   
Finally, I would like to thank my parents (Dalip singh, Satya Devi) and family (Shweta, 
Pari, Aayush) for their love and affection. They have always been there to cheer me, 
encourage me with enthusiasm and words of wisdom. 
 
 
 
 
 
5 
 
Contents 
SUMMARY .................................................................................................................................. 2 
DECLARATION .......................................................................................................................... 3 
ACKNOWLEDGEMENT ............................................................................................................. 4 
ABBREVIATIONS USED ......................................................................................................... 11 
INTRODUCTION ....................................................................................................................... 13 
CHAPTER 1 .............................................................................................................................. 16 
THE DEFINITION OF HEART FAILURE.................................................................................. 17 
1.1 Role of echocardiography ........................................................................................... 18 
1.2 ESC definition of heart failure ..................................................................................... 19 
1.3 Grading of severity of HF ............................................................................................ 19 
CHAPTER 2 .............................................................................................................................. 21 
LITERATURE REVIEW ............................................................................................................ 22 
HISTORICAL PERSPECTIVE ....................................................................................................... 22 
2.1 TREATMENT ...................................................................................................................... 24 
2.1.1 Dawn of the diuretics ................................................................................................ 25 
2.1.2 Emergence of angiotensin converting enzyme inhibitors (ACEi) ............................. 28 
2.1.3 Beta-blockers ........................................................................................................... 29 
2.2 EVIDENCE BASED TREATMENT FOR LVSD .......................................................................... 30 
2.2.1 Angiotensin converting enzyme inhibitors ................................................................ 30 
2.2.2 Angiotensin converting enzymes inhibitors post Myocardial Infarction.................... 31 
2.2.3 Angiotensin – II receptor blockers ............................................................................ 33 
2.2.4 Evidence for beta blockers in heart failure ............................................................... 37 
2.2.5 Beta - blockers in advanced heart failure ................................................................. 40 
2.2.6 Beta-Blockers in post Myocardial Infarction LV dysfunction .................................... 41 
2.2.7 Aldosterone Antagonist in heart failure .................................................................... 42 
2.2.8 Digoxin in heart failure ............................................................................................. 45 
2.2.9 Role of Ivabradine .................................................................................................... 45 
2.2.10 Device therapy in heart failure ............................................................................... 46 
2.2.11 Current treatment guidelines for LV systolic dysfunction ....................................... 50 
2.3 LITERATURE REVIEW OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) .... 51 
2.4 PROGNOSIS IN HEART FAILURE ........................................................................................... 53 
2.4.1 Prognosis in LVSD ................................................................................................... 54 
2.4.2 Prognosis in HFpEF ................................................................................................. 55 
CHAPTER 3 .............................................................................................................................. 57 
HEART FAILURE: NATIONALLY AND IN THE NORTH EAST ............................................. 58 
3.1 The North East region ................................................................................................. 58 
3.2 The burden of coronary heart disease: ....................................................................... 58 
3.3 Heart failure ................................................................................................................. 60 
3.4 Access to Health care ................................................................................................. 62 
CHAPTER 4 .............................................................................................................................. 63 
MODELS FOR PROVIDING HEART FAILURE SERVICE ...................................................... 64 
4.1 OPEN ACCESS ECHOCARDIOGRAPHY .................................................................................. 64 
4.2 VARIATION AMONG HF CLINICS .......................................................................................... 67 
4.2.1 Nurse led intervention programmes ......................................................................... 67 
6 
 
4.3 SPECIALIST HEART FAILURE CLINICS ................................................................................. 69 
4.4 HISTORY OF HEART FAILURE CLINIC IN DARLINGTON .......................................................... 72 
4.4.1 Rational for one stop diagnostic heart failure clinic ................................................. 72 
4.4.2 Aims of the heart failure clinic service: ..................................................................... 74 
4.5 CLINIC STRUCTURE ............................................................................................................ 74 
4.5.1 Referral criteria ......................................................................................................... 74 
4.6 STAFFING OF THE CLINIC .................................................................................................... 75 
4.6.1 Role of the GP specialist in cardiology .................................................................... 75 
4.6.2 Role of the specialist heart failure and auxiliary nurse ............................................ 75 
4.6.3 Role of the consultant cardiologist ........................................................................... 76 
4.6.4 Heart failure review clinic ......................................................................................... 76 
CHAPTER 5 .............................................................................................................................. 77 
METHODOLOGY ...................................................................................................................... 78 
5.1 Introduction.................................................................................................................. 78 
5.2 Development of the study protocol ............................................................................. 79 
5.2.1 Phase 1 (Hospital Phase) ........................................................................................ 80 
5.2.2 Phase 2 (General practice phase) ........................................................................... 81 
5.2.3 Phase 3 (Medical Research Information Service phase) ......................................... 81 
5.3 Ethics Committee Approval ......................................................................................... 82 
5.4 The sample size calculation ........................................................................................ 84 
5.5 The database .............................................................................................................. 85 
5.6 Transfer of data to SPSS ............................................................................................ 86 
5.7 Case records ............................................................................................................... 86 
5.8 Heart failure with preserved ejection fraction (HFpEF) ............................................... 87 
5.9 The third group “Others” .............................................................................................. 88 
5.10 Cause of death in Heart Failure Patients .................................................................. 88 
5.11 METHODS ........................................................................................................................ 90 
5.11.1 The Cox proportional hazard model ....................................................................... 90 
5.11.2 Paired samples T test ............................................................................................ 92 
5.11.3 Median follow up time ............................................................................................ 92 
CHAPTER 6 .............................................................................................................................. 93 
DIASTOLIC HEART FAILURE: A WORKING DEFINITION ................................................... 94 
6.1 What is Diastolic Heart Failure? .................................................................................. 94 
6.2 Background ................................................................................................................. 94 
6.3 Definition of Diastolic heart failure: Current perspective ............................................. 95 
6.4 Developing a working definition for HFpEF to be adopted in DROPSY ..................... 97 
6.5 Evidence of ventricular diastolic dysfunction .............................................................. 98 
6.6 Early (E) / Atrial (A) filling ratio of the Left ventricle .................................................... 98 
6.7 Atrial fibrillation ............................................................................................................ 99 
6.8 HFpEF- working definition adapted in DROPSY ....................................................... 101 
RESULTS ................................................................................................................................ 103 
Demographics ................................................................................................................. 103 
CHAPTER 7 ............................................................................................................................ 105 
HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) - RESULTS ....... 106 
7.1 DESCRIPTIVE ANALYSIS OF FIRST CLINIC REVIEW ............................................................... 106 
7.1.1 Demographics and past medical history ................................................................ 106 
7.1.2 Smokers ................................................................................................................. 107 
7.1.3 Presenting symptoms ............................................................................................. 107 
7.1.4 NYHA class ............................................................................................................ 107 
7.1.5 Clinical examination findings .................................................................................. 108 
7 
 
7.1.6 ECG findings .......................................................................................................... 109 
7.2 ECHOCARDIOGRAPHIC FINDINGS ...................................................................................... 109 
7.2.1 E/A ratio and Left atrial diameter............................................................................ 109 
7.2.2 Left ventricular hypertrophy .................................................................................... 110 
7.2.3 Valvular heart disease ............................................................................................ 110 
7.3 BLOOD TESTS.................................................................................................................. 110 
7.4 MEDICATIONS ON PRESENTATION ..................................................................................... 111 
7.4.1 Diuretics ................................................................................................................. 111 
7.4.2 ACE inhibitors / ARBs ............................................................................................ 111 
7.4.3 Beta blockers.......................................................................................................... 112 
7.4.4 Other medications .................................................................................................. 113 
7.5 MEDICATIONS CHANGED IN THE CLINIC.............................................................................. 113 
7.6 CAUSE OF SHORTNESS OF BREATH (ASCRIBED IN THE HF CLINIC) ...................................... 113 
7.7 FOLLOW UP ..................................................................................................................... 114 
7.7.1 Other procedures performed .................................................................................. 115 
7.8 FIRST ADMISSION TO HOSPITAL ........................................................................................ 115 
7.8.1 Presenting complaints on admission ..................................................................... 116 
7.8.2 Patient characteristics on admission ...................................................................... 116 
7.8.3 Clinical examination findings on admission ........................................................... 118 
7.8.4 ECG and Chest X-ray on admission ...................................................................... 118 
7.8.5 Blood tests.............................................................................................................. 119 
7.9 MEDICATIONS ON ADMISSION ........................................................................................... 121 
7.9.1 Medications changed in hospital ............................................................................ 121 
7.10 FREQUENCY OF ADMISSION TO HOSPITAL ........................................................................ 121 
7.11 OTHER CO-MORBIDITIES DEVELOPED .............................................................................. 122 
7.12 EXPOSURE TO MEDICATIONS .......................................................................................... 123 
7.12.1 Survival analysis for total drug duration ............................................................... 124 
7.12.2 Univariate analysis for total drug duration ............................................................ 124 
7.12.3 Multivariate analysis for total drug duration ......................................................... 124 
7.13 REPEAT ECHOCARDIOGRAM .......................................................................................... 125 
7.14 MORTALITY AND PLACE OF DEATH .................................................................................. 126 
7.15 ALL CAUSE MORTALITY .................................................................................................. 126 
7.15.1 Univariate analysis ............................................................................................... 126 
7.15.2 Multivariate analysis ............................................................................................. 127 
7.15.3 Cox forward conditional regression analysis........................................................ 128 
7.16 ANALYSIS OF SURVIVAL FUNCTION USING STRATIFICATION .............................................. 130 
7.16.1 Hypertension ........................................................................................................ 130 
7.16.2 NYHA class .......................................................................................................... 131 
7.16.3 Admission to the hospital ..................................................................................... 131 
7.17 AGE BAND ANALYSIS ..................................................................................................... 132 
7.17.1 Multivariate and regression analysis using age band .......................................... 134 
7.17.2 Stratification with age band .................................................................................. 134 
7.17.3 Ageband and gender interaction .......................................................................... 135 
7.18 CAUSE OF DEATH .......................................................................................................... 136 
7.19 PROGNOSTIC FACTORS FOR CARDIOVASCULAR DEATHS .................................................. 137 
7.19.1 Univariate and multivariate risk factor analysis .................................................... 137 
8 
 
7.19.2 Forward conditional regression analysis .............................................................. 139 
7.20 STRATIFICATION FOR CARDIOVASCULAR RISK FACTORS .................................................. 139 
7.20.1 Gender ................................................................................................................. 139 
7.20.2 Diabetes ............................................................................................................... 140 
7.20.3 Atrial fibrillation ..................................................................................................... 140 
7.21 CONCLUSIONS AND DISCUSSION ..................................................................................... 141 
7.21.1 Descriptive analysis ............................................................................................. 141 
7.21.2 Admission data analysis ....................................................................................... 142 
7.21.3 Drug data analysis ............................................................................................... 143 
7.21.4 All cause mortality data analysis .......................................................................... 144 
7.21.5 Cardiovascular mortality data analysis ................................................................ 144 
CHAPTER 8 ............................................................................................................................ 146 
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD) - RESULTS ............................. 147 
8.1 DEMOGRAPHICS .............................................................................................................. 147 
8.1.1 Smoking history ...................................................................................................... 147 
8.2 DESCRIPTIVE ANALYSIS OF CLINICAL FEATURES ................................................................ 147 
8.2.1 Referral symptoms ................................................................................................. 147 
8.2.2 NYHA class ............................................................................................................ 148 
8.2.3 Clinical examination ............................................................................................... 148 
8.2.4 Blood pressure and heart rate................................................................................ 149 
8.2.5 ECG findings .......................................................................................................... 149 
8.2.6 Chest X- ray ........................................................................................................... 150 
8.2.7 Echocardiography .................................................................................................. 151 
8.2.8 Blood tests in the clinic ........................................................................................... 152 
8.2.9 Medications ............................................................................................................ 152 
8.2.10 Other medications in the clinic ............................................................................. 153 
8.2.11 Changes made to medication .............................................................................. 153 
8.2.12 Evidence based medical therapy prescribed in the clinic .................................... 153 
8.2.13 Cause of LVSD .................................................................................................... 154 
8.2.14 Follow up in the clinic ........................................................................................... 154 
8.3 ADMISSION TO HOSPITAL ................................................................................................. 155 
8.3.1 Time to first admission ........................................................................................... 155 
8.3.2 Reason for admission ............................................................................................ 155 
8.3.3 Systolic and diastolic blood pressure ..................................................................... 156 
8.3.4 Comparison of clinic and admission blood pressures ............................................ 157 
8.3.5 Clinical characteristics ............................................................................................ 158 
8.3.6 Blood tests on admission ....................................................................................... 158 
8.3.7 Comparison of the clinic and admission blood tests .............................................. 159 
8.3.8 Other investigations on admission to hospital........................................................ 161 
8.3.9 Medications on admission ...................................................................................... 161 
8.3.10 Change in medication doses ................................................................................ 162 
8.3.11 Length of stay in hospital ..................................................................................... 162 
8.3.12 Co-morbidities developed during follow-up .......................................................... 163 
8.4 OPTIMAL MEDICAL THERAPY (OMT) AND DURATION OF USE .............................................. 163 
8.5 Univariate analysis of duration of drug use ............................................................... 164 
8.6 Multivariate analysis of duration of drug use ............................................................. 164 
8.7 SURVIVAL ANALYSIS FOR ALL CAUSE MORTALITY .............................................................. 165 
8.7.1 Place of death ........................................................................................................ 165 
8.7.2 Univariate and multivariate survival analysis ......................................................... 165 
8.7.3 Forward conditional regression analysis ................................................................ 166 
8.8 ALL CAUSE MORTALITY STRATIFICATION FOR MODEL CHECKING ........................................ 166 
9 
 
8.8.1 NYHA class ............................................................................................................ 167 
8.8.2 Smoking status ....................................................................................................... 167 
8.8.3 Admission to hospital ............................................................................................. 168 
8.9 AGE BAND AND GENDER ANALYSIS ................................................................................... 169 
8.10 CAUSE OF DEATH .......................................................................................................... 170 
8.11 SURVIVAL ANALYSIS FOR DEATH FROM CARDIOVASCULAR CAUSE .................................... 171 
8.11.1 Multivariate survival analysis................................................................................ 172 
8.11.2 Forward conditional logistic regression ................................................................ 173 
8.11.3 Stratification analysis ........................................................................................... 174 
8.12 CONCLUSION AND DISCUSSION ....................................................................................... 175 
8.12.1 Descriptive analysis ............................................................................................. 175 
8.12.2 Medication usage ................................................................................................. 177 
8.12.3 Survival analysis for all cause mortality ............................................................... 178 
8.12.4 Survival analysis for cardiovascular mortality ...................................................... 179 
CHAPTER 9 ............................................................................................................................ 180 
THE “OTHER” (OT) GROUP ................................................................................................. 181 
9.1 Demographics and past medical history ................................................................... 182 
9.2 Smoking status .......................................................................................................... 182 
9.3 Echocardiographic findings ....................................................................................... 182 
9.4 ECG and Chest x-ray findings................................................................................... 183 
9.5 Medications on presentation ..................................................................................... 183 
9.6 Cause of shortness of breath .................................................................................... 183 
9.7 MORTALITY ..................................................................................................................... 185 
9.7.1 Cause of death ....................................................................................................... 185 
9.7.2 All cause mortality survival analysis ....................................................................... 186 
9.8 DISCUSSION AND CONCLUSION ......................................................................................... 188 
CHAPTER 10 .......................................................................................................................... 190 
COMPARATIVE ANALYSIS OF LVSD AND HFPEF PATIENTS ......................................... 191 
10.1 REFERRAL SYMPTOMS ................................................................................................... 191 
10.1.1 New York Heart Association (NYHA) class .......................................................... 192 
10.1.2 Blood pressure and heart rate ............................................................................. 192 
10.1.3 Jugular Venous Pressure ..................................................................................... 193 
10.1.4 Clinical Findings ................................................................................................... 193 
10.1.5 Chest X-ray findings ............................................................................................. 194 
10.1.6 Echocardiogram findings ...................................................................................... 194 
10.1.7 ECG findings ........................................................................................................ 195 
10.2 BLOOD TEST RESULTS ................................................................................................... 196 
10.3 MEDICATIONS ON PRESENTATION ................................................................................... 196 
10.3.1 Medications started in the clinic ........................................................................... 197 
10.3.2 Follow up in HF titration clinic .............................................................................. 197 
10.4 ADMISSION .................................................................................................................... 197 
10.4.1 Time to admission ................................................................................................ 198 
10.4.2 Reasons for first admission .................................................................................. 200 
10.4.3 Blood pressure and heart rate on admission ....................................................... 200 
10.4.4 Clinical findings on admission .............................................................................. 201 
10.4.5 Blood tests on admission ..................................................................................... 201 
10.4.6 NYHA class on admission .................................................................................... 202 
10.4.7 ECG on admission ............................................................................................... 202 
10.4.8 Medications on admission .................................................................................... 203 
10 
 
10.5 FIRST ADMISSION ........................................................................................................... 203 
10.5.1 Total number of admissions ................................................................................. 203 
10.5.2 Total days as inpatient ......................................................................................... 204 
10.6 EXPOSURE TO MEDICATIONS .......................................................................................... 204 
10.6.1 ACE inhibitors / ARBs .......................................................................................... 205 
10.6.2 Beta blockers ....................................................................................................... 206 
10.6.3 Aldosterone antagonist ........................................................................................ 207 
10.6.4 Digoxin ................................................................................................................. 208 
10.7 ALL CAUSE MORTALITY .................................................................................................. 209 
10.8 CARDIOVASCULAR MORTALITY ....................................................................................... 210 
10.9 OTHER CO MORBIDITIES DEVELOPED .............................................................................. 211 
10.10 PLACE OF DEATH ......................................................................................................... 212 
10.11 CONCLUSIONS AND DISCUSSION ................................................................................... 213 
10.11.1 HF Clinic review analysis ................................................................................... 213 
10.11.2 Admission to hospital data analysis ................................................................... 214 
10.11.3 Mortality .............................................................................................................. 215 
CHAPTER 11 .......................................................................................................................... 216 
HEART RATE AND SURVIVAL ............................................................................................. 217 
11.1 LVSD group ............................................................................................................. 217 
11.2 HFpEF group ........................................................................................................... 218 
11.3 Heart rate and beta blockers ................................................................................... 219 
11.4 Conclusion and Discussion ..................................................................................... 221 
CHAPTER 12 .......................................................................................................................... 223 
DISCUSSION AND CONCLUSIONS ..................................................................................... 224 
12.1 MAIN FINDINGS OF THE STUDY ........................................................................................ 225 
12.2 LIMITATIONS OF THE STUDY ............................................................................................ 232 
12.3 IMPLICATIONS OF THE RESEARCH ................................................................................... 233 
12.4 REFLECTIONS ................................................................................................................ 233 
12.5 FUTURE WORK .............................................................................................................. 234 
12.6 CONCLUSIONS ............................................................................................................... 234 
REFERENCES ........................................................................................................................ 236 
APPENDIX 1 ........................................................................................................................... 255 
APPENDIX 2 ........................................................................................................................... 258 
APPENDIX 3 ........................................................................................................................... 260 
APPENDIX 4 ........................................................................................................................... 263 
 
11 
 
Abbreviations used 
AAA = Abdominal aortic aneurysm  
ACC = American College of Cardiology 
ACEi = Angiotensin converting enzyme inhibitors 
AHA = American Heart Association 
ARB = Angiotensin receptor blockers 
AR = Aortic regurgitation 
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AT 1= Angiotensin receptor 1 
AT 2 = Angiotensin receptor 2 
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12 
 
IHD = Ischemic heart disease 
JVP = Jugular venous pressure  
IVSDs = Interventricular septal diameter in systole 
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Introduction 
Heart failure (HF) is a common condition responsible for significant morbidity and 
mortality, placing a substantial burden on the health care system (1). Even for those 
with mild heart failure five-year mortality approaches 50%, which is worse than for 
most forms of cancer (2, 3). In terms of morbidity, heart failure impairs quality of life 
more than any other common chronic condition (including hypertension, diabetes, 
arthritis, chronic lung disease and angina) (4, 5).  
The preceding three decades have seen an improved appreciation of the 
pathophysiology of HF and its management. Whereas in the past diuretics and 
digoxin were the principal treatment, the outcome of several randomised controlled 
clinical trials have brought about a paradigm shift, changing the focal point to the use 
of angiotensin converting enzyme inhibitors (ACEi), beta blockers,  aldosterone 
antagonist, and angiotensin receptor blockers (ARBs) as the indispensable first line 
treatment for the management of HF patients. The role of diuretics and digoxin has 
become supportive. 
The identification of HF, which until the 1980s had relied to a great deal on the clinical 
expertise of the physician, saw wider utilization of echocardiography for verifying the 
diagnosis. Additionally clinical guidelines were published by the European Society of 
Cardiology (ESC), the American Heart Association (AHA), and the American College 
of Cardiology (ACC), streamlining the diagnosis and management of HF. 
Enhanced appreciation of the pathophysiology of HF has also led to the 
acknowledgement that there may be two distinct types of HF. Firstly, where there are 
symptoms (breathlessness and / or fatigue) and signs of fluid retention, with objective 
evidence of left ventricular systolic dysfunction (LVSD), principally by 
echocardiography.  Secondly, where the symptoms and clinical features of HF are 
14 
 
present but echocardiography shows a normal or preserved systolic function, so-
called diastolic HF or HF with preserved systolic function, or HF with preserved 
ejection fraction (HFpEF). 
Despite the recent advances, diagnosis and management of HF remains a problem 
with over diagnosis and under treatment (6), such that patients do not gain the full 
benefits of clinical research. 
This could be due to a number of reasons. HF is mainly diagnosed and managed by 
the general practitioners (GPs) who have traditionally had limited access to 
echocardiography. Other factors include diagnostic uncertainty, amplified by limited 
access to diagnostic services, lack of awareness of research evidence and 
guidelines, concerns about adverse effects, perceived problems with ACE inhibitors, 
beta-blockers, and poor communication between primary and secondary care (7, 8). 
There is also uncertainty as to how evidence based management can be best 
delivered to patients. Should it occur in primary care where GPs have open access to 
echocardiography, the so called “open-access model” (9, 10)?  Alternatively, is it best 
delivered by a specialist HF clinic in secondary care (11)?  
In 2002, a weekly one-stop diagnostic HF clinic was established in Darlington 
Memorial Hospital. This was led by a GP with a special interest in cardiology and a 
HF nurse. This clinic runs in parallel to a consultant cardiologist clinic. Patients are 
referred from primary care. All have clinical assessment, blood tests, chest- X ray, 
electrocardiogram (ECG), and trans-thoracic echocardiography (TTE).  Other 
investigations are performed as required. The left ventricular systolic function is 
assessed by “eye ball” assessment, with Simpson’s rule and measuring wall motion 
index when possible. Patients in whom HF or LVSD is not confirmed are discharged 
back to the general practitioners, or if necessary, to another physician. For those with 
15 
 
HF due to LVSD, a management plan is formulated which includes patient education, 
initiation of evidence-based treatment and follow up in a nurse-led titration clinic. 
A retrospective cohort study of the records of all the patients presenting to the one 
stop HF clinic at Darlington Memorial Hospital from Jan 2002 to Dec 2007 was 
performed to ascertain patient characteristics and their clinical outcomes.  
I reviewed the case notes of all these patients referred to the one stop HF clinic. 
Subjects found to have clinical signs and symptoms of the HF were identified. They 
were further studied and categorised based on their echocardiography (TTE) results 
in two groups: 
1) Those with impaired contraction (systolic) function of their left ventricle (LVSD). 
2) Those with preserved contraction (systolic) function of the left ventricle (HFpEF). 
I followed up the management and outcome of this cohort of patients, utilising their 
hospital and general practice records, and data from the Medical Research 
Information Service (MRIS), to answer the primary research question, “What is the 
long term outcome in patients with heart failure who are managed as per clinical 
guidelines?” 
16 
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 The Definition of Heart failure 
Although the diagnosis and management of heart failure is one of the largest tasks for 
the physicians, it has been a challenge to provide an all-encompassing definition for 
this syndrome (12). In 1933 Thomas Lewis in his book, Disease of the Heart, stated 
that “the very essence of cardiovascular practice is the recognition of early heart 
failure” (13).  
Advances in the understanding of the cardiac physiology have rendered earlier 
definitions inadequate. Physicians have used the term in a practical way to convey 
information about an individual patient, but the work of the clinical scientist and 
epidemiologist necessitate a more rigorous approach to the definition of HF (14). 
Also, as no single measurement reliably discriminates between the normal and failing 
heart, no definition is universally accepted (12).  
Over a period, different authors have variously defined HF. Lewis, in 1930, defined 
HF as a condition in which the heart fails to discharge its contents adequately (13). In 
1950, Wood defined HF as a state in which the heart fails to maintain an adequate 
circulation for the needs of the body despite adequate filling pressure (15). In 1977 
Wagner et al defined HF “as a state that exists when either the systolic or diastolic 
operation of the ventricle is impaired to a degree that, despite compensatory 
mechanisms, the demands of the peripheral organs are not satisfied, the peripheral 
muscle shortens inadequately, and / or the pulmonary and systemic venous system 
becomes congested from high filling pressures” (16). And in 1980 Braunwald defined 
HF as “a pathophysiological state in which an abnormality of cardiac function is 
responsible for the failure of the heart to pump blood at a rate commensurate with the 
requirements of the metabolising tissues” (17).  
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This highlights the difficulty in defining HF, as these definitions emphasise one or 
several features of this complex syndrome, such as hemodynamic, oxygen 
consumption, or exercise capacity (18).    
More recently the European Society of Cardiology (ESC) published guidelines for the 
diagnosis of HF in 1995 (19), 2001 (20), 2005 (21),  2008 (18), and in 2012 (22). In all 
these documents, the task force members acknowledge, “a simple objective definition 
of the heart failure is currently impossible as there is no cut off value of cardiac or 
ventricular dysfunction or change in flow, pressure, dimension, or volume that can be 
used reliably to identify patients with heart failure”.    
ESC guidelines, for practical purposes, consider the essential component of HF to be 
“a syndrome in which the patient should have the following features: symptoms of 
heart failure, typically breathlessness or fatigue, either at rest or during exertion, or 
ankle swelling and objective evidence of cardiac dysfunction at rest”. 
1.1 Role of echocardiography  
Echocardiography remains the gold standard for evaluation of left ventricular function 
as in clinical practice it is widely available and easily reproducible. Assessment of the 
left ventricular systolic function is of paramount importance as it not only provides 
prognostic information but also helps guide appropriate therapy to be instituted (22). 
Left ventricular systolic function can be assessed in great detail. This can be analysed 
and quantified using a number of methods. 
These are qualitative, semi quantitative and quantitative assessments. “Eye ball” 
assessment of the global left ventricular (LV) function is the qualitative method. Semi 
quantitative assessment is performed using a wall motion score / index. For 
quantitative assessment measurements include fractional shortening, ejection 
fraction, LV volumes in systole and diastole, and the myocardial performance index.     
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Ejection fraction, which is most commonly used, is the stroke volume [calculated as 
(end diastolic volume – end systolic volume] divided by end diastolic volume.  
For the present study evaluation of the systolic function was done using ejection 
fraction where possible or the “eye ball” assessment. Both approaches are validated 
for use in clinical practise (23).  
1.2 ESC definition of heart failure (22) 
HF is a clinical syndrome in which patients have the following features: 
Symptoms typical of HF (breathlessness at rest or exertion, fatigue, tiredness, ankle 
swelling); Signs typical of HF (tachycardia, tachypnoea, pulmonary rales, pleural 
effusion, raised jugular venous pressure, peripheral oedema, hepatomegaly); 
Objective evidence of a structural or functional abnormality of the heart at rest 
(cardiomegaly, third heart sound, cardiac murmurs, abnormality on the 
echocardiogram, raised natriuretic peptide concentration) 
Similarly, the American College of Cardiology Foundation (ACCF) and the American 
Heart Association (AHA) (24) in 2009 defined HF as a “complex clinical syndrome that 
can result from structural or functional cardiac disorder that impairs the ability of the 
ventricle to fill with or eject blood”. Here the authors have also emphasised that HF is 
largely a clinical diagnosis, which is based on a careful clinical history and a thorough 
physical examination. 
1.3 Grading of severity of HF 
HF patients are usually classified according the severity of their symptoms and 
exercise capacity. The most commonly used classification system is the New York 
Heart Association (NYHA) functional classification system (25).  
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Table 1.4 NYHA classification 
Class 1 (mild): No limitation of physical activity. Ordinary physical activity does not 
cause undue fatigue, palpitations, or dyspnoea. 
Class 2 (mild): Some limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in fatigue, palpitations, or dyspnoea.  
Class 3 (moderate): Marked limitation of physical activity. Comfortable at rest, but less 
than ordinary activity causes fatigue, palpitations or dyspnoea. 
Class 4 (severe): Unable to carry out any physical activity without discomfort. 
Symptoms of cardiac insufficiency present at rest. If any physical activity is 
undertaken discomfort is increased. 
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Chapter 2 
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Literature review  
“The longer you look back, the further you can look forward.” Sir Winston Churchill.  
Historical perspective 
Writings from the times of the Greek and the Egyptian civilizations tell us that HF was 
a fairly well recognised condition. Narratives of HF exist from ancient Egypt, Greece, 
and India, and foxglove was used as a medicine by the Romans (26). Understanding 
the nature of HF improved after William Harvey described the circulation in 1628.  
Wilhelm Conrad Röntgen discovered X rays in the 1890’s (27). His discovery has 
arguably had the greatest impact on the way we view ourselves. His report of the 
accidental discovery of a new form of radiation that penetrates through almost 
everything was revolutionary at that time. The value of being able to see inside a body 
without having to perform surgery was immediately obvious, and scientists and 
physicians rushed to find bigger and better uses for X-rays.  
Around the same time a Dutch physician and physiologist, William Einthoven 
developed the first Electro Cardiograph (ECG) Machine, using a simple string – 
galvanometer, which led to improvements in the investigation of HF (28).  
The Italian naturalist Lazzaro Spallanzani (1729-1799) first demonstrated the 
importance of echo reflection, the principle behind echocardiography. With his 
extensive experiments on the navigation by bats in complete darkness, he concluded 
that they use sound and their ears for navigation, called echo reflection. Pierre and 
Jacques Currie in 1880, discovered the piezo-electric effect, a peculiar phenomenon 
in certain quartz crystals which were the basis of early ultrasound systems (29).   
The first experiments using ultrasonic  echo reflection for examining the heart were 
initiated by a cardiologist  Inge Edler and a physicist Carl Hellmuth Hertz in Lund, 
Sweden in 1953 and produced the first echocardiogram of the heart (30). For his 
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pioneering work Inge Edler has also been called the father of echocardiography (31). 
Cardiac ultrasound has been the most important advancement in diagnostic 
cardiology since the discovery of X-rays. In the past 25 to 30 years, echocardiography 
has become a basic examination in clinical cardiology. Echocardiography provides 
information regarding cardiac morphology, function and hemodynamics non-
invasively. It is the most frequently performed cardiovascular examination after 
electrocardiography and chest X-ray (31). In less than half a century, this technique 
has evolved to a mainstay of cardiovascular medicine. Among the many forms of  
echocardiography are M-mode, two-dimensional, Doppler, stress, trans oesophageal, 
intraoperative, contrast, digital, three-dimensional and intracardiac echocardiography 
(32). The evolution of echocardiography has been dramatic, and its ultimate 
capabilities are still unrealized.  
The evolution of cardiac catheterization has occurred over the last four centuries. 
Stephen Hales (1677-1761), a botanist and physiologist, performed the earliest 
known cardiac catheterization. In 1711 he inserted brass cannulae  through the 
venous and arterial system into the ventricles of a horse by route of  the jugular vein 
and carotid artery (33). 
In 1929, Dr Werner Forssman (1904 – 1979), a 25 year old surgical trainee in a 
German town near Berlin, explored methods for a more direct access to the cardiac 
chambers, initially experimenting on himself and thus performing the first right heart 
catheterization in a  human (34).  The advent of cardiac catheterization represents a 
major medical and scientific achievement. It has revolutionised the diagnosis and 
treatment of cardiovascular disease and played a critical role in the advancement of 
the scientific knowledge (29).   
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The advent of echocardiography, cardiac catheterisation, and nuclear medicine have 
improved the diagnosis and investigation of patients with suspected HF thus helping 
provide evidence based management and improve survival.  
2.1 Treatment 
For 2000 years, HF had been treated with bloodletting and leeches. Bloodletting 
dates at least from the Hippocratic days. It  was avidly pursued  in the 17th and 18th 
centuries, particularly in France and Italy and the practice became highly specialised 
in the hands of the barber surgeons (35). Many families had their own equipment for 
catching blood. Bloodletting and leeching went out of vogue in the late 18th century 
(35). For centuries Ayurveda, the traditional Indian  medical system, has used Arjuna 
bark (Terminalia Arjuna) for treatment of HF (36). In the 19th and early 20th centuries, 
HF associated with fluid retention was treated with Southey's tubes, which were 
inserted into oedematous peripheries, allowing some drainage of fluid (26). In the 17th 
-19th century “dropsy” was the word associated with fluid overload. This was 
considered a primary disease, as physicians were not able to distinguish between the 
cardiac and renal dropsy. 
Dropsy was treated with herbal medications. Medicinal properties of the digitalis 
(foxglove) plant were well recognised and have been used in medicine for centuries. 
Leonard Fuchus (1501-1566), a German physician and humanist, named  the plant 
Digitalis in his book Historia Stripium (1542), and recommended it for “the scattering 
of dropsy” (37). William Withering (1741-1799), who was aware of the work of 
Fuchus, encountered the plant again when he met a “wise woman” who used 
foxglove as one of the components of her medicine for dropsy. 
Withering’s specific contribution was to place digitalis on a proper scientific footing, 
and thereby eliminate much of its folklore and superstition. He established that the 
dried powdered leaf of the plant was five times as effective as the fresh leaf. The 
25 
 
powder was also better than a decoction, as boiling seemed to destroy some of the 
active principle. He then went on to study 163 patients with dropsy, and recorded his 
results carefully (38). Withering’s recognition of the foxglove as the active principle of 
the various witches' brews that had been used to treat dropsy (oedema) was primed 
by his extensive botanical studies and investigations (37). Withering published his 
major work on the foxglove (digitalis) - "An account of the Foxglove and some of 
its Medical Uses” in 1785 (39). 
2.1.1 Dawn of the diuretics 
Diuretics were the most important medications for treating dropsy in the late 19th and 
early 20th century. Many agents were used including the bitartrate, acetate, nitrate of 
potash, digitalis, and squill, spirit of nitrous ether, scoparium, juniper, copaiba, 
turpentine, cantharides, and gin. These diuretics were predominantly useful in cardiac 
and renal dropsy; they had no effect upon portal dropsy (40). Digitalis was 
acknowledged as a medication of astonishing efficacy in many cases of cardiac 
dropsy, and principally in cases where the heart's action was irregular (40).  
In the 19th century mercury and its compounds began to be used as diuretics. 
Mercury had been used in industry and medicine for many centuries, but the 
pharmacological properties of mercury were not well understood. Despite the obvious 
utility of these compounds in the past, their toxicity overshadowed their usefulness.  
Rediscovery of the diuretic effects of mercurous chloride by Wood in 1849 and by 
Jendrassick in 1886 contributed to the development of their place in the treatment of 
the oedema (41). 
Working in Vienna in 1919, Arnold Vogl a third year medical student, made the 
chance discovery that the parenteral administration of an organic mercurial 
compound, Marbaphen (Novasurol), when used to treat a girl with congenital syphilis, 
produced unexpected diuresis (42). This initiated a new phase and led to the 
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development of less toxic organomercurial diuretics which were regarded as the 
“most reliable and powerful diuretic agents” (43). Organomercuial diuretics were the 
main stay of therapy for congestive symptoms till the 1950s (42). 
Digitalis and mercury were extensively used for the management of patients with 
signs and symptoms of congestive HF both for inpatient and out patients (44). Guy’s 
Pill :- [a mixture of mercurial pill (Blue Pill), digitalis leaves in powder, squill in powder, 
extract of gentian, - one thrice daily] was well known and widely prescribed for cardiac 
dropsy (45). 
In 1932, a German bacteriologist Gerhard Domagk proclaimed the discovery of a red 
dye prontosil that was active against streptococcal infections in mice and humans. 
Soon after it was shown that the active ingredient of this antimicrobial agent was 
sulphanilamide (46). Around the same time  Meldrum and Roughton described the 
enzyme carbonic anhydrase in 1932 (47).  It was noted by Pitt that sulphanilamide 
alkalinized the urine and this process and bicarbonate reabsorption were dependent 
on the enzyme carbonic anhydrase (48). Schwartz was the first to connect hydrogen 
secretion and sodium reabsorption in this context and gave sulphanilamide to treat 
congestive HF. This ushered in a new diuretic age and Roblin synthesized the new 
and more powerful carbonic anhydrase inhibitor acetazolamide (48). These 
compounds block hydration of carbon dioxide in tubular cells so that the bicarbonate 
ion cannot be reabsorbed and thus carries sodium, water and potassium with it. 
These were the first orally effective diuretics (49). Unfortunately, they had low potency 
and became ineffective if used for a prolonged duration. 
In 1957 Novello and Sprague, while studying the aromatic sulphonamides, observed 
unexpectedly high activity with benzenedisulfonamides. These compounds exhibited 
an order of inhibition of carbonic anhydrase observed previously with heterocyclic 
sulphonamides. In addition, they also produced a marked increase in chloride 
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excretion and caused diuresis not unlike that observed with the organic mercurials 
(50).  Thiazides were effective orally even in those patients who had become resistant 
to mercurial diuretics and were less toxic (51, 52). These drugs exert their effect 
primarily by inhibiting reabsorption in the early segment of the distal tubule of the 
nephron (49).  Thiazides were not without side effects and the commonest were 
hypokalemia, and sensitizing the heart to actions of digitalis (53).       
For years it was believed that secondary hyperaldosteronism was mainly responsible 
for the salt and water retention  in congestive cardiac failure and much research was 
concentrated on this (54, 55).  Spironolactone (a specific aldosterone antagonist) was 
not very effective in cardiac oedema. It was shown that aldosterone levels were 
slightly raised in untreated HF and fell to normal as body weight went down with 
diuretics, and only rose as the body was depleted of salt (56).  Spironolactone 
competitively inhibits the effects of aldosterone on the distal tubule, and is more 
effective when used with a diuretic that increases the load of sodium presented to the 
distal tubule. (57) 
Further exploration of the sulphonamide structure and substituting the existing 
thiazides with a sulfamyl-benzene group produced a dramatic change in the 
qualitative nature of the renal response. This new potent compound named 
furosemide was developed in 1963 (42).  These sulphamoylbenzoate diuretics 
interact with a Na, K, 2CI-cotransporter within the luminal membrane of the ascending 
limb of the loop of Henle (58). Furosemide proved more effective than comparable 
standard doses of other diuretics. Higher doses were successfully used in resistant 
oedema and intravenous furosemide was of particular value in acute pulmonary 
oedema (59). These new and powerful diuretics made it possible for the physician to 
control the symptoms in most patients with cardiac oedema. 
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Other drugs, which have been used in the past for treatment of congestive cardiac 
failure, are xanthines, glucocorticoids, mannitol, alcohol and serum albumin. These 
are rarely used now (49).  
Up till the 1970s complete immobilisation was advocated and shown to reduce 
cardiac size and improve symptoms for patients with HF (60). However it was seen 
that symptoms re appeared after mobilisation and also patients had a high incidence 
of thromboembolic complications. 
2.1.2 Emergence of angiotensin converting enzyme inhibitors (ACEi) 
The emergence of angiotensin converting enzyme inhibitors (ACEi) ranks amongst 
one of the major therapeutic advances of the 20th century. Their discovery, like that of 
the diuretics, was essentially by chance.  Our understanding of the renin-angiotensin 
system (RAS) can be traced back to the 19th century when Tigerstedt  and Bergman 
published an article on renin in 1889 (61). Angiotensin converting enzymes (ACE), 
like carbonic anhydrase, is also a zinc-metalloproteinase belonging to a large group of 
related enzymes that include carboxypeptidase A and alkaline phosphatise (62).  A 
scientific group in London was working on the mechanisms whereby the venom of the 
Brazilian snake Bothrops jaracopa caused circulatory collapse. The venom was found 
to contain peptides that inhibited ACE and potentiated bradykinin (63).  Subsequently 
these peptides were also shown to inhibit the conversion of angiotensin I to 
angiotensin II  by canine pulmonary tissue (64). 
The first ACEi studied in man was a synthetic nonapetide, teprotide which in patients 
with elevated renin activity, was able to block the pressor response to infused 
angiotensin I and lower blood pressure (42).  In 1980 a systematic enquiry  by 
Cushman and Ondetti (65)  into the snake venom led them to develop the first orally 
active ACEi, captopril.  It was soon realised that the mercapto group in the captopril 
caused side effects like rash, taste disturbance and proteinuria. This heralded the 
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search to synthesise an ACEi lacking the mercapto group and Enalapril was 
developed by Patchett in 1984 (66). Enalapril is an esterified pro-drug that yields the 
free acid, enalaprilat, an active ACEi.  By changing the amino acid backbone from 
proline to lysine, the orally active lisinopril has been produced.  
Over the years, various other ACEi agents have been developed and many 
randomised controlled trials have proved their efficacy in improving symptoms, 
reducing hospitalisation, and improving survival in patients with heart failure. 
2.1.3 Beta-blockers  
In the 1940s and 50s nitro-glycerine was well known as a vasodilator agent and 
widely used for angina treatment. It was assumed that as nitrates dilated peripheral 
blood vessels they would also dilate blood vessels in the heart, increasing blood flow 
and thus oxygen delivery to the myocardium. So the main thrust of research was on 
the development of vasodilators for increasing the oxygen supply to the heart in 
patients with angina (67).  
At the same time in 1948, Raymond P Ahlquist proposed that there were two distinct 
types of adrenotrophic receptors which he tentatively named as alpha and beta 
receptors (68). He also demonstrated that it was the beta receptor which caused 
myocardial stimulation (68). 
Sir James Black was impressed by Ahlquist’s theory of beta-receptors in the heart. He 
was aware that systemic blood pressure and heart rate determined myocardial 
demand for oxygen (69). Unlike others who were working on ways to increase the 
oxygen supply to the myocardium, Sir James Black started to work on ways to reduce 
myocardial demand for oxygen in hearts whose oxygen supply was restricted due to 
arterial narrowing. 
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Ahlquist’s alpha and beta-receptors gave him the starting point. He wanted to find a 
beta-receptor antagonist to slow the heart rate and thus reduce the myocardial 
demand for oxygen. He first produced pronethalol (which never came into widespread 
clinical use) and then propranolol in 1965. Propranolol, and subsequently other beta 
blockers, have changed the face of  cardiovascular medicine (70). Initially they were 
used to treat hypertension, angina and arrhythmias. But over the last 25 years beta-
blocker therapy has also proved the most effective treatment for chronic HF.   
2.2 Evidence based treatment for LVSD 
In the recent past many guidelines and systematic reviews have been published on 
the management of chronic HF. These provide recommendations for the diagnosis 
and use of evidence based treatment. 
2.2.1 Angiotensin converting enzyme inhibitors 
The majority of trials in HF failure have involved ACE inhibitors. In 1983 the 
Captopril-Multicentre study (71), was one of the first randomized, double blind, 
placebo controlled trials in heart failure refractory to digitalis and diuretic therapy. 
Patients treated with captopril showed improvement in exercise tolerance and New 
York Heart Association (NYHA) functional class compared to those on placebo.  This 
also heralded the era of HF trials. 
The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) 
group (72)  in 1987, randomized 253 patients  with NYHA class 4 HF on conventional 
therapy to either enalapril (2.5 to 40 mg per day) or placebo. At 6 months, mortality 
was 26 percent in the enalapril group and 44% in the placebo group- a reduction of 
40% (p = 0.002). Mortality was reduced by 31% at one year (p = 0.001). In addition, a 
significant improvement in NYHA class was observed with enalapril, together with a 
reduction in heart size and a need for other medication for HF. This was the first trial 
to show improved survival with an ACEi. 
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Studies of Left Ventricular Dysfunction (SOLVD) Trial (1991) 
In the SOLVD – Treatment trial (73), one of the largest trials with enalapril,  2569 
patients with congestive HF NYHA class 2 and 3, and an EF of 35% or less  who 
were already taking conventional therapy other than ACE inhibitors were randomised 
to receive 2.5 mg to 20 mg twice daily enalapril or placebo. Patients were followed up 
for an average of 41 months. There were 510 (39.7%) deaths in the placebo group as 
compared with 452 in the enalapril group (35.2%). There was 16% reduction in risk in 
total mortality, and fewer patients were hospitalised for worsening HF. This was the 
first large scale trial in HF which showed that the mortality benefit shown in 
CONSENSUS could be applied to milder forms of HF. 
SOLVD - prevention (74)  trial examined the effect of enalapril on asymptomatic left 
ventricular dysfunction. 4228 patients with an ejection fraction of 35% or less, who 
were not receiving diuretics, digoxin, or vasodilators for treatment of HF, were 
identified. Patients were randomised to receive either 2.5 mg to 20 mg twice-daily 
enalapril or placebo. Patients were followed up for average of 37 months. There was 
reduced incidence of HF and related hospitalizations, with a trend toward fewer 
cardiovascular deaths.  
2.2.2 Angiotensin converting enzymes inhibitors post Myocardial Infarction 
Survival and Ventricular Enlargement (SAVE) Trial (75) enrolled 2231 patients 3 to 
16 days after an acute myocardial infarction with a left ventricular ejection fraction of 
40% or less but without overt HF or symptoms of myocardial ischemia. Patients were 
randomly assigned to receive either placebo or captopril 50 mg three times daily, and 
followed up for an average of 42 months. There was 19% risk reduction in all-cause 
mortality and incidence of both fatal and non-fatal major cardiovascular events was 
consistently reduced in the captopril group. These benefits were observed in patients 
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who received thrombolytic therapy, aspirin, or beta-blockers as well as those who did 
not. This was the first trial to show prevention of congestive HF. 
The Acute Infarction Ramipril Efficacy (AIRE) study (76) recruited 2006 patients, 3 
– 10 days post myocardial infarction who had shown clinical evidence of either 
transient or ongoing HF. They were randomly allocated to placebo or ramipril 5 mg 
twice daily.  Follow up was continued for a minimum of 6 months and an average of 
15 months. There was a 27% risk reduction in all-cause mortality in the ramipril group. 
This benefit was evident as early as 30 days and was consistent across a range of 
subgroups. 
Trandolapril Cardiac Evaluation (TRACE) study (77) recruited 1749 patients, 3 – 7 
days post myocardial infarction with an ejection fraction of 35% or less with or without 
symptomatic HF. Patients were randomly assigned to receive placebo or trandolapril 
4 mg once daily. Follow up was for 24 to 50 months. There was a 22% relative 
reduction for overall mortality with trandolapril. There was a reduction in deaths from 
cardiovascular causes, sudden deaths, and the development of severe HF. 
Dose ranging trials with Angiotensin converting enzyme inhibitors 
In Assessment of Treatment with Lisinopril And Survival (ATLAS) trial (78) 3164 
patients with NYHA class 2 to 4 and an ejection fraction ≤ 30% were randomly 
assigned to either low doses (2.5 – 5 mg daily)  or high doses (32.5 to 35 mg daily)  of 
lisinopril. The study population was followed up for 46 months.  When compared with 
the low dose group, patients in the high-dose group had a significant (12%) lower risk 
of death or hospitalisation for any reason (p = 0.002) and 24% fewer hospitalisations 
for HF (p = 0.002). This highlighted that even therapy that exerts positive effects in 
clinical trials may not be effective in clinical practice if the doses in the study are not 
used.       
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Conclusion: The NICE HF guidelines of 2010 (79)  recommended ACE inhibitors, 
titrated to the target doses obtained from clinical trials, as the first line therapy in 
patients with LVSD. 
2.2.3 Angiotensin – II receptor blockers 
Angiotensin - II type 1 - receptor blockers (ARBs) act by a different mechanism from 
ACE inhibitors, although both reduce the stimulation of angiotensin II receptors. ACE 
inhibitors block the formation of angiotensin II, a potent vasoconstrictor agent, thereby 
decreasing the amount of angiotensin available to both angiotensin type 1 (AT1) and 
angiotensin type 2 (AT2) receptors. ARBs selectively block the binding of angiotensin 
II to the AT1 receptors, but do not affect the AT2 receptors. In the management of 
hypertension, ARBs were found to be an effective alternative to ACE inhibitors, 
particularly when side effects such as cough are encountered. A potential role in the 
management of HF was also postulated. 
Major trials with Angiotensin - II type receptor blockers (ARBs) are broadly divided 
into three groups. 1) Patients intolerant to ACE inhibitors (CHARM Alternative) 2) 
ACEi vs. ARB (ELITE I / II, OPTIMAL, VALLIANT) and 3) ACEi added with ARB 
(CHARM added, Vel-HEFT) 
Group 1  
Candesartan in Heart failure Assessment of Reduction in Mortality and 
morbidity (CHARM) Alternative (80) enrolled 2028 adult patients (≥ 18 years) with 
symptomatic congestive HF (NYHA class 2-4 ) for at least 4 weeks. The ejection 
fraction must have been ≤ 40% and determined within six months. They were not 
receiving ACEi because they were previously intolerant of them. 740 patients 
experienced the primary outcome of cardiovascular death or hospitalisation for CHF: 
334 (33%) in the candesartan group and 406 (40%) in the placebo group [(unadjusted 
hazard ratio 0.77), 95% CI 0.67 - 0.89: p = 0.004]. The average annual event rates 
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were 13.8% in the candesartan group and 18.2% in the placebo group. The absolute 
risk reduction of 7 major events per 100 patients corresponds to treating 14 patients 
with candesartan for 1 year to prevent one cardiovascular death or hospitalisation for 
CHF. Candesartan was generally well tolerated and reduced cardiovascular mortality 
and morbidity in patients with symptomatic HF and intolerant to ACE inhibitors.   
Group 2   
Evaluation of Losartan  in the Elderly (ELITE) study (81) was designed to 
determine the safety and efficacy of AT1 receptor blockade with losartan in the 
treatment of HF in elderly (65 years or more) compared to the ACE inhibitor captopril.  
Seven hundred and twenty two ACE inhibitor naive patients with NYHA class 2-4 HF 
and EF of 40 percent or less were randomised to losartan 50 mg once daily or 
captopril 50 mg three times daily. There was no difference in renal dysfunction in the 
two groups, losartan was better tolerated than captopril and fewer patients 
discontinued losartan therapy. Unexpectedly in this study of the elderly, treatment 
with losartan was associated with lower mortality than the captopril group (4.8 % vs. 
8.7 %; risk reduction 46%; 95% CI 5-69%: p = 0.035)       
The Losartan Heart Failure Survival study ELITE II (82) was designed to confirm 
whether losartan is superior to captopril in improving survival and is better tolerated. 
There were 3152 patients aged 60 years or older with NYHA class 2-4 heart failure 
and ejection fraction of 40% or less. Patients, stratified for beta blocker use, were 
randomly assigned to losartan 50 mg once daily or captopril 50 mg three times daily. 
The primary and secondary end was all cause mortality. Median follow up was 1.5 
years. There was no difference in all-cause mortality in the losartan group (17.7%) vs. 
15.9% in the captopril group (hazard ratio 1.13% [95.7% CI 0.095 – 1.35] p = 0.16). 
Losartan was not superior to captopril in improving survival in the elderly HF patients, 
but significantly better tolerated. 
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Optimal trial in Myocardial Infarction with the Angiotensin II Antagonist 
Losartan (OPTIMAAL) (83) was designed to compare the effects of losartan 50 mg 
once daily with those of captopril 50 mg three times daily on mortality and morbidity in 
patients with acute myocardial infarction and evidence of HF or left- ventricular 
dysfunction. All cause mortality was not significantly different in the two groups with 
499 (18%) deaths in the losartan group vs. 447 (16%) in the captopril group, over an 
average follow up of 2.7 years (range 0-9). This trial also did not show superiority or 
non-inferiority of losartan relative to captopril, though it was better tolerated.  
Valsartan in Acute Myocardial Infarction (VALIANT) (84) was a prospective, 
multicentre, double blind, randomised, active control trial with three parallel treatment 
groups. Post myocardial infarction patients with signs and symptoms of HF or LVSD 
(ejection fraction ≤35% on echocardiography) and receiving conventional therapy 
were randomly assigned to additional therapy with valsartan 160 mg alone, valsartan 
80 mg twice daily plus captopril 50 mg three times daily, or captopril 50 mg three 
times daily. The primary end point was death from any cause. 
After a median follow up of 24.7 months, 979 patients in valsartan group died, as did 
941 patients in the valsartan and the captopril group and 958 in the captopril group. 
Mortality from any cause and cause specific mortality were similar in the three 
treatment groups.  
Group 3 
Candesartan in Heart Failure Assessment of Reduction in Mortality and 
Morbidity (CHARM)- Added trial (85) enrolled 2548 patients with NYHA class 2-4 
and an ejection fraction of 40% or less who were being treated with ACEi. Patients 
were randomly assigned to candesartan (n = 1276, target dose 32 mg once daily) or 
placebo (n = 1272). 55% of the patients were receiving beta blockers and 17% 
spironolactone at baseline. The primary outcome was a composite of cardiovascular 
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death or hospital admission for CHF and the median follow up period was 41 months. 
483 (38%) patients in the candesartan group and 538 (42%) in the placebo group 
experienced the primary outcome of cardiovascular death or admission to hospital for 
CHF (HR 0.85, 95% CI 0.75 - 0.96, p = .011). This was equivalent to an absolute 
reduction of 4.4 patients with events per 100 patients treated corresponding to a 
number to treat of 23 to prevent one event of cardiovascular death or CHF admission. 
All cause mortality did not differ in both groups. 
Valsartan-Heart Failure Trial (Val-HeFT) (86) investigated the effect of valsartan 
when added to an ACE inhibitor. Patients receiving background therapy for heart 
failure were eligible if they had NYHA class 2-4 symptoms, ejection fraction of 40% or 
less and a left ventricular internal diameter in diastole (LVIDd) of more than 2.9 
cm/m2. 
3034 patients receiving an ACE inhibitor but not beta-blocker at baseline were 
randomly assigned to receive placebo or valsartan 160 mg twice daily. Mortality was 
not affected by valsartan but morbidity endpoints were significantly reduced (36.3% in 
placebo, 31.0% in valsartan; p= 0.002) in patients receiving an ACEi but no beta-
blocker. Valsartan also reduced HF hospitalisation and slowed remodelling in patients 
treated with an ACEi in the absence of beta- blockade, particularly in those on lower 
dose of ACEi. Interestingly in the subgroup analysis, patients receiving triple therapy 
with ACEi, beta blockers, and valsartan there was a significant increase in mortality 
[129 (17%) vs. 97 (13%) deaths], hazard ratio (HR) 1.42, 95% CI 1.09-1.85, p = 
0.009, compared with those on ACE inhibitors, beta blockers, and placebo.   
Conclusion: In August 2010 NICE (79) looking at all the evidence regarding the 
ARBs in management of chronic HF recommended that clinicians: 
a) Consider an ARB licensed for HF as an alternative to ACEi in patients with HF due 
to LVSD who have intolerable side effects with ACEi.  
37 
 
b) Monitor serum urea, electrolytes, creatinine and eGFR for signs of renal 
impairment and hyperkalaemia. 
2.2.4 Evidence for beta blockers in heart failure 
For a long time beta blockers have been considered to be contraindicated in HF due 
to their negative inotropic effect and thus their use in HF may seem counterintuitive. 
In 1975, Waagstein et al used a beta blocker in seven patients. All patients had 
resting tachycardia, and advanced congestive HF. Over a period of 2 to 12 months 
these patients had improvement in symptoms, echocardiography measurements, and 
X-ray appearances (60). 
In 1980 Karl Swedberg et al (87), gave twenty eight patients with HF, beta blockade 
for six to 62 months. There was improvement in the ejection fraction on 
echocardiography, functional class, and reduced mortality in this severely ill group. 
This initial work supported the hypothesis that excessive catecholamine cardiac 
stimulation was important in the pathophysiology of congestive cardiac failure and this 
could be reduced by chronic beta blockade. These studies also suggested that beta 
receptor blockers should be added to conventional treatment with digitalis and 
diuretics in all patients with severe congestive cardiomyopathy. 
The Metoprolol in Dilated Cardiomyopathy (MDC) (88) was a multi centred  
randomised, placebo controlled parallel group trial of metoprolol on mortality and 
need for heart transplantation in patients with symptomatic idiopathic dilated 
cardiomyopathy. 383 patients with HF and an EF of < 40% were randomised to 
receive 100 – 150 mg metoprolol daily or placebo over the background treatment.  
Metoprolol was well-tolerated, improved symptoms and cardiac function, prevented 
clinical deterioration but had no significant effect on the all-cause mortality. 
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The Cardiac Insufficiency Bisoprolol study (CIBIS) (89)  was a placebo controlled, 
randomised, double blind study that recruited 641 patients with chronic HF and an EF 
of <40% in NYHA class 3 (95%)  or 4 (5%). All patients received diuretics and 90% 
were receiving ACEi. 320 patients were randomised to bisoprolol 5 mg/day and 321 to 
placebo. Mean follow up was 1.9 years. Primary end point was total mortality. 
There were 67 (20%) deaths in the placebo group compared to 53 (16.6%) in the 
bisoprolol group (p = 0.22). Relative risk of death was 0.80 with 95% CI of 0.56 to 
1.15. The observed difference in mortality between the two groups did not reach 
statistical significance, but the increasing doses of beta blocker in severe HF 
conferred functional benefit. The authors postulated that the reason for statistical non-
significance was probably because only half the patients were titrated to the target 
dose of 5 mg bisoprolol, in patients who were already on standard therapy for HF 
(diuretics and ACEi)          
Carvedilol Heart Failure Study Group (90) enrolled 1094 patients with chronic HF in 
a double blind, placebo controlled, stratified programme. Patients were assigned to 
one of the four treatment protocols based on their exercise capacity. Within each of 
the four protocols patients with mild, moderate, or severe HF with left ventricular 
ejection fraction of ≤ 0.35 were randomly assigned to receive either placebo (n = 398) 
or carvedilol (n = 696). Patients were already receiving conventional therapy for HF. 
The primary end point was death or hospitalisation for cardiovascular reasons.    
There were 31 (7.8%) deaths in the placebo group and 22 (3.2%) deaths in the 
carvedilol group after a median follow up of 6.5 months. This represented a 65% 
reduction in the risk of death (95% CI 39 to 80%; p<0.001) in patients receiving 
carvedilol.  As compared to placebo, there was also a 27% reduction in the risk of 
hospitalisation for cardiovascular causes in the carvedilol group (19.6% vs. 14.1% p = 
0.036) as well as a 38% reduction in the combined risk of hospitalisation or death 
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(24.6% vs. 15.8%, p<0.001). The study was stopped before schedule due to a 
significant reduction in mortality in the carvedilol group. 
Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) 
The  Cardiac insufficiency  bisoprolol study (CIBIS) had shown a non-significant trend 
towards lower mortality and 30% fewer admissions to hospital for worsening heart 
failure (89). CIBIS II was designed to test this evidence further. 2647 symptomatic 
patients in NYHA 3 or 4, with an left ventricular ejection fraction of ≤ 35%, on diuretics 
and ACEi were randomly assigned to bisoprolol (n = 1327), starting dose at 1.25 mg 
increased to maximum of 10 mg per day  or placebo (n = 1320). Mean follow up was 
1.3 years. All-cause mortality in the bisoprolol group was 156 (11.8%) vs. 228 (17.3%) 
in the placebo group, with a hazard ratio of 0.66 (95% CI 0.54-0.81, p < 0.001) at the 
second interim review. There were also fewer sudden deaths in the bisoprolol group. 
The study was stopped early after these results. 
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure 
(MERIT-HF) (91) enrolled 3991 patients with chronic HF and NYHA class 2 - 4 with 
an ejection fraction ≤ 40%, stabilised with standard therapy. A total of 1990 patients 
were randomised to metoprolol CR/XL 12.5 mg (NYHA 3-4) or 25 mg once daily 
(NYHA 2) and 2001 patients were randomised to placebo. The target dose was 200 
mg once day. Primary end point was all cause mortality.  
145 patients in the metoprolol group and 217 in the placebo group died (p = 0.009, p 
= 0.062 after adjustment for the first and second interim analysis). This was a 34% 
reduction in all-cause mortality in clinically stable patients with symptomatic HF and 
thus requiring 27 patients to be treated for one year to prevent one death with 
metoprolol CR / XL.      
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2.2.5 Beta - blockers in advanced heart failure 
Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) study 
(92). 2289 patients with symptoms of HF at rest and an EF <25% (but not volume 
overloaded) were randomised to receive carvedilol (n = 1156) or placebo (n = 1133) 
for an average of 10.4 months. Carvedilol was started at 3.125 mg twice daily, and 
thereafter titrated to a target dose of 25 mg twice daily. The annual mortality rate in 
the placebo group was 19.7%, which was reduced to 12.8% in the carvedilol group: a 
35% risk reduction of death (p = 0.001). Carvedilol also reduced the risk of death or 
any hospitalisation by 24% (p = 0.004) prompting early termination of the study. 
Carvedilol or Metoprolol European Trial (COMET) (93)  
COMET included 3029 patients with chronic HF, NYHA class 2-4, an EF <35%, and a 
previous admission for cardiovascular reasons who were on optimum treatment with 
diuretics and an ACEi. 1511 patients were randomised to receive carvedilol 25 mg 
twice daily, and 1518 to metoprolol 50 mg twice daily. The primary end point was all 
cause mortality. Patients had a mean age of 63 years and mean follow up of 58 
months. 512 (34%) patients died in the carvedilol group and 600 (40%) in the 
metoprolol group. The hazard ratio 0.83 (95% CI 0.74-0.93, p = 0.0017), suggesting 
that carvedilol extends survival compared with metoprolol. 
This is the only major clinical trial comparing two beta blockers in HF. There was a 
17% reduction in mortality with carvedilol as compared to metoprolol. This has raised 
the question whether one particular beta blocker is better than another for patients 
with HF. 
The results of this trial have been partly explained by the fact that the preparation of 
metoprolol used was short acting and that possibly carvedilol provided additional 
benefit other than just beta blockade to account for better survival in this group. 
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The Beta-Blocker Evaluation Of Survival trial (BEST) (94).  
2708 patients with an EF of 35% or lower, and NYHA class 3 (92%) and 4 (8%) were 
randomly assigned to double blind treatment with either bucindolol (1354 patients) or 
placebo (1354 patients) and followed for the primary end point of death from any 
cause. The study was stopped after the seventh interim analysis. At that time, there 
was no significant difference in the mortality between the two groups. There were a 
total of 449 (33%) deaths in the placebo group as compared to 411 (30%) in the 
bucindolol group (adjusted p = 0.13). Thus in patients with advanced HF there was no 
significant overall survival benefit. This is the only large study that did not show 
survival benefit with beta blockers in patients with HF. This could be because of 
different pharmacological properties of bucindolol. Bucindolol is a non selective beta 
blocking agent with intrinsic sympathomimetic activity. It has mild vasodilator 
properties with strong β2-adrenergic blockade and only weak α1- blocking properties 
which makes bucindolol uniquely sympatholytic among the beta blockers evaluated in 
HF (95). This sympatholysis can produce an irreversible loss of adrenergic support 
that can be deleterious to the failing heart    
2.2.6 Beta-Blockers in post Myocardial Infarction LV dysfunction 
Carvedilol Post Infarct Survival Control in LV Dysfunction (CAPRICORN)  (96). 
One thousand nine hundred and fifty nine patients with a proven acute myocardial 
infarction and left ventricular EF of ≤40% were randomly assigned to  6.25 mg 
carvedilol (975 patients), titrated to a maximum of 25 mg twice daily, or placebo (984 
patients). For the primary end point of all-cause mortality or cardiovascular 
hospitalisation there was no difference between the carvedilol and the placebo groups 
[340 (35%) vs. 367 (37%), hazard ratio 0.92 (p = 0.296, 95% CI 0.80 - 1.07)]. 
However all-cause mortality alone was significantly lower in the carvedilol group than 
in the placebo group [(116 (12%) vs. 151 (15%), hazard ratio 0.77 (p = 0.03, 95% CI 
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0.60 – 0.98)].  Carvedilol also reduced cardiovascular mortality and the rate of non-
fatal myocardial infarction. 
Cardiac Insufficiency Bisoprolol Study (CIBIS) III (97) tested whether beta 
blockers as initial therapy may be as useful as adding beta blockers to a regimen 
containing an ACE inhibitor. 1010 patients with mild to moderate HF and an EF ≤ 
35%, who were not receiving ACE inhibitor, beta blocker, or ARBs were randomised 
to open label mono therapy with either bisoprolol (target dose10 mg daily; n = 505) or 
enalapril (target dose 10 mg twice daily; n = 505) for 6 months, followed by their 
combination for 6 to 24 months. The combined primary end point was all cause 
mortality or hospitalisation. 
Bisoprolol first treatment was non-inferior to enalapril-first treatment in the intention to 
treat analysis but not in the pre specified statistical criterion for non-inferiority. There 
was no difference in terms of safety and efficacy.   
Conclusion: NICE (79) recommends that all patients with HF should be offered ACEi 
and beta blockers licensed for HF, using clinical judgement when deciding which drug 
to start first. NICE also recommends that licensed beta-blockers should be offered to 
patients who are older adults, with peripheral vascular disease, erectile dysfunction, 
diabetes mellitus, interstitial pulmonary disease and chronic obstructive pulmonary 
disease (COPD) without reversibility. 
2.2.7 Aldosterone Antagonist in heart failure 
Rationale:  Aldosterone has an important role in the pathophysiology of HF.  
Angiotensin stimulates the release of aldosterone from the adrenal cortex which plays 
an important role in blood pressure regulation and fluid balance. Aldosterone not only 
causes reabsorption of sodium and water in to the blood, but also promotes loss of 
potassium and magnesium, sympathetic activation, parasympathetic inhibition, 
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myocardial fibrosis,  baro receptor dysfunction, vascular damage, and impairs arterial 
compliance (98). 
Many physicians have assumed that inhibition of the RAAS by an ACE inhibitor will 
suppress the formation of aldosterone, but even when the highest tolerated doses of 
ACEi are used they may not completely suppress the RAAS and aldosterone 
production may only be transiently suppressed. 
Even if angiotensin 2 production is completely suppressed there is evidence that 
aldosterone production may not be completely inhibited (99). Also there is evidence to 
suggest that angiotensin 2 may be produced by non-ACE dependent mechanisms 
(100). So it was hypothesised that blocking the aldosterone receptors would 
significantly reduce the risk of death from all causes among patients who had severe 
HF, regardless of ACEi / ARB usage.(101)  
Randomised Aldactone Evaluation Study (RALES) (101) enrolled 1663 patients 
who had symptomatic severe HF (NYHA 3-4)  and left ventricular EF ≤ 35%, who 
were being treated with an ACE inhibitor, a loop diuretic, and in most cases digoxin. 
822 were randomly assigned to receive spironolactone 25 mg daily and 841 to 
receive placebo. The primary end point was all cause mortality. 
There were 386 (46%) deaths in the placebo group and 284 (35%) in the 
spironolactone group (Relative risk of death 0.70; 95% CI .60 to 0.82; P < 0.001). This 
30 percent reduction in the risk of death with spironolactone was attributed to both 
lower risk of death from progressive HF and sudden death from cardiac causes. 
There was also improvement in symptoms of HF as assessed by the NYHA class. 
10% patients had gynecomastia or breast pain with spironolactone as compared to 
1% with placebo.  This trial was stopped early after a mean follow up of 24 months as 
interim analysis determined that spironolactone was more efficacious. 
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Eplerenone Post-Acute Myocardial Infarction Heart Failure and Survival study 
(EPHESUS) (102)   
Following the results of the RALES trial (101), the role of aldosterone blockade in 
reducing mortality and the rate of hospitalisation among patients with acute 
myocardial infarction complicated by HF and left ventricular systolic dysfunction (EF 
<40%) was investigated using eplerenone an aldosterone blocker that selectively 
blocks the mineralocorticoid receptor and not glucocorticoid, progesterone, or 
androgen receptors.  
3313 patients were randomly assigned to receive eplerenone (25 mg initially titrated 
to 50 mg per day) and 3319 patients to receive placebo in addition to optimal medical 
therapy. 
During the mean follow up period of 16 months there were 478 (14.5%) deaths in the 
eplerenone group and 554 (16.7%) in the placebo group (relative risk, 0.85; 95% CI 
0.72 to 0.94; p = 0.005). eplerenone also reduced the risk of hospitalisation. The rate 
of serious hyperkalemia was 5.5% in the eplerenone group and 3.9% in the placebo 
group (p = 0.002), while the rate of hypokalemia was 8.4% in the eplerenone group 
and 13.1% in the placebo group (p < 0.001).    
Eplerenone in Mild Patients Hospitalisation and Survival Study in Heart Failure 
(EMPHASIS-HF) trial (103) 
This was a randomised, double blind, placebo controlled trial that recruited 2737 
patients with NYHA class 2 HF and EF < 35%.  Patients who were on recommended 
therapy were randomised to eplerenone (up to 50 mg daily) or placebo, with a median 
follow up of 21 months when the trial was stopped because of significant benefit in the 
eplerenone group. The results showed a 37% reduction in the primary end point of 
the composite of cardiovascular death or hospitalisation for HF [18.3% vs. 25.9%, 
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hazard ratio 0.63, (95% CI 0.54 – 0.74), p = <0.001]. There was a 24% reduction in 
cardiovascular deaths and a 42% reduction in hospitalisation for HF. The main side 
effect was hyperkalemia with eplerenone (11.8% vs. 7.2%). 
These results were consistent with the findings from the RALES trial (in more severe 
HF), and EPHESUS trial (post myocardial infarction with LV dysfunction) and 
provided compelling evidence for use of aldosterone blockade in patients with mild 
HF.   
2.2.8 Digoxin in heart failure  
Digitalis Investigation group (DIG) (104) recruited patients with left ventricular EF 
<45%, who were receiving diuretics and ACEi and were in sinus rhythm. They were 
randomly assigned to digoxin (n=3397) or placebo (n=3403). Patients were followed 
up for an average of 37 months. Overall mortality was not affected as there were 
1181 (34.8%) deaths in the digoxin and 1194 (35.1%) in the placebo group (relative 
risk, 0.99; 95% CI 0.91 to 1.07; p = 0.08). However there was a trend to reduced 
deaths attributed to HF (relative risk 0.88: 95% CI 0.77 to 1.01; p = 0.06). 
Hospitalisation due to HF or other cardiovascular causes was substantially reduced.  
NICE (79) recommends use of digoxin for worsening or severe HF due to left 
ventricular dysfunction despite first and second line treatment for HF. 
2.2.9 Role of Ivabradine  
Ivabradine is drug that inhibits the If channel in the sinus node. Its only 
pharmacological effect is to slow the heart rate in patients with sinus rhythm.  
Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT) 
(105). This study enrolled 6588 patients in NYHA class 2-4, sinus rhythm with a rate 
of ≥ 70 / minute, an EF < 35% and, hospitalization in the previous 12 months.  
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Patients on optimal medical therapy (OMT) were randomized to ivabradine (up-
titrated to a maximal dosage of 7.5 mg twice daily) or placebo. The median follow-up 
was 23 months. The primary composite outcome of cardiovascular death or HF 
hospitalisation in the Ivabradine group was 793 (24%) vs. 937 (29%) in the placebo 
group [hazard ratio 0.82 (p = 0.0001 95% CI 0.75 – 0.90)]. There was no difference in 
all-cause mortality. The absolute risk reduction (ARR) in the primary composite 
mortality–morbidity endpoint was 4.2%, equating to an NNT (for an average of 23 
months to postpone one event) of 24. Ivabradine also improved LV function and 
quality of life. 
Morbidity - mortality evaluation of the If inhibitor Ivabradine in patients with 
coronary disease and left ventricular dysfunction (BEAUTIFUL) trial (106) was a 
randomised placebo controlled trial that enrolled 10917 patients with coronary artery 
disease and an EF of less than 40%. Ivabradine did not improve cardiac outcomes 
but it was well tolerated.  
2.2.10 Device therapy in heart failure 
Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) (107) This trial 
hypothesised that in patients with prior myocardial infarction and reduced left 
ventricular function, the scarred myocardium would trigger malignant ventricular 
arrhythmias and sudden death.  
The MADIT II trial was designed to evaluate the potential survival benefit of a 
prophylactically implanted defibrillator in patients with prior myocardial infarction and a 
left ventricular ejection fraction of 30% or less. 1232 patients were recruited and 
randomly assigned in a 3:2 ratio to receive implantable defibrillator (n=742) or 
conventional therapy (n=490). The primary end point was all cause mortality. 
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During an average follow up period of 20 months, there were 105 (14.2%) deaths in 
the ICD group and 97 (19.8%) in the conventional group. Hazard ratio 0.69 (95% CI, 
0.51 to 0.93; p = 0.016). As compared to the conventional therapy, defibrillator 
therapy was associated with a 31% reduction in the risk of death. 
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (108)      
2521 patients with NYHA class 2 or 3 and a left ventricular EF of 35% or less were 
randomised to conventional therapy for HF (847 patients), conventional therapy plus 
amiodarone (845 patients), or conventional therapy plus a conservatively 
programmed shock only, single lead ICD (829 patients). Median follow up was 45.5 
months. There were 244 (29%) deaths in the conventional therapy group, 240 (28%) 
in the amiodarone group, and 182 (22%) in the ICD group. As compared to placebo 
amiodarone was associated with a similar risk of death (hazard ratio- 1.06, 97.5% CI, 
0.86 to 1.30; p = 0.53) and ICD therapy was associated with a decreased risk of 
death of 23% (hazard ratio 0.77; 97.5% CI, 0.62 to 0.96; p = 0.007) and an absolute 
reduction of 7% in mortality, equating to an NNT (for 45.5 months to postpone one 
death) of 14.   
Up to 50% patients with systolic HF have an intraventricular conduction defect such 
as left bundle branch block which results in abnormal electrical depolarisation and 
dyssynchrony. Prolonged QRS duration results in abnormal intraventricular septal 
motion, reduced contractility and diastolic filling time and prolonged duration of mitral 
regurgitation. This places the failing heart under considerable stress and mechanical 
disadvantage. In many patients this is reversed with complex cardiac pacing known 
as cardiac resynchronisation therapy (CRT). 
Multicentre In Sync Randomised Clinical Evaluation (MIRACLE) (109) 453 
patients with moderate to severe symptoms of HF associated with an ejection fraction 
of ≤ 35% and a QRS interval 130 msec or more were randomised to receive cardiac 
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resynchronisation (n = 228) or to a control group (n = 225) for six months while 
conventional therapy was maintained. The primary end point was NYHA functional 
class, quality of life, and distance walked in six minutes. 
As compared with the control group, patients assigned to the cardiac 
resynchronisation group experienced an improvement in the distance walked in six 
minutes (+39 vs. +10m, p = 0.005), functional class (p < 0.001), quality of life (-18.0 
vs. -9.0 points, p = 0.001) and ejection fraction (+4.6% vs. -0.2%, P < 0.001). Thus 
there was significant clinical improvement with cardiac resynchronisation for a 
subgroup of patients with QRS morphology.     
Comparison of Medical Therapy, Pacing and Defibrillation in heart failure 
(COMPANION) (110) 
1520 patients with advanced HF (NYHA 3 or 4), with QRS duration of at least 120 
msec or more, were assigned in a 1:2:2 ratios to OMT, optimal therapy plus cardiac 
resynchronisation therapy with pacemaker (CRT-P) or CRT with defibrillator (CRT-D). 
The primary end point was composite of death and all cause hospitalisation.  
The risk of the combined end point of death or hospitalisation for HF was reduced by 
34% in the pacemaker group (p < 0.002) and by 40% in the CRT-D group (p < 0.001 
for the comparison with the pharmacologic-therapy group). A pacemaker reduced the 
secondary end point of death from any cause by 24 % (p = 0.059), and a CRT-D 
reduced the risk by 36% (p = 0.003). In patients with advanced HR, and prolonged 
QRS interval, CRT decreased the combined risk of death from any cause or first 
hospitalisation and, when combined with an implantable defibrillator, significantly 
reduced mortality.  
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Cardiac Resynchronization- Heart Failure (CARE-HF) Study  (111) 
Patients with NYHA 3-4, HF symptoms due to LVSD and cardiac dyssynchrony, who 
were on standard pharmacological therapy, were randomly assigned to receive 
medical therapy alone or with cardiac resynchronisation. The primary end point was 
all cause mortality or unplanned hospitalisation. 
 A total of 813 patients were enrolled and followed up for a mean of 29 months.  
There were 82 (20%) deaths in the CRT group as compared to 120 (30%) in the 
medical therapy only group (Hazard ratio 0.64, 95% CI: 0.48 - 0.85, p=0.002). cardiac 
resynchronisation also reduced the Interventricular mechanical delay, the end systolic 
index, and the area of the mitral regurgitant jet. 
The authors concluded that CRT provided benefits in addition to the standard 
pharmacologic therapy by improving symptoms, quality of life and reduced 
complications and risk of death.   
NICE (112) in May 2007 recommended cardiac resynchronisation therapy with a 
pacing device as a treatment option for people with HF who are:-  
Currently experiencing NYHA class 3-4 symptoms; are in sinus rhythm with either 
QRS duration of 150 msec or longer, or with QRS duration of 120- 149 msec on ECG 
and mechanical dyssynchrony that is confirmed by echocardiography; have an EF of 
35% or less and on optimal medical therapy. 
Since the publication of the NICE guidance there have been further trials designed to 
evaluate expanded indications for CRT in HF patients. The major targets for 
expansion have been advanced HF with narrow QRS complex (<120msec) and 
patients with mild HF (NYHA class 1 and 2) 
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The REVERSE (113) and the MADIT-CRT (114) trials used hospitalisation for HF and 
all cause mortality as primary end points.  The REVERSE study included 610 patients 
with an EF less than of 40%, QRS duration of more than 120 ms, and NYHA class 1 
or 2. All patients were implanted with a CRT device with or without ICD and then were 
randomised to CRT-ON and CRT-OFF. In the European cohort, 19% of patients with 
CRT-ON had a worsened clinical composite response vs. 34% in CRT-OFF (p = 
0.01). In the MADIT-CRT study 17.2% of patients in the CRT-D group experienced 
death or a HF event, whereas 25.3% reached a primary end point in the ICD-only 
group (p < 0.001). 
Thus CRT improves quality of life, enhances reverse LV remodelling, and reduces HF 
hospitalisation regardless of the severity of symptoms. These changes are reflected in 
the European Society of Cardiology (ESC) guidelines for the diagnosis and treatment 
of acute and chronic HF 2012 (22). They recommended CRT for NYHA class 3-4 
patients in sinus rhythm with a QRS duration of 120ms, LBBB QRS morphology, and 
EF ≤ 35% with good functional status and expected to survive > 1 year.  CRT has 
also been recommended for NYHA class 2 patients in sinus rhythm on optimal 
medical therapy with a QRS duration of >130 sec, LBBB QRS morphology, and EF of 
≤30% who are expected to survive for > 1 year with good functional status.  
2.2.11 Current treatment guidelines for LV systolic dysfunction 
 According to the ESC HF guidelines (22) patients with systolic HF should receive, a 
beta blocker, an ACE inhibitor, and in most cases a diuretic which should be started 
soon after diagnosis. This is because ACEi have a positive remodelling effect on the 
LV and have been shown to improve survival and reduce rehospitalisation. Beta 
blockers also lead to a substantial improvement in EF and in certain subsets of 
patients their anti-ischemic and anti-arrhythmic effects may be beneficial. Angiotensin 
receptor blockers are recommended in patients unable to tolerate ACEi.    
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Mineralocorticoid / aldosterone receptor antagonists (spironolactone / eplerenone) are 
recommended for all patients with persisting symptoms despite treatment with an 
ACEi and beta blocker to reduce the risk of HF hospitalisation and the risk of 
premature death. 
Ivabradine should be considered for patients who are in sinus rhythm with a resting 
pulse rate > 70 bpm despite being on an ACEi and a beta blocker. Ivabradine should 
also be offered to patients who have a high resting pulse rate but are intolerant to 
beta blockers. This reduces the risk of hospitalisation. 
Digoxin may be considered for symptomatic patients in sinus rhythm intolerant of beta 
blockers and receiving ACE inhibitor and mineralocorticoid / aldosterone receptor 
antagonists. 
2.3 Literature review of heart failure with preserved ejection fraction 
(HFpEF) 
The EF is important not only for its prognostic importance but most clinical trials have 
used it for patient selection. As a result the vast majority of the major trials have 
selected patients with EF less than 35%. This has immensely benefited patients with 
HF and reduced EF (HF-REF); effective evidence exists for reducing both morbidity 
and mortality. 
An EF of > 50% is generally considered to be normal (22). Some of the trials have 
enrolled HF patients with an EF of more than 40-45% and no other cardiac 
abnormality especially of the systolic function. To describe this cohort of patients who 
have clinical signs and symptoms of HF but preserved or mildly reduced ejection 
fraction the term heart failure with preserved ejection fraction (HFpEF) was created. 
Assuming that patients with LV systolic dysfunction and HFpEF have the same 
underlying pathophysiological process, attempts have been made to extrapolate 
evidence from the HF trials with LV systolic dysfunction to the HFpEF patients.   
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This has led to the designing of few randomised trials with ACEi, ARBs and beta 
blockers in patients with HFpEF. 
Candesartan in Heart Failure: Assessment of reduction in Mortality and 
Morbidity (CHARM) – Preserved (115) trial enrolled 3023 patients with NYHA class 
2-4 and an EF of >40%. Primary outcome was cardiovascular death or admission to 
hospital for CHF with a median follow up of 36.6 months. There was no difference in 
the patients experiencing the primary outcome with 333 (22%) in the candesartan 
group and 366 (24%) in the placebo group [hazard ratio 0.89 (p = 0.118, 95% CI .077 
– 1.03)]. It only had moderate effect in reducing hospitalisation. 
The perindopril in elderly people with chronic heart failure (PEP-CHF) study 
(116) This trial randomized 850 HF patients who were at least 70 years of age, EF of 
45% or more, and evidence of diastolic dysfunction on echocardiography. The 
primary endpoint was a composite of all-cause mortality and HF related 
hospitalisation. Patients were followed up for minimum of one year and median follow 
up was 2.1 years. Poor recruitment, large numbers of withdrawals and the open label 
prescription of ACEi reduced the power of the study. There were 107 deaths in the 
perindopril group vs. 100 in the placebo group [hazard ratio = 0.92. (p = 0.545, 95% 
CI 0.70 – 1.21)]. Perindopril was associated with a reduction in heart failure 
hospitalisation as well as an improvement in symptoms and 6 minute walk test. 
However uncertainty remains about these conclusions as the study had insufficient 
power for its primary end point.  
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction (I -
PRESERVE) (117) was the third major trial to examine the role of the renin-
angiotensin-aldosterone system in HFpEF patients. This trial randomised 4128 
patients aged ≥ 60 years with NYHA class 2-4, and an EF of ≥45% to receive 
Irbesartan or placebo. The primary end point was all cause mortality and patients 
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were followed up for 4 years. 742 (36%) patients with irbesartan and 763 (37%) 
patients in the placebo group reached the primary end point [hazard ratio 0.95 (p = 
0.35, CI (0.86 – 1.05)].   
The SENIORS Study (Study of the Effects of Nebivolol Intervention on 
Outcomes and Rehospitalisation in Seniors with Heart Failure) (118) was the first 
major trial with beta blockers in patients with HFpEF. It randomised 2128 HF patients, 
70 years or older with a history of HF. 1359 (64%) had impaired EF≤35% and 752 
(36%) had an EF > 35%. There was no difference in the effect of Nebivolol vs. 
placebo between the reduced (EF ≤ 35%) [HR 0.86; 95%CI: 0.72-1.04, p=0.117) and 
preserved (EF> 35%) [HR 0.81; 95% CI: 0.63-1.04, p=0.720) groups.  
These trials have failed to show any significant benefit an ACEi / ARB or beta 
blockers. The present ESC guidelines (22) acknowledge that at present there are no 
proven treatments for HFpEF patients. The main emphasis of managing these 
patients is to use diuretics for HF symptoms, achieve adequate control of blood 
pressure and manage myocardial ischemia appropriately.   
2.4 Prognosis in heart failure 
Cardiovascular diseases are a leading cause of death in the population. Over the last 
few decades with improvement in diet, cholesterol, blood pressure control and early 
diagnosis and management of coronary heart disease there has been a decline in 
overall IHD mortality (119). Equally survival after the onset of HF has improved in 
recent decades. This improvement is likely a consequence of changes in relative 
contribution of hypertension, coronary heart disease, valve disease and also the 
increasing use of evidence based pharmacologic therapies (73). However the death 
rate remains high as ≈ 50% of people diagnosed with HF will die within 5 years. (120) 
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2.4.1 Prognosis in LVSD 
The prevalence of HF with LVSD is high and continues to increase. This is because 
ischemic heart disease, the major precursor of LVSD, is being managed more 
efficiently and effectively leading to an ageing population with a high prevalence of HF 
(121). In a population based study Redfield et al (122) found the prevalence of HF to 
be 2.2%, which increased from 0.7% in persons aged 45 years to 8.4% in those aged 
75 and over. Along with the increasing prevalence the incidence is also higher in the 
older population (123).  
Heart failure mortality is higher than that associated with the most other chronic 
conditions. One study comparing survival of heart failure and cancer patients (124) 
showed that , with the exception of the lung cancer, HF carried the poorest 5 year 
survival rate (approximately 25% for both sexes) compared to breast, large bowel, 
and ovarian cancer. In the Framingham heart study (125) the overall 1 year and 5 
year survival rates for men were 57% and 25%  and 64% and 38% for women. By 
comparison, 5 year survival for all cancers among men and women in the US during 
the same period was approximately 50%. 
Even in the population based study reports HF continues to have poor survival. In the 
ECHOES (Echocardiographic Heart of England Screening Study) (126) the 5 year 
survival rate in patients with HF and LVSD was 53%. In another community based 
study Danielle et al (127) found a 5 year survival rate of 45% in HF patients with 
reduced ejection fraction. In a population based study of incident (new) HF by Cowie 
et al (128) survival was found to be 81% at one month, 75% at three months, 70% at 
six months, 62% at 12 months, and 57% at 18 months. Thus one third of the new HF 
patients had died at one year.   
Patients who have LVSD and are on optimal medical therapy (an ACEi or an ARB, 
plus a beta blocker) continue to have poor prognosis. Allen-LaPointe and colleagues 
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(129) evaluated the survival pattern in patients who were on long term beta blockers 
and ACEi / ARBs for LVSD. After a mean follow up of 4.9 years 46.5% of the patients 
had died. Interestingly in this study they found that only beta blocker use in the long 
term provided survival benefit.   
Survival in the elderly population is equally dismal. In a study of elderly (>75 years) 
patients, the first year mortality was 28% (130) Thus in spite of the advances made in 
treating patients with LVSD prognosis remains poor. 
2.4.2 Prognosis in HFpEF 
There have been conflicting reports of mortality in patients with HFpEF. Initial studies 
of HFpEF epidemiology showed that the survival was similar to the LVSD patients. In 
a population based study Bhatia et al (131) found that the mortality rate in patients 
with reduced ejection was similar to the preserved ejection fraction patients. Owan 
and colleagues (132) studied all consecutive patients hospitalised with 
decompensated HF from 1987 through 2001. This study showed that there was no 
improvement in the HFpEF mortality trends over each successive 4 year time period.  
However, other studies have suggested that mortality in the HFpEF group was better 
than the LVSD patients. The Euro Heart Failure Survey (133) followed up patients for 
12 weeks. All-cause mortality although high in both groups was higher in patients with 
LVSD than those without (12% vs. 10% OR 1.35, 95% CI: 1.13-1.62). 
In a literature based meta analysis Somaratne et al (134) reviewed 24501 patients 
with HFpEF and LVSD. After a mean follow up of 47 months mortality in the HFpEF 
group was 32% compared to 40% in the LVSD group.  
A more recent meta analysis [Meta-analysis Global Group in Chronic Heart Failure 
(MAGGIC)] by Doughty et al (135) compared survival in patients with HFpEF and 
those with LVSD using individual patient data. They included 31 studies comprising 
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41972 patients. HFpEF was present in 10347 patients and LVSD in 31625. Patients 
with HFpEF had a lower mortality than the LVSD group [hazard ratio 0.68, 95 CI: 
0.64, 0.71). In an adjusted Cox proportional hazards model, patients with HFpEF had 
a lower risk of cardiovascular death than those with the LVSD [hazard ratio 0.55 (95% 
CI: 0.49, 0.61)]    
Despite the results of the studies mortality in both HFpEF and LVSD patients 
continues to be high.  
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Chapter 3 
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Heart Failure: Nationally and in the North East 
3.1 The North East region  
The North East of England is a mixed urban and rural region extending from the 
Scottish border to Yorkshire and from the Pennine Hills to the North Sea. It is the 
smallest of the English regions in both area and population.  As per the office of the 
national statistics, 2,607,000 people live in the north east region (136). 
Darlington is one of the five unitary authorities, along with Hartlepool, Middlesbrough, 
Redcar & Cleveland, and Stockton on Tees. It has a population of more than 100,000.  
Life expectancy in the North East is lower than the national average, reflecting higher 
levels of illness and of smoking. In county Durham, life expectancy is 76.9 years for 
men and 80.7 years for women, compared with England as a whole (78.3 and 82.3 
years respectively). In Darlington life expectancy at birth is 76.6 years for men and 
80.8 years for women, average for the north east region (137).   
In common with the national picture, Darlington has an ageing population. There are 
increasing numbers of elderly, fewer young people, with a fall in the number of 
working age adults (138). This changing demography will present a considerable 
challenge for the region.  
A detailed report on demographic change in the region (139) forecasts the population 
structure up to 2041, and states that  population change in the North East of England 
(due to outward migration, better life expectancy and falling fertility rates) is likely to 
be more pronounced than any other region in England. The implications of the ageing 
population are likely to be felt in almost every aspect of life.    
3.2 The burden of coronary heart disease: 
Coronary heart disease (CHD), stroke and related diseases are responsible for over 
one third of all deaths and a significant burden of ill health in the population (140).   
59 
 
In the last ten years death rates in the UK have been falling. Despite the decline in 
death rates from cardiovascular disease in the UK, rates are still high compared to 
other Western European countries, at 350 per 100,000 CHD deaths in men in 2003 
(140). 
Death rates from CHD are highest in Scotland and the North of England, lowest in the 
south of England (140). The North East has the highest premature death rate 
(158/100,000 in the under 75 years) from circulatory disease, in the country. This is 
significantly higher than that of England as a whole (128/100,000) and than the other 
government office regions (139). 
Within the region there are significant variations. Middlesbrough, Easington, and 
Wansbeck have significantly higher mortality rates from circulatory disease than the 
North East region as a whole. North Tyneside, Berwick upon Tweed, Castel, Morpeth 
and Tyndale have significantly lower mortality rates. For Darlington the age 
standardised death rates from CHD for men and women under the age of 75 years for 
years 2006/08 were 73.54/100,000, and 21.90/100,000 respectively (140). 
The overall health of the populations of County Durham and Darlington is poor 
compared with the national picture and inequalities in health remain persistent and 
pervasive 
The standardised mortality ratio (SMR) for all causes of death for County Durham is 
114 and for Darlington 111 (significantly worse than England). The SMR for all 
circulatory disease in county Durham was 117 and in Darlington 113 (2004-2006), 
significantly worse than England (141). 
In Darlington, over the last ten years, the death rate from all causes has gradually 
declined for both men and women, but remains worse than the England average. 
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Early deaths from heart disease and stroke have decreased markedly, especially over 
the last four years (142).  
3.3 Heart failure 
Heart failure occurs in around 1% of the adult population rising to 7% in those aged 
over 75 years and 15% for those aged 85 and over (143). Most cases of HF are due 
to coronary heart disease (approximately 70%) and most cases have or have had 
hypertension. Although there has been an overall decline in mortality from coronary 
heart disease (CHD), the number of patients with HF is increasing (144). This is due 
to an ageing population combined with improved survival rates after a heart attack in 
patients with left ventricular dysfunction. The majority of patients admitted to hospital 
are over 60 and fall within two age groups: 60–74 (24.6%) and over 75 (68.3%) (145). 
HF has a significant impact on patient outcomes. Survival rates are worse than for 
breast and prostate cancer, with annual mortality ranging from 10% to 50% 
depending on severity, and a high risk of sudden death. Newly diagnosed patients 
have a 40% risk of dying within a year of diagnosis (128). Patients with HF experience 
a poor quality of life, with over a third experiencing severe and prolonged depressive 
illness. 
Providing services to patients with HF costs the NHS an estimated £625 million per 
year (145). HF places a significant demand on hospital facilities and resources 
through emergency admissions and readmissions. Almost 90% of HF admissions are 
emergency admissions (146), and it accounts for 5% of all medical admissions. The 
readmission rate for HF has been estimated to be as high as 50% over 3 months 
(147-149).  
There is good evidence that appropriate diagnosis, treatment and ongoing support 
can improve quality of life and help reduce admissions and readmissions, morbidity 
and mortality. The National Service Framework (NSF) for Coronary Heart Disease 
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(CHD) (150) emphasises the need to develop a systematic approach to the diagnosis, 
investigation, treatment and ongoing support of people with heart failure throughout 
the NHS.  
In a national review of CHD services, the Healthcare Commission found that despite 
significant progress in implementing the NSF, progress in meeting the HF standards 
had been slow (151). 
A subsequent review of HF services in 2007 (152), showed that substantial progress 
had been made in the two years after the NSF review. However, there was still 
variation across the country in relation to the confirmation of diagnosis, access to 
evidence based treatment and HF specialist staff.  
The second piece of work (153) focused on the inpatient admission routes and used 
patients with HF to examine access to diagnostics and key treatment. The results 
indicated that many patients admitted to acute hospitals in England, Wales and 
Northern Ireland are not managed fully in accordance with international evidence-
based guidelines. Only a minority of patients with HF are seen, or followed up, by a 
specialist service. Whilst most trusts (86.5%) have a lead consultant for the care of 
patients with HF, only 22.3% of patients admitted to hospital with HF were referred to 
the lead clinician or a cardiologist (145).  
Access to specialist HF teams was also shown to be extremely variable with averages 
for trusts varying from 0% to 74%. There are also differences in access to evidence-
based clinical treatment between different groups of patients. Women appear to be 
less well managed against recommended guidelines and are less likely to be 
prescribed anti-failure medication, except diuretics, on discharge. This may reflect 
differences in age (women are older) and the greater prevalence of HF with a 
preserved ejection fraction, for which guidelines provide little advice on treatment 
(145).  
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2008-2009 QOF data for Darlington PCT has 846 patients on the HF register from a 
population of 105402 giving a prevalence rate of 0.8%. Since April 2006 there were 
218 patients with echo or specialist proven diagnosis and 397 of the eligible 430 
(92.3%) on an ACE inhibitor (154). 
3.4 Access to Health care 
NHS Darlington is one of the 12 primary care trusts (PCTs) which are managed by 
the NHS Northeast - the Strategic Health Authority for the North East. Working in 
partnership with NHS County Durham, NHS Darlington is responsible for 
commissioning health service on behalf of around 600,000 people living in County 
Durham and Darlington. Around 100,000 of these live in Darlington. 
There are 11 GP practices in Darlington providing primary care services.  Darlington 
Memorial Hospital at Darlington provides secondary level care. 
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Models for providing heart failure service 
Traditionally HF patients have been managed in the community by general 
practitioners. In the UK , where the general practitioner (GP)  act as the gate keeper 
to health care, not all patients are referred on to specialist, or for secondary care 
assessment (155). 
Previous studies have highlighted the fact that in the community less than 50% 
patients have HF correctly diagnosed, as compared to a standard of specialist clinical 
assessment based on a clinical scoring system (156). In another study only 53% of 
the patients receiving loop diuretics had left ventricular systolic dysfunction on their 
echocardiogram. This was more so in female patients (157). These studies have 
highlighted that left ventricular systolic dysfunction is difficult to diagnose solely on the 
basis of signs and symptoms in the community, resulting in frequent misdiagnosis and 
inappropriate management (158). In the National Service Framework (NSF) for CHD 
published in 2000, it stated that “doctors should arrange for people with suspected HF 
appropriate investigations (electrocardiography, echocardiography) to confirm or 
refute the diagnosis of HF”. The authors detail various service models, whereby 
echocardiography by trained operators with competent interpretation could be made 
available to suspected HF patients by one of the following means: 
 Open access echocardiography from primary care 
 Specialist heart failure clinic 
 Cardiology out- patients 
4.1 Open access echocardiography 
The simplest confirmation of left ventricular systolic dysfunction is provided by the 
echocardiogram, which remains the gold standard. Previously access to 
65 
 
echocardiography had not been directly available to the general practitioners. With 
the advent of open access echocardiography (OAE), defined as echocardiography 
requested by a GP without prior clinical assessment by a cardiologist (159), more and 
more centres have been providing this service to their local GPs (160). The rationale 
is that HF is a common condition, especially affecting the elderly, carrying a poor 
prognosis but which can be effectively treated with ACEi, reducing mortality by 23% 
(161).  The estimated annual economic burden of treating HF patients has been 
estimated at £360 million on hospital services (162). Timely diagnosis and 
management of HF has the potential to reduce the burden on hospital services.  
Francis et al (9) reviewed 259 OAE referrals with suspected HF over five months. Of 
the 119 patients being treated for suspected HF, only 26% (31/119) of these had 
serious left ventricular systolic dysfunction. Twelve percent were inappropriate 
referrals and 69% had their medications changed. This service was not truly an OAE 
service as the echocardiograms were reported by a cardiologist who also 
recommended further management regarding medications and other investigations as 
appropriate.  How many of the recommendations made were implemented was not 
known. Also only 17% (93 / 550) of the GPs took part in the referral process 
suggesting low uptake for the service. 
In Darlington, Murphy and colleagues (163) reported an OAE service made available 
to five GP practices covering a population of 48,000.  In 23 months 250 patients were 
referred. Forty nine (20%) were found to have significant left ventricular systolic 
dysfunction (EF < 40%). Twenty (8%) were found to have significant valve disease. 
Echo reports were sent back to the GPs with no specific recommendations regarding 
further management other than current NICE guidelines.  
Case records of these patients were reviewed at the practices two months after the 
OAE. ACE inhibitor treatment had been started in 78% (38 / 49) of patient with 
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significant left ventricular systolic dysfunction. Of the patients with haemodynamically 
significant valvular disease 14 of the 20 had been referred to the hospital for further 
cardiology opinion. Thus appropriate management decision had been reached in the 
majority of the patients by providing GPs with the echo report and broad management 
guidelines (as published by NICE). 
Similar UK experience was reported from Newport and Edinburgh in a systemic 
review of OAE observational studies reported by Khunti (10). 
Open access services are less well established in continental Europe (164). An open 
access echocardiography service was started in the Netherlands in 2002. They 
looked at 625 consecutive patients from Dec 2002 to March 2007. GPs could refer 
patients with dyspnoea, heart murmurs or peripheral oedema. Results of the echo 
were returned to the GPs with recommendation on management of the patients.  OAE 
was popular with GPs as 81% utilised the service and the majority of the patients 
were referred appropriately.  
Thus it seems that OAE is well received by the general practitioners and utilised in an 
appropriate way. Also initial fears that GPs would use the service indiscriminately and 
cause an unmanageable burden on the  echocardiographic services (165), have not 
proved true (166).  
For the future OAE will continue to be available to the GPs in various forms as it has 
proved to be an efficient way of investigating patients with suspected HF, and also it 
reduces the burden on the outpatient service in hospital.  
However, as shown in Chapter 3, HF management has become increasingly complex. 
In a qualitative study published in 2003, Fuat et al explored barriers to the diagnosis 
and management of HF in primary care. Clinical uncertainty and the complexity of 
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care were major issues and they have supported the establishment of specialist heart 
failure services.   
4.2 Variation among HF clinics 
There is lack of uniformity in the published data to describe which patients are offered 
treatment and follow up in the HF clinics. Also there is great variability in the setup of 
these clinics. Patients are either referred from primary care or they are followed up in 
the community after discharge from the hospital.  The aims of and the interventions 
provided by these clinics and programmes are also quite variable. In some clinics 
patients are not only investigated and started on evidence based management but 
also followed up by a nurse to titrate up their medication either in the community or at 
the hospital. Others provide information, education and self care for the HF patients. 
Most of the studies aimed to assess the impact of these interventions on hospital 
readmissions but very few reported impact on survival.  
Broadly these can be categorised as nurse led disease management programmes, 
primarily community based intervention programmes, and the specialist HF clinics in 
the hospital. 
4.2.1 Nurse led intervention programmes  
One of the earliest studies in 1997 by Rich et al (167) examined the effect of nurse 
led multidisciplinary intervention in the community on patients 70 years or more, 
discharged from the hospital after being treated for congestive HF. Primary outcome 
for survival at 90 days without admission was achieved in 91 of 142 patients in the 
treatment group as compared with 75 of the 140 patients in the control group who 
received conventional care (p = 0.09). Also, the number of readmissions in the 
intervention group was lower than that of the control group (risk ratio - 0.56; p = 0.02).  
In another study Fonarow and colleagues (168) over a 3 year period provided  
adjustment to medications and intensive patient education to 214 patients with 
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advanced HF (NYHA 3-4), accepted for heart transplant after discharge. 
Comprehensive HF management led to improved functional status and an 85% 
decrease in the hospital admission rate for patients with advanced HF. 
In another study using a MULTIFIT model that emphasises the development of a 
cognitive, executive, and organisational infrastructure to promote optimal chronic 
disease management, West et al (169) evaluated a physician supervised, nurse 
mediated, home based system for HF, implementing clinical guidelines for 
pharmacologic and dietary therapy. Fifty one patients with a clinical diagnosis of HF 
were followed for 138 days by nurse managers for promotion of optimal doses of ACE 
inhibitor or isosorbide dinatrate / hydralazine therapy, promotion of daily sodium 
intake of < 2 g; and surveillance for symptoms, signs, and laboratory evidence of 
worsening HF.   Compared with the 6 month before enrolment and normalised for 
variable follow up, the frequency of general medical and cardiology visits declined by 
23% and 31% respectively (both p < 0.03). Hospitalisation rates for HF and all causes 
declined by 87% and 74% respectively (p = 0.001), compared to a year before. 
In another study Ekman et al (170) examined the feasibility of a nurse monitored, out - 
patient care programme for patients hospitalised with chronic HF.  Of the 158 patients 
who met the eligibility criteria 79 patients were randomised to structured care. There 
was no difference between the two groups regarding the number of hospitalisations 
and the days spent in the hospital.  This study did not provide evidence of benefit of 
the nurse led HF programme with advanced heart failure. In another  study 
Strömberg and colleagues (171) randomised 106 patients to either follow up at 
the nurse led HF clinic or to usual care. After 12 months there were fewer 
events (death or admission) in the intervention group compared to the control 
group (29 vs. 40, p=0.03). Overall most disease management programmes found 
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beneficial effects on patient readmission to hospital and some showed improved 
survival (171-177) 
4.3 Specialist Heart Failure Clinics  
Although open access echocardiography service can be provided to the primary care 
physicians, echocardiography can be difficult to do and even more difficult to interpret, 
and primary care physicians may have difficulty in understanding the technical 
reports. Even when OAE is provided, HF patients may not be optimally treated as per 
clinical guidelines (7). For some patients with suspected heart failure a shared plan 
between the cardiologist and the GP may be warranted (160). Sensing the need for 
an integrated diagnostic and therapeutic service it was proposed to set up 
multidisciplinary HF clinics (178).This has led to the development of specialist HF 
clinics in secondary care hospitals. 
The set up and design of the specialist HF clinics reported in the literature varies 
widely.  Some clinics accept patients who have been discharged from hospital (167, 
171) whereas in other patients are referred by GPs or other hospital physicians.  
One of the earliest reports on specialist HF clinics was by Fox and colleagues (155). 
They established a “walk in” HF clinic in 1996 and reported the results for the first 15 
months. The clinic ran from 1200 to 1600 hrs each weekday. A doctor took the clinical 
history, examined the patient and then performed echocardiography. Patients had 
blood samples taken and were informed of the clinical diagnosis, management and 
follow up plans. An ACEi was prescribed in patients diagnosed with HF. Three 
hundred and eighty three patients were seen in the clinic with a median age of 75 
years, and 44% were males. Though 101 (26%) were diagnosed as having definite 
HF, only 78 had systolic dysfunction. Six had primary valve disease and 17 had 
normal systolic function. There was very little further follow up of these patients by the 
clinic after diagnosis.  
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In Sweden HF clinics are run by HF nurses. In a descriptive survey of HF services in 
Sweden 66% (57/86) of hospitals had nurse led HF clinics (175). The clinics provide 
patient education, telephone counselling and drug titration apart from follow up after 
hospitalisation. In 40 of the 57 hospitals nurses also made protocol led changes to 
medications of these patients. These nurse led HF clinics only see patients diagnosed 
and treated for HF from the hospital. There is no mention about the role of the 
cardiologist in clinic.   
 A HF clinic based upon an integrated approach to diagnosis and therapeutic 
management of HF patients was reported from Copenhagen by Galatius et al (179). 
The service is provided by physicians with training in cardiology, who take the history, 
conduct the physical examination, and perform transthoracic echocardiography in the 
diagnostic unit. This is an open access service to patients with suspected HF from 
primary and secondary care. Patients confirmed as having LVSD by 
echocardiography (EF<45%) are referred to the therapeutic clinic for optimisation of 
medical therapy. Over 21 months 460 patients were seen in the clinic. Three hundred 
and twenty patients (70%) were found to have clinical evidence of HF. Of these 283 
(88%) had LVSD.   LVSD patients had a mean age of 73 years, and 70% were male. 
At base line 55% patients were on ACEi therapy and 29% were taking beta-blockers. 
The authors observed a 23% decline of HF related hospital admissions during the 21 
months of study period.  
This study provides a description of the HF clinic but no information is given of the 
impact of the HF clinic on the increase in the number of prescription for ACEi therapy 
or beta-blockers. Also there are no published data on the outcome of these patients.   
Another descriptive study of the specialist HF clinic in Birmingham is by Shah et al 
(180). GPs referred patients if they clinically suspected HF. This was a weekly 
diagnostic clinic but later on patients were also followed up for treatment optimisation. 
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Over eight years 963 patients were seen. All patients had their history taken, and 
physical examination, ECG, chest X-ray and echocardiography performed. Only 30% 
of the patients were diagnosed with LVSD (EF < 55%). At the time of clinic review 
only 21% patients were taking an ACEi and 10% were on a beta blocker. A further 
16% were initiated on an ACEi and then up-titrated, 15% on a beta blocker after being 
diagnosed with LVSD.   
Azevedo and colleagues (181) assessed 339 patients discharged after being admitted 
for decompensated HF. Patients were either seen in the HF clinic (n = 157) or 
discharged back to their primary care physicians (n = 182), in non random fashion. 
The HF clinic was run by cardiology specialists. Patients in the HF clinic group were 
older (69 yrs vs. 65 yrs), and had more males (60% vs. 45%) than the usual care 
group whereas there were more patients with atrial fibrillation in the usual care group 
(46% vs. 30%). Patients seen in the HF clinic had their medications adjusted and 93% 
were on an ACE inhibitor although only 37% received a beta blocker. After a mean 
follow up of 373 ± 196 days there were significantly fewer deaths  in the HF clinic 
group 39 (25%) as compared to 63 (35%) in the GP group (adjusted hazard ratio 
0.52; 95% CI 0.34 – 0.81).  
This study provided some data on the long term outcome of HF patients discharged 
after hospital. Although a high proportion of the patients seen in the HF clinic were on 
an ACEi, very little is known about the management of the patients discharged back 
to the primary care other than the mortality data. Also the study was not randomised 
which limits any meaningful conclusions about its applicability to the wider patient 
population. 
Thus there is marked variability in the set up, design, referral criteria, and staffing of 
and intervention provided by the specialist HF clinics reported in the literature. 
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4.4 History of Heart Failure clinic in Darlington 
The one-stop diagnostic HF clinic was established in January 2002 as a joint venture 
between Darlington PCT and South Durham NHS Trust, and the British Heart 
Foundation which funded a specialist nurse. Whilst there have been other reports of 
rapid access clinics in the UK (155, 180, 182, 183), this was probably the first GP 
specialist led diagnostic and management clinic.  
The one-stop HF clinic is run by a GP specialist and a HF nurse. This service is 
based upon local HF guidelines and protocols. The weekly clinic runs in parallel to a 
consultant cardiologist’s clinic and is sited within the general medical outpatient 
department of Darlington Memorial Hospital. The clinic template allows for six new 
and five follow up patients to be seen.   
4.4.1 Rational for one stop diagnostic heart failure clinic 
(This has been discussed in detail by Dr A Fuat in his PhD thesis “The Diagnosis and 
Management of heart failure across primary and secondary care”, 2006 Durham 
University) (184). Much of the data in this section is reproduced from Dr Fuat’s thesis 
work with his consent. 
Even when facilities for the accurate diagnosis of HF exist (open-access or consultant 
screened echocardiography) the initiation of evidence based treatment remains an 
issue in primary care (7, 185, 186). For low rates of usage of ACEi, beta-blockers and 
spironolactone, the plausible causes can be related to wide-ranging factors, e.g., 
difficulties in interpretation of echocardiography results, lack of awareness of 
treatment regimens, concerns with possible side effects, and workload pressures (7, 
187). Moreover, target doses of these agents are often not achieved (185, 188-191).  
The rate of “over-diagnosis” remains around 40% (192, 193), with less than 40% of 
patients receiving an ACEi (188). 
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Fuat’s study pointed out that there needs to be equity of access for patients with heart 
failure to the most effective and cost-effective treatment available. General 
Practitioners should be in a position to be able to offer or arrange optimal 
management. Evidence based guidelines (194-197) have established the need for an 
accurate diagnosis of HF, essentially with echocardiography, but doubts remain about 
the effective use of echocardiography services, and many secondary care clinicians 
favour referral to hospital (11, 198).  
There is increasing pressure within the NHS towards the implementation of evidence-
based clinical guidelines (194-197). PCTs need to collaborate with secondary care for 
the provision of services. The advent of clinical governance is a further imperative 
towards streamlining the provision of care in this field. 
The National Service Framework for Coronary Heart Disease (NSF for CHD)  (178) 
recommendations include echocardiography for all patients with suspected heart 
failure, the development of a consistent and systematic approach to identify patients 
with HF or at high risk of developing it, and delivery of appropriate care to those 
diagnosed with HF, together with regular review.  
Hence, possible factors for change in the management of HF due to LVSD include the 
extensive evidence base and the various national guidelines (197, 199, 200). In 
addition to the NSF for CHD (201), the new General Medical Services contract (202) 
and the CHD and Primary Care Collaborative (including MINAP, the Myocardial 
Infarction National Audit Project) are policy-based strategies that are helping to close 
the evidence-treatment gap.       
The NSF for CHD proposes development of newer models of care for diagnosis and 
management of LVSD (201). Coinciding with a government call for more GPs with a 
specialist interest, a GP specialist led one-stop diagnostic clinic was established, to 
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enable expedient diagnosis and appropriate initiation of evidence-based therapy if 
LVSD is confirmed.  
The primary aim of the service was to identify patients with LVSD and offer evidence 
based treatment. Given the debate concerning the existence of HFpEF, the lack of 
accepted diagnostic criteria, and the absence of treatments, the clinicians involved 
generally avoided making the diagnosis of HFpEF. 
4.4.2 Aims of the heart failure clinic service:  
The aims of the heart failure diagnosis clinic are: 
 To provide rapid access to diagnostic facilities for patients with HF symptoms 
 To provide a consistent approach to the diagnosis of HF 
 To maximise evidence-based treatment for patients with confirmed LVSD. 
4.5 Clinic structure  
4.5.1 Referral criteria 
Patients access the clinic via: 
 GP referral for patients with suspected HF 
 GP or HF specialist nurse may refer patients with confirmed HF who require 
symptomatic assessment 
 Referral from other physicians for assessing patient’s symptoms. 
For GP referrals, there is a standard one-page referral form.  Referral forms for the 
HF diagnostic clinic are received and processed by the central appointments patient 
office; appointment letters are then sent via post. All patients are sent an information 
leaflet regarding the diagnostic clinic and which has been produced by the HF team. 
The GP is asked to undertake baseline blood tests, ECG and chest X-ray. At the clinic 
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all patients have clinical assessment, relevant blood tests, chest X-ray (if not done by 
the GP), ECG, echocardiography and selected patients undergo pulmonary function 
tests. British Society of Echocardiography accredited cardiac physiologists perform 
the echocardiogram. Left ventricular function is assessed by “eyeball” assessment, 
with Simpson’s rule and wall motion index measurements when possible.  The patient 
brings the report back to the clinic in a sealed envelope. The cardio-respiratory 
laboratory provides six dedicated echocardiography slots for use by the clinic.  
Patients in whom HF or LVSD is not confirmed are discharged back to the GP or, if 
necessary, to another physician (e.g. respiratory physician or general cardiologist). If 
LVSD is confirmed, a management plan is formulated which includes patient 
education and initiation of evidence-based treatment.  
4.6 Staffing of the clinic 
4.6.1 Role of the GP specialist in cardiology 
The GP specialist in cardiology provides the main clinical leadership to the HF team.   
The role of the GP specialist includes: 
 Clinical assessment, and organise baseline investigations (blood test, chest X-
ray, ECG and echocardiogram)  of all referred patients 
 Establish a working diagnosis, and formulate a management plan for patients 
with confirmed LVSD. 
 Refer to other specialist services as appropriate. 
 Decision to discharge or follow up patients in the clinic 
4.6.2 Role of the specialist heart failure and auxiliary nurse 
The specialist nurses see patients in clinic after they have received the appropriate 
diagnostic tests and HF is confirmed by the medical practitioner at the clinic. 
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The specialist and auxiliary nurses provide the link between the diagnosing clinician, 
the patient and the organisation of community based care. They collate the results, 
counsel the patients and carers and ensure follow-up in the clinic, GP or domiciliary 
setting. They are also responsible for effecting the day-to-day management of the HF 
patient in relation to specific items such as daily weighing to evaluate fluid overload 
and exercise regimens.  
4.6.3 Role of the consultant cardiologist 
The main roles include: 
 Overall clinical responsibility for patient care and 
 Advice to GP specialist and specialist nurses  
4.6.4 Heart failure review clinic 
Workload pressure of follow up patients, especially those needing beta-blocker 
titration, led to the development of a nurse led review clinic. The review clinic provides 
an integrated and consistent approach to the optimisation of medications. This nurse 
led review clinic runs parallel the HF clinic, who can seek advice from a clinician if 
need be.  
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Chapter 5 
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Methodology  
5.1 Introduction  
The interest for the present study arose from the work I had previously undertaken for 
a project that had involved collection of data from the HF clinic at Darlington Memorial 
Hospital during 2008.  
Patients were referred to this clinic if their doctor suspected HF. At the clinic, all 
patients had a clinical assessment, relevant blood tests, a chest X-ray, an 
electrocardiogram (ECG), and an echocardiogram. A British Society of 
Echocardiography accredited cardiac physiologist performed the echocardiogram. 
Left ventricular function was assessed by “eyeball” assessment, with Simpson’s rule 
and wall motion index measurement when possible. 
Based on the results of the echocardiogram and other investigations, patients were 
given a diagnosis of HF due to left ventricular systolic dysfunction (LVSD) or “No HF”. 
Patients who were confirmed as having LVSD were then started on evidence-based 
treatment and followed up in the HF clinic until they were titrated to the maximal 
tolerated doses of the medications. Patients in whom LVSD was not confirmed were 
discharged back to the care of their GPs, or if necessary, to another physician.    
This study had looked at the patients who had been referred to the clinic from its 
inception in Jan 2002 up to Dec 2007. Data were collected on the total number of 
patients seen in the clinic in these six years; how many had been diagnosed with 
LVSD on the basis of an echocardiogram; what proportion were on evidence based 
treatment (ACEi, beta blockers); and how many had died in this group. 
Of the 1041 new patients who were seen in the HF clinic from Jan 2002-Dec 2007, 
only 270 had been diagnosed as having HF based on reduced ejection fraction. 
Seven hundred and seventy one patients were diagnosed not to have HF based on 
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the echocardiogram result and were discharged back to their own doctors or referred 
to other specialists to find other cause for their breathlessness. 
I was interested to know what had happened to the 771 patients suspected to have 
HF by their doctors, but where the echocardiogram result had shown them to have 
normal ejection fraction. How many of those discharged might have had HF with 
preserved ejection fraction (HFpEF)? Was the HFpEF group different from the LVSD 
group in terms of age, gender, co morbidities, management, hospitalisation and 
outcome? Did the HFpEF group fare differently than the LVSD group? And what was 
the cause of death in patients of both groups; did they die of HF or some other 
cause? 
The present study was therefore designed as a more comprehensive follow up of the 
whole cohort referred to HF clinic. In addition to the long-term outcome of patients 
diagnosed with HF due to LVSD, I also categorised those with preserved systolic 
function (in to HFpEF and non-HF) and obtained long term follow up of the whole 
cohort.  
5.2 Development of the study protocol 
Patients who attended the HF clinic from Jan 2002 to Dec 2007 were identified from 
the hospital database electronic system. From this a master list was prepared. The 
master list was initially divided into two groups of LVSD and “others”. The “others” list 
was separated into HFpEF and non HF groups (the operational definitions for these 
groups will be discussed later). These three groups were each given a unique 
alphanumeric code. The unique alphanumeric code began with the group identifier 
“LVSD”, “HFpEF”, and “OT” for each group. The beginning of the unique number code 
was “2066” for the LVSD and HFpEF and the non HF or “other” group was identified 
using “OT” followed by number “2067”.         
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The unique alphanumeric code for the study patients enabled the separation of the 
master list and the lists based on the unique study codes, which were used for data 
collection. The master list linking patients to the unique study code was in an 
electronic format, kept on an encrypted and password protected Trust computer with 
limited access in the research office. This study was conducted in two phases. 
In an addition to the initial protocol we added Phase 3 to the study whilst completing 
the phase 1. This was for obtaining data from the medical research information 
service (MRIS). Details for this are presented below. For Phase 3 we obtained ethical 
committee approval separately.  
5.2.1 Phase 1 (Hospital Phase)  
The case notes of all the patients who were referred to the one stop diagnostic HF 
clinic during the period (Jan 2002-Dec 2007) were reviewed, and subjects who were 
clinically found to have signs and symptoms of HF were identified. This cohort of 
patients were further studied and categorised, based on echocardiography results into 
two groups 
 Patients having impaired systolic contraction and thus having a reduced 
ejection fraction of their left ventricle (LVSD) 
 Patients with normal systolic function and thus having preserved ejection 
fraction (HFpEF). 
The case notes of these two groups of patients were studied in detail regarding their 
initial presentation, clinical examination, electrocardiogram, and chest X - ray report. 
These were then correlated with the findings and the report of the echocardiogram. 
Once the diagnosis of LVSD was established, the uptake of evidence based 
medications (beta blockers, ACEis, and spironolactone), and their titration up to the 
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target dose at subsequent follow up visits in the HF clinic was ascertained for each 
patient. 
5.2.2 Phase 2 (General practice phase) 
This part of the study was conducted at the GP surgery of the identified patients. This 
involved accessing patient data held at the practice to answer the following questions: 
 Was HF treatment continued after discharge from the hospital clinic? 
 For how long were the HF medications continued? 
 Why and by whom were medications changed or discontinued? (Hospital /GP) 
 Current medications and their doses 
 If the patients were admitted to the hospital, then for how long and how many 
times? 
 Any other co morbidities developed since discharge from the HF clinic 
 Vital status and cause of mortality? 
5.2.3 Phase 3 (Medical Research Information Service phase) 
At the end of Phase 1 of the study, there was an addition to the study protocol: Phase 
3 was added. This part of the study was to obtain mortality data from the Medical 
Research Information Service (MRIS). MRIS is an organisation forming part of the 
NHS information service. MRIS holds data for patient events (death) and the cause of 
death as put on the death certificates of these patients.  
The initial protocol did not specifically have ethics committee approval for obtaining 
data from the MRIS. For this we went back to the ethics committee and obtained 
Chairman’s approval. MRIS was provided with a list of study subjects in the three 
groups.  
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5.3 Ethics Committee Approval  
As this study included National Health Service (NHS) staff and patients, study 
approval was obtained from my NHS trust (County Durham & Darlington Foundation 
NHS Trust) research governance committee (Appendix 1). They suggested that a 
consultant be made the chief investigator (Professor J.J. Murphy), who would also act 
as the data custodian. This change was duly made. 
Then I obtained ethical approval from my host university, Durham University 
(Appendix 2). Finally, the study was submitted to the National Research Ethics 
Service (Newcastle & North Tyneside 2 Research Ethics Committee) (Appendix 3). 
Two ethical issues were raised during the review. The first was as to whether this 
study would classify as research or audit.    
There were three questions in this study: 
Are we treating patients with heart failure in accordance with evidence based national 
guidelines? To answer this question we were reviewing the current clinical practice at 
Darlington Memorial Hospital, against a set standard of evidence based treatment 
guidelines, and this would technically constitute an audit (203). 
Does treating HF according to evidence based guidelines have an impact on patient 
outcomes in terms of mortality and morbidity? There is a paucity of data on the long 
term benefit of evidence based treatment in HF patients, even more so in the “real 
world”. By answering this question we hoped to generate new knowledge (203), 
outside the selective recruitment of large multicentre controlled trials. 
What is the outcome of patients with HF and preserved left ventricular systolic 
function (HFpEF) or diastolic HF?  Again, very little is known about the natural history 
of HFpEF patients. Is the natural history of HFpEF and LVSD groups similar or 
different? What do these patients die from? We hoped to generate new knowledge by 
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answering the above question with regard to the diagnosis, management and 
outcome of HFpEF patients and this would constitute research (203). 
Thus, the study would combine features of both audit and research. 
The second ethical issue raised was access to patient records without consent of the 
patient.  
The database, which was developed from the hospital records, identified these 
patients only by their unique alphanumeric code. This part of the project was 
effectively an audit. As Prof Murphy and I were both part of the clinical care team 
looking after these patients, for this part of the project we did not require patient 
consent. 
a) Phase 2 of the study provided information on subsequent management and 
outcome following discharge back to primary care. The research team anticipated 
ethical issues regarding access to GP patient records so we contacted the National 
Information Governance Board (NIGB) for clarification.  
General practices were given a list of the patients registered with their practices. This 
included the patient’s name, date of birth and the unique alphanumeric code for the 
study, drawn from the hospital master list. The practices were asked to provide a 
computer printout with information regarding medication, doses, co-morbidities, 
number of hospitalisations, and outcome in the form of mortality.  
The practices printed out data sheets without patient identifiable data by selecting the 
page to be printed from a menu of print options. 
These data were entered on to the research database after which any link with the 
master list was broken. There was no patient identifiable information on the database. 
I quote the specific guidance that we had from NIGB in this regard: 
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“As long as no identifiable information will be available to the researcher at the GP 
surgery and the printouts only contain anonymised information along with the study 
number, i.e. not name, demographic data, NHS number, date of birth or death etc, 
and the GP information will remain pseudo-anonymised then this is fine”. 
b) The issue of obtaining patient consent was debated at length within the research 
team.  
As Phase 1 of the study involved auditing clinical practice at Darlington Memorial 
Hospital, this part of the study was discussed with the trust Caldecott Guardian, who 
gave his approval for the study process. Thus, for accessing patient data from the 
hospital information system and notes, individual patient consent was not required. 
For phase 2, the issue of consent was debated within the research team. This was a 
retrospective review of an opportunistic cohort of patients who attended the heart 
failure clinic from 2002 - 2007. Obtaining consent would be fraught with difficulties 
and in many cases impossible. If we assumed 50% mortality in 5 years, there would 
be a large number of patients in this cohort who would no longer be alive or who 
might have lost capacity to consent. Guidance was sought from the NIGB in this 
regard and their advice was clear: as long the researcher has no access to any 
patient identifiable data (such as name, demographic data, NHS number, date of birth 
or death etc), access to pseudo-anonymised data from the general practice did not 
require individual patient consent. 
5.4 The sample size calculation 
Patients with HF fell in two groups, those with LVSD and those with HFpEF. The 
principal long term outcome was mortality. Based upon the published series, I 
estimated that those with LVSD were likely to have a 5-year mortality of 50% (204). 
The research team decided that an absolute difference in mortality between the two 
groups at 5 years of 15% (i.e. a 3% annual difference) would be clinically significant. 
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Two hundred and forty patients in each group (LVSD and HFpEF) would provide a 
90% probability of detecting an absolute difference of 15% (50% to 35% or 65%) in 
mortality over an average follow-up period of 5 years (i.e. 3% annual difference), 
using two tailed statistics at the 5% significance level.  
5.5 The database    
Having previously worked and collected data on Microsoft Office Excel 2007, I used 
the same software to set up data for this project. Three separate excel spreadsheets 
were generated and titled LVSD, HFpEF, and Others. Auto fill function was used to 
generate the unique alpha numeric code to identify the study subjects in all three 
sheets. The unique alpha numeric code linked the data set to the master list. Data 
sheets were set up using a hospital computer that was pass-word protected and 
stored data in an encrypted form.  
The following broad categories (in bold) were used to record data for each patient on 
the data sheet. Also some of the subheadings in these categories are presented here.   
Table 5.5 Headings used for data collection 
First review in the clinic 
Alpha numeric code 
Patient demographics 
Past medical history 
Symptoms on presentation 
Clinical assessment on presentation 
Investigation results- CXR, ECG, ECHO, blood tests 
Medications on presentation 
Presentation and clinical assessment 
1st admission to the hospital 
Results of investigation 
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Medications and their doses on admission 
Medication changed in hospital 
Discharge diagnosis 
No of total admission and days spent in hospital 
Date of start and stop of medications and dose achieved 
Date, place and cause of death 
BNP and NTproBNP value (where available) 
For each patient this resulted in 203 data items under which data were collected. Data 
items were built over a period of few weeks through an iterative process.  
Data were entered by the researcher from the case notes. This was done for the 
LVSD group first followed by the HFpEF group. For quality assurance and rule out 
systematic errors, double data entry was done for 10% of the patients. This was done 
by a research nurse (G Brennan). She would randomly select and order case notes 
for the patients who had already been reviewed by the researcher. Double data entry 
by the research nurse was performed using the same headings as the researcher and 
data were entered using the similar alphanumeric code as used by the researcher on 
MS excel spreadsheet. The research nurse checked these entries against the original 
data sheet to check for any inconsistencies. In a few of the records, minor variations 
e.g. data missed was found in some the data entries. These were corrected by 
referring to the case notes. No systematic errors were discovered. 
5.6 Transfer of data to SPSS  
Data were collected on the Microsoft Excel spread sheet. For the purpose of the 
analysis data were transferred to SPSS statistics 19.0.   
5.7 Case records 
The research nurse was provided with a printout of the hospital numbers and date of 
birth of the patients. She requested the case notes of the patients on the list from the 
87 
 
records library in the hospital. This was done using the hospital tracking system. The 
request tracked these records to be delivered to the cardiac research office at 
Darlington Memorial Hospital. The records were requested in batches of ten. 
Delivered case notes were stored in a safe cabinet in the research office with limited 
access. 
The next sets of notes were only requested once the data from the initial sets had 
been entered on the database. This usually resulted in requesting notes once a week 
and coincided with the working day of the research nurse. Once the data had been 
entered on the database, the case records were returned by the research nurse to the 
records library.  
Some of the case notes had to be requested repeatedly. This was especially the case 
where patients either had frequent visits to various outpatient clinics or had frequent 
admissions. Case notes for four patients were not available during the study period. 
These were two patients in the LVSD group and two in the HFpEF groups. Data for 
these four patients were not used in some of the analysis. 
After finishing the data collection from the case notes fifty patients were identified who 
did not have their prescribing history data complete. The research nurse contacted 
their general practices requesting them to fax the last prescription of the patient after 
removing any identifiable information. All practices responded except in four cases 
where the patients had changed their practices and had been lost to the follow up. 
5.8 Heart failure with preserved ejection fraction (HFpEF) 
After the data collection for the LVSD group, I reviewed the major clinical trials in 
heart failure with preserved ejection fraction (HFpEF). These were: Candesartan in 
Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-
preserved study (115), Irbesartan in Patients with Heart Failure and Preserved 
Ejection Fraction study (I-PRESERVE) (117), and The Perindopril in Elderly People 
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with Chronic Heart Failure study (PEP-CHF) (116). A working definition of HFpEF was 
thus established after the review of these clinical trials (see Chapter 6). 
Clinical letters from the HF clinic were reviewed against the criteria for HFpEF and a 
master list was prepared. This had the details of the patients who fulfilled the inclusion 
criteria. All patients were given a unique trial number. The master list was kept in a 
secured locker in the research office at Darlington Memorial Hospital with limited 
access. The research nurse requested the case notes of these patients from the 
records library through the hospital records tracking system. 
A separate workbook of “Microsoft Excel 2007” was established to enter the data of 
HFpEF patients on to the hospital computer in an anonymised form. All except three 
case notes for the patients who fulfilled the criteria for HFpEF were available.  
5.9 The third group “Others” 
For patients who did not fall into either of the two groups, a separate list was created. 
They were given an alphanumeric code that began with the code of “OT” followed by 
the numeric code. The data for this group were recorded on a separate Microsoft 
Excel 2007 data sheet. Data for this group were collected from the clinical letters only 
and detailed case notes were not reviewed. Mortality data were obtained from the 
MRIS.  
5.10 Cause of death in Heart Failure Patients 
Mortality in HF is high. Why and how patients with HF die remains of keen interest 
and is the subject of much on-going debate and research (205-207). This interest 
arises due to no clear appreciation of the impact of interventions that are provided as 
part of the treatment, and for a better understanding of the natural history and the 
pathophysiology of HF. 
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One way to appreciate how these patients died is to ascertain the mode of death or 
factors listed as leading to it. This was planned to be studied from the death certificate 
of these patients. The Medical Research Information Service (MRIS), part of the NHS 
Information Centre, holds this information. MRIS was approached with a request to 
release data for the cohort of patients in the study. 
An application form was filled and sent to the MRIS. After scrutinising the application, 
MRIS specifically queried whether the study has Ethics Committee approval for 
accessing patient data from the MRIS as part of the protocol?   
The initial application to the Ethics Committee had specifically not mentioned access 
to patient data from the MRIS. We therefore applied for and received Chairman’s 
approval for obtaining cause of death from the MRIS. 
The revised application was returned to MRIS with the above clarification. On further 
review of the application, MRIS felt that, as we will be accessing confidential patient 
data (cause of death) without patient consent we ought to have Section 251 of the 
NHS Act 2006 support from the National Information Governance Board (NIGB) for 
Health and Social Care (an independent statutory body established to improve and 
monitor information governance in health and adult social care).  This act allows the 
common law duty of confidentiality to be set aside in specific circumstances where 
anonymised information is not sufficient and where patient consent is not practicable. 
The full committee for NIGB discussed and reviewed our application for section 251 
support. In a major policy decision, the NIGB board decided that where the clinical 
care team looking after the patient wants to access patient death data from the MRIS, 
it would not be necessary for section 251 support from the NIGB. This change in 
policy by the NIGB board will help other research teams by saving a lot of time.   
Subsequently, an application was sent to the MRIS for access to patient data 
regarding the cause of death as recorded on the patient’s death certificate. A data 
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sharing agreement was signed with the MRIS and they set up a project team to liaise 
with us. Patient data were sent in a secure encrypted format using the NHS.net email 
on a Windows 2007 excel spread sheet. A separate excel sheet was used to send 
data. Mortality data were returned to us over a secure connection on two separate 
occasions, with a downloadable link that was password protected. The data file could 
only be downloaded once before it would automatically be erased. The data file thus 
received was stored on an encrypted and password protected computer that could 
only be assessed by the researcher. It was linked to the master list by the unique 
study alphanumeric number present on the data file. The cause of death was copied 
to the working data file thus breaking any link with the master list and patient 
identifiable information.  
5.11 Methods   
Data were collected on a separate Microsoft excel spread sheet for each of the three 
groups. Data were transferred to the SPSS 19 sheets separately. 
Data analysis was done using descriptive statistics first. Prognostic factors for the 
model were analysed using the Cox proportional hazard regression method.  
5.11.1 The Cox proportional hazard model 
The Cox proportional hazards (PH) regression model is a semi-parametric model (it 
imposes no assumption about the distribution of the time) is commonly used. This 
model assumes that the ratio between the hazards (instantaneous risk of death) of 
the two patient groups remains constant over the complete follow-up period. This 
builds a predictive model for time to event data and produces a survival function that 
predicts the probability that the event of interest has occurred at a given time t for 
given values of predictor variable (208). 
Censored data: survival times are calculated from some baseline date that reflects a 
natural “starting point” for the study until the patients reach the endpoint of interest 
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(e.g. death). However we may not know when a patient reached the endpoint, but 
only that they remained free of the end point at the end of the study. If the event has 
not occurred, the case is said to be censored. These patients were known not to have 
reached the end point when they were last under follow up (right censored).  In the 
Cox proportional hazard model censored cases are not used in the computation of the 
regression coefficients, but are used to compute the baseline hazard (209). 
Stratification: The Cox proportional hazard model provides a way to adjust for 
confounding factors by stratification. Here data are grouped into strata that are 
defined by different levels stratification variables. Stratification can be used for model 
checking, if for a variable non-proportional hazards are detected.  
Explanatory terms used in the Cox regression model are presented here. 
B -This is the coefficient for the constant (also called the "intercept") in the null model. 
Cox regression coefficient signs are relative to death, not survival.  So a positive sign 
means that larger values of the independent variable have higher death rates.  And 
negative signs mean that larger values of the independent variable have lower death 
rates. 
SE -This is the standard error around the coefficient for the constant.  
Wald and P - This is the Wald chi-square test that tests the null hypothesis that the 
constant equals 0.  The Null hypothesis is rejected if the p-value (listed in the column 
called “p") is smaller than the critical p-value of 0.05 or less 
df -This is the degrees of freedom for the Wald chi-square test.  There is only one 
degree of freedom because there is only one predictor in the model, namely the 
constant. 
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Odds ratio - is a measure of the association between two variables, and indicates the 
effect of other variables on their relationship. 
5.11.2 Paired samples T test 
The paired samples T test was used to compare the means of the variables from the 
clinic appointment and the admission data. This computes the differences between 
values of the two variables for each case and tests whether the average differs from 
0. 
5.11.3 Median follow up time 
The median follow up time for this study was calculated using the method suggested 
by Schemper and Smith (210). This method has been described as the Kaplan-Meier 
estimate of potential follow up (KM-PF) also termed “reverse Kaplan Meier”. It is 
calculated in the same way as the Kaplan-Meier (211) estimate of the survival 
function but with the meaning of the status indicator reversed. Thus death (s = 1) 
censors the true but unknown observation time of an individual, and censoring (s = 0) 
is an end point. This creates a Kaplan Meier curve where loss of follow up is the event 
being followed, and death is treated as the censoring data. 
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Chapter 6 
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Diastolic Heart Failure: A working definition  
6.1 What is Diastolic Heart Failure? 
Systolic HF is characterised by reduced left ventricular (LV) ejection fraction often 
accompanied with progressive chamber dilation and eccentric (increased size and 
volume) remodelling. On the other hand, diastolic dysfunction can be defined as the 
condition whereby increased filling pressure is required in order to maintain a normal 
cardiac output.  This is characterised by a normal left ventricle volume, concentric 
(increased thickness and reduced volume) remodelling, normal LV chamber systolic 
properties, and abnormalities of diastolic relaxation, filling, or distensibility of the LV. 
When these diastolic mechanical alterations are associated with signs and symptoms 
of exertional dyspnoea it is termed diastolic HF (DHF)      
6.2 Background 
Many physicians imagine that the typical patient with congestive heart failure (CHF) 
has a low ejection fraction. The usual response of clinicians to an echocardiogram 
report that suggests normal or preserved LVEF is to look for an alternative diagnosis 
for patient’s symptoms. This focus on the systolic dysfunction is well seen in the large 
multicentre trials over the years which have defined the management of CHF as they 
have excluded patients with LVEF > 35% or >40% (212). This has certainly benefited 
patients with left ventricular systolic dysfunction (LVSD),  leading to substantial 
advantage for the patients, with advances in the appreciation of pathophysiology and 
natural history, and has provided the consequent strong evidence for effectual 
treatment strategies (72, 213, 214) .    
As the prime focus has been on systolic dysfunction, there is paucity of data in 
patients with HFpEF. However, since the 1970s, reports have appeared in the 
literature suggesting that half of all patients with clinical features of CHF have a 
normal (or near normal) ejection fraction (EF) (123, 215). These patients have been 
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labelled as “heart failure with normal ejection fraction” (HFNEF), “heart failure with 
preserved ejection fraction (HFpEF) or “diastolic heart failure” (DHF). All terms are 
frequently used interchangeably. For the purpose of this thesis I have used the term 
“heart failure with preserved ejection fraction” as it is the most accurate label and 
does not imply a mechanism.  
The true incidence, prevalence and prognosis of the HFpEF remain debatable.  Early 
studies which primarily looked at patients referred for HF into the hospital reported 
prevalence rates of HFpEF from 13% to 74% (215). Later community based studies 
found prevalence rates of 40 to 71 percent (216, 217).  Using the European Study 
group (218) definition of diastolic HF Fischer et al found a prevalence rate of 11.1 % 
(219). 
Incident rates also vary. In the Olmsted County study, 59 of the 139 (43%) patients 
had a preserved EF (ejection fraction ≥50 %). Of these 5 also had a predominant 
valvular lesion, so 54 (39%) had HFpEF or DHF (220). In another study 49 of 310 
(16%) newly diagnosed patients with HF had a normal qualitative assessment of the 
left ventricle (221).  
Predisposing conditions for HFpEF are older age, female gender, obesity, diabetes, 
arterial hypertension, and left ventricular hypertrophy (LVH) (219, 222). Patients who 
are diagnosed to have HFpEF also have rates of recurrent admissions to hospital as 
high as those with HF with LVSD (223), and marked all cause mortality (224, 225). 
There have been reports of a steady increase in the incidence and prevalence of 
HFpEF in the past decade, likely related to changing population demographics and  
associated cardiovascular disease in the population (132). 
6.3 Definition of Diastolic heart failure: Current perspective  
The reported wide variation in the incidence and prevalence of HFpEF highlights the 
fact that studies have not used a uniform definition to identify patients. The gold 
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standard for defining HFpEF is left heart catheterisation with angiography and 
simultaneous evaluation of pressure, volume and geometry throughout the cardiac 
cycle (226). This procedure is not only invasive and impractical for the routine 
assessment of HF patients but is also expensive and time consuming. 
In a consensus statement on diastolic HF, the HF and Echocardiography Association 
of the European Society of Cardiology (ESC) proposed the presence of three 
obligatory conditions for the diagnosis of diastolic HF (227). These are (i) the 
presence of signs or symptoms of congestive HF (ii) presence of normal or mildly 
abnormal LV systolic function, and (iii) evidence of diastolic LV dysfunction. Signs and 
symptoms of congestive HF include lung crepitation, pulmonary oedema, ankle 
swelling, hepatomegaly, dyspnoea on exertion and fatigue. 
The presence of normal or mildly abnormal LV function is the second criterion in the 
ESC guidelines for the diagnosis of HFpEF.  They propose a left ventricular (LV) 
ejection fraction (EF) of > 50 % consistent with the presence of normal or mildly 
abnormal LV systolic function.  However, the choice of a specific cut- off for LVEF 
remains arbitrary. Major randomised control trials in patients with HFpEF have used 
different definition to define their patient cohort. The trial “Effects of candesartan in 
patients with chronic heart failure and preserved left ventricular ejection fraction 
(CHARM preserved)” (228), defined eligible patients as 18 years or older with a New 
York Heart Association functional (NYHA) class II-IV of at least 4 weeks duration, who 
had a history of hospital admission for a cardiac reason, and had a EF ≥ 40 %.  
The “Irbesartan in patients with heart failure and preserved ejection fraction (I-
PRESERVE)” trial (117), had patients of at least 60 years of age who had HF 
symptoms and a EF ≥ 45%.  
Cleland et al, in the “Perindopril in elderly people with chronic heart failure study 
(PEP-CHF)”(116), defined their cohort of patients as aged ≥ 70 years and treated with  
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diuretics for a clinical diagnosis of CHF due to LV diastolic dysfunction. They 
excluded patients with a wall motion index of <1.4 roughly equivalent to an EF of 
40%.  (Table 6 shows comparative inclusion and exclusion criteria of these trials.)   
In the SENIORS (Study of the Effects of Nebivolol Intervention on Outcomes and 
Rehospitalisation of Seniors with HF) trial, an EF >35% was used as inclusion criteria 
(229). 
In the Hong Kong diastolic HF study the inclusion was age >18 years, clinical history 
of HF within 2 months prior to screening, including a chest X ray demonstrating 
pulmonary congestion, NYHA class II – IV, LVEF  >45% by 2D echocardiography or a 
radionuclide technique (230) . 
Beta blockers in heart failure with normal left ventricular ejection fraction (β-
PRESERVE) is a study that is currently recruiting and the inclusion criteria include an 
LVEF ≥ 50% (231). 
6.4 Developing a working definition for HFpEF to be adopted in DROPSY 
For the present study patients were required to have ongoing NYHA class II-IV 
symptoms, ± signs of fluid retention and a LVEF > 40% by Simpsons rule, or normal 
function on “eye balling” as the essential inclusion criteria. Further evidence to 
indicate a cardiac cause for the symptoms, based on the echocardiogram, ECG or 
chest X-ray was also necessary (qv).  
In the present study cardiac function was assessed by EF was assessed by 
Simpson’s rule, regional wall motion index where possible, or by a semi quantitative 
“eye balling” method. Detailed clinical methods used to calculate EF are often not 
applicable in clinical practice. Thus, a visual estimate, which is a validated technique 
of assessing LVEF, was used (232, 233) .  
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Patients who fulfilled the above criteria also needed to have a chest X-ray showing 
cardiomegaly or pulmonary congestion and / or an electrocardiogram (ECG) that 
showed left bundle branch block (LBBB) or left ventricular hypertrophy (LVH) by 
Sokolow-Lyon criteria. 
6.5 Evidence of ventricular diastolic dysfunction 
The need to obtain positive evidence of LV diastolic dysfunction remains 
controversial. The ESC lists this as the third obligatory condition for the diagnosis of 
DHF (227). It has been argued that this clinical definition lacks sensitivity and 
specificity especially in women, the elderly and in the obese (234). Equally, others 
have argued that measurement of LV relaxation rates is of doubtful diagnostic value 
(235). Also there is no single index of diastolic function that is as useful and widely 
applicable as ejection fraction in patients with systolic dysfunction (236) 
In one study, 92% of patients with a history of HF, EF >50 %, and evidence LV 
concentric remodelling had an elevated LV end diastolic pressure and all had at least 
one hemodynamic or Doppler echocardiographic index of abnormal LV relaxation, 
filling, or diastolic stiffness. This study questioned the need for formal assessment of 
LV diastolic dysfunction (236). For the present study left ventricular hypertrophy (LV 
septum or posterior wall > 12 mm), left atrial diameter of >40 mm, and E/A ratio of < 
0.5 on echocardiography will be used as surrogate markers of diastolic dysfunction.  
6.6 Early (E) / Atrial (A) filling ratio of the Left ventricle  
During ventricular diastole, blood flows from the atrium to fill the ventricular chamber. 
This occurs in two phases. The first phase starts with the opening of the mitral valve 
when there is a rapid movement of blood into the LV cavity in early diastole due to the 
pressure gradient from the left atrium to the apex. This is called the early (E) phase. 
As the LV fills up the pressure gradient from left atrium to the LV decreases and then 
transiently reverses. This brief period in diastole is called diastasis. Late in diastole, 
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atrial contraction augments LV filling.  This is due to atrial systole and called the atrial 
(A) phase (237). 
In hearts with normal filling pressures the E/A ratio is usually more than 1. A reversal 
of this ratio is indicative of abnormal filling and impaired relaxation of the left ventricle, 
a marker of diastolic dysfunction.   
6.7 Atrial fibrillation   
Patients with atrial fibrillation (AF) are inadequately assessed using Doppler–
Echocardiographic techniques (238). This is because of the altered left atrial pressure 
and loss of synchronized atrial contraction (239). Both the ESC guidelines on 
diagnosis of DHF (227) and  PEP-CHF (116) have included AF as a marker of 
diastolic dysfunction and for the present study AF is included as evidence of diastolic 
dysfunction.  
The main exclusion criteria for the present study were patients with significant valvular 
heart disease and those with a pulmonary cause of shortness of breath. 
As there continues to be disagreement and debate about the best method for 
diagnosis of diastolic heart failure, the present study used a practical, realistic, and 
workable definition of identifying patients with DHF in clinical practice without the 
constraint of having to follow complex diagnostic algorithms. The working definition of 
heart failure with preserved ejection fraction (HFpEF) for the present study is 
presented in section 6.8. 
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Table 6.7 Inclusion criteria for three major trials in HFpEF 
 
Criteria CHARM  
preserved 
I PRESERVE PEP-CHF 
Age > 18 years 60years ≥ 70 & on diuretics for 
clinical CHF 
NYHA 2-4 2-4  
Duration of symptoms ≥ 4 weeks   
ECHO- EF% >40% ≥ 45% Wall motion index 
<1.4. EF- > 40% 
History of hospitalisation for 
cardiac cause 
Yes Yes, in the previous 6 
months 
Yes in the previous 6 
months 
If not hospitalised  NYHA 2-4, corroborative 
evidence 
 
Other   Walk 6 min 
unaided(r/o-frail) 
 
Corroborative evidence: - Pulmonary congestion on CXR, LVH or LA enlargement on 
echocardiography, or LVH or LBBB on ECG 
 
PEP-CHF: - 3 of 9 clinical and at least 2 of 4 Echo criteria 
  
Clinical criteria ECHO criteria 
 
1) Exertion SOB,  
 
2) Orthopnoea or PND;  
 
3) Ankle swelling;  
 
4) Improved breathlessness with diuretic 
  
5) Increased JVP;  
 
6) Prior episode of clinical pulmonary  
oedema;  
 
7) Prior MI;  
 
8) Cardiothoracic ratio .0.55;  
 
9) Previous radiological pulmonary oedema. 
 
i) LVEF fraction between 40 and 50%, 
(since abnormal diastolic dysfunction is often 
associated with some impairment of systolic 
function) 
 
ii) LA diameter >25 mm/m2 body surface 
area or >40 mm  
 
iii) IV septum or posterior LV wall thickness 
≥12 mm  
 
iv) Evidence of impaired LV filling by at least 
one of the criteria recommended by the 
ESC:- 
 
 a) E/A ratio<0.5 or deceleration time of 280 
ms  
Isovolumic relaxation time of 105ms 
 
b) Atrial Fibrillation 
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6.8 HFpEF- working definition adapted in DROPSY 
Inclusion criteria  
1) Hospital admission for cardiac cause in the last 6 months  
                    
                                 With – NYHA class 2-4 
                         
                                ± Signs of fluid retention 
                                     
2) If not hospitalised – 
 
Ongoing NYHA 2-4 HF symptoms ± signs of fluid retention 
 + (any two of the following) 
 
a) CXR - Pulmonary congestion/ oedema, or Cardiomegaly  
 
                                   Or 
 
b) ECHO -    LVH (LV septum or posterior wall > 12mm) 
                                      Left atrial diameter > 40 mm 
                                      E/A ratio < 0.5 
 
                                   Or 
 
c)  ECG – LBBB or LVH (Sokolow-Lyon criteria)  
            Or Atrial Fibrillation  
 
 
Essential criteria on 2D echocardiography 
 
EF fraction > 40% (Simpsons rule) 
 
 Normal LV systolic function by semi quantitative assessment, or on “eye balling” 
Exclusion criteria 
       
Pulmonary cause of shortness of breath 
 
Significant valvular heart disease 
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Results  
The Darlington Retrospective Outpatient Study (DROPSY) was carried out at the 
Darlington Memorial Hospital Darlington. From Jan 2002 to Dec 2007, 1041 patients 
were reviewed in the HF clinic. Of these 270 (26%) were diagnosed as having LVSD. 
Of the 771 patients who did not have systolic dysfunction, we identified 243 patients 
who fulfilled the study criteria for heart failure with preserved ejection fraction 
(HFpEF). The remaining 528 patients formed the non heart failure (Other) group. 
 
Case records of two patients in the LVSD group and two patients in the HFpEF group 
were not available for review. For these four patients we only had the demographic 
and outcome data. Final analysis of the data was performed without taking these four 
patients into account.  Six patients from the Non HF (Other) group had no data 
available and the analyses were confined to 522 patients only. 
Demographics  
Comparative analysis of the three groups shows that the HFpEF group patients were 
older; more had hypertension and diabetes than the other two groups. The LVSD 
group had more male and diabetic patients while the third group of non HF had more 
Total number of 
patients 
1041 
LVSD 
270 
HFpEF 
243 
Other  
528 
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COPD.  The subsequent chapters will look at the patients with LVSD, HFpEF and non 
HF in more detail. 
Table: Demographics for all three groups 
 LVSD HFpEF 
Non HF 
(Other) 
p value 
Total number of 
patients 
268 241 522  
Average age years 
(range) 
74 (60) 78 (52) 75 (61) 0.01 
Males 164 (61%) 84 (35%) 183 (35%) 0.00 
Females 104 (39%) 157 (65%) 339 (65%) 0.00 
Hypertension  114 (43%) 202 (84%) 253 (49%) 0.01 
Atrial fibrillation 66 (25%) 86 (36%) 74 (14%) 0.01 
Ischemic heart disease 140 (52%) 101 (42%) 138 (26%) 0.00 
Diabetes  42 (16%) 55 (23%) 63 (12%) 0.01 
Stroke  34 (13%) 10 (4%) No data 0.00 
COPD/ Asthma 58 (22%) 11 (5%) 144 (28%) 0.00 
 
Results for individual group and a combined analysis are provided in 
subsequent chapters. 
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Chapter 7 
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Heart failure with preserved ejection fraction (HFpEF) - Results  
Two hundred and forty three (243) patients fulfilled the study inclusion criteria for 
HFpEF. Case notes for review were available for all except two patients. These two 
patients were not included in the final analysis leaving 241 patients in this cohort.  
7.1 Descriptive analysis of first clinic review 
HFpEF patients were older, comprised more females and more had atrial fibrillation 
than the LVSD and Non HF groups. Although history of COPD was an exclusion 
criterion, 11 patients who had history of mild asthma (not any regular medications) 
were also found eligible and included in the study. The demographics and past 
medical history are presented in the table below. 
7.1.1 Demographics and past medical history  
Total number of patients 241 
Males  84 (35%) 
Females 157 (65%) 
Average age, years (range) 78 (52) 
Past medical history  
    Hypertension 202 (84%) 
Diabetes mellitus 
55 (23%) 
Atrial fibrillation 
40(17%) 
Ischemic heart disease 
101(42%) 
Stroke 10 (4%) 
Mild Asthma 11 (5%) 
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7.1.2 Smokers   
One hundred and fifteen people had never smoked, 117 were ex smokers (stopped 
smoking before the clinic review). Only a small number were current smokers.  
Smoking  history Frequency Percent 
Never 115 47.7 
Current 9 3.7 
Ex 117 48.5 
Total 241 100.0 
 
7.1.3 Presenting symptoms   
The majority of the patients seen in the clinic were referred because of either 
shortness of breath or swollen ankles. One hundred and eighty eight (78%) patients 
were referred to the clinic due to swollen ankles, but on clinic examination only 102 
(42%) had swollen ankles. Table 7.1.3 
Table 7.1.3 Presenting symptoms 
Shortness of breath (SOB) 231 (96%) 
Swelling of the ankles (SOA) 102 (42%) 
Orthopnoea  47 (20%) 
Paroxysmal nocturnal dyspnoea (PND) 13 (5%) 
Fatigue 7 (3%) 
Palpitations 7 (3%) 
 
7.1.4 NYHA class 
On average patients had been symptomatic for 5.6 months (median 6 months) before 
being referred to the HF clinic. At the time of review in the clinic patients were most 
likely to have NHYA class 2 symptoms. A small number of patients were in class 1 & 
4. (Table 7.1.4)     
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Table 7.1.4 NYHA class in clinic 
NYHA class Frequency Percent 
Class 1 6 2.5 
Class 2 157 65 
Class 3 75 31 
Class 4 3 1.5 
Total 241 100 
 
7.1.5 Clinical examination findings  
Jugular venous pressure (JVP) was raised in 27 (11%) and normal in 214 (89%) 
patients. The mean systolic and diastolic blood pressure was 153 and 84 (median 150 
and 80 and range 115 and 95) mmHg respectively. The average weight of the HFpEF 
group was 80 (median 77 / range 136) kg. [Body mass index (BMI) was not calculated 
as the data for height was not routinely recorded].  A systolic murmur was present in 
78 (32%) patients and 7 patients had a diastolic murmur. The majority of the patients 
had clear lung fields on auscultation but 30 (12%) had crepitation. 
7.1.6 Chest X-ray findings   
Two hundred and seventeen patients had cardiomegaly on their chest X-ray when 
reviewed in the clinic. This was one of the inclusion criteria for patients with HFpEF. 
Table 7.1.6 Chest X-ray findings 
Normal  18 (8%) 
Cardiomegaly 217 (90%) 
Upper lobe diversion 61 (25%) 
Pulmonary oedema 12 (5%) 
Pleural effusion  9 (4%) 
Other findings 1 
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7.1.6 ECG findings  
All the 241 patients at the clinic appointment had an ECG recorded. This was 
reviewed by the clinician at the time of their consultation. Forty seven new patients 
were diagnosed with atrial fibrillation after the clinic review. Table 7.1.6 
Table 7.1.6 ECG findings 
Normal 71 (30%) 
Left axis deviation 11 (5%) 
Left bundle branch block 15 (6%) 
Left ventricular hypertrophy 34 (14%) 
Bradycardia 11 (5%) 
Atrial fibrillation 87 (36%) 
Right bundle branch block 14 (6%) 
T wave inversion 12 (5%) 
 
7.2 Echocardiographic findings 
Echocardiographic assessment of the heart is the gold standard for measurement of 
both systolic and diastolic function. This not only helps to classify patients into 
reduced or preserved EF but also guides management. Of the 241 patients in this 
cohort only 53 (22%) patients had their LV ejection fraction assessed by Simpson’s 
rule on echocardiography. Average EF was 63% (median and mode of 63%). The 
remainder had semi quantitative “eye ball” assessment of their global systolic function 
which was reported as “good / normal LV systolic function”. 
7.2.1 E/A ratio and Left atrial diameter 
One hundred and twelve (47%) patients had the E/A ratio measured at 
echocardiography. Eighty six (36%) of these had reversal of the E/A ratio suggestive 
of a stiff ventricle and impaired diastolic filling. The left atrial diameter was measured 
in 195 patients. The mean (and median) diameter was 45 mm (range 47). 
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7.2.2 Left ventricular hypertrophy 
Interventricular septal diameter in diastole (IVSDd) and posterior wall (PW) thickness 
of more than 12mm is considered suggestive of left ventricular hypertrophy (LVH). In 
the HFpEF patients the mean IVSDd was 14mm and the mean PW thickness was 
12mm.  IVSDd in 139 (58%) patients and PW thickness in 100 (41%) patients was ≥ 
12 mm, suggestive of left ventricular hypertrophy. (Table 7.2.2)    
 Table 7.2.2 Left ventricular hypertrophy 
 
Interventricular septal   
diameter in diastole (IVSDd) 
Posterior  wall 
thickness 
Data available, n (%) 175 (73) 165 (68) 
Not available, n (%) 66 (27) 76 (32) 
Thickness  ≥ 12 mm, n  (%) 139 (79) 100 (61) 
Mean (mm) 14 12 
Median (mm) 14 12 
Mode (mm) 13 10 
Range  18 14 
 
7.2.3 Valvular heart disease 
Significant valvular heart disease was not present in any of the patients. Moderate 
mitral regurgitation (MR) was present in 52 (21%), moderate tricuspid regurgitation 
(TR) in 27 (11%), severe TR in 7 (3%), moderate aortic regurgitation (AR) was 
present in 6 (2.5%), and moderate aortic stenosis (AS) in 3 (1%) of the patients.  
7.3 Blood tests  
All the patients had blood tests done either on the day of the appointment or 
previously by the referring physician. These were reviewed at the time of consultation. 
All patients had serum sodium, potassium, urea, creatinine and full blood count 
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checked. The results were then available to guide further management with respect to 
the drug therapy. (Table 7.3)  
Table 7.3 Blood tests in the clinic 
 Mean Median Minimum Maximum 
Sodium (mmol/L) 140 140 127 147 
Potassium (mmol/L) 4.2 4.2 3 6 
Urea (mmol/L) 8 7 3 24 
Creatinine (µmol/L) 109 98 62 657 
Haemoglobin (mg/dl) 13 13 9 16 
MCV (Fl) 90 90 73 109 
 
7.4 Medications on presentation 
7.4.1 Diuretics  
One hundred and ninety two (80%) of the patients had been prescribed a diuretic by 
their physician before being referred to the HF clinic. This was to help patients with 
shortness of breath and swollen ankles. The majority of patients were taking only one 
loop diuretic, but 9 (4%) were taking an aldosterone antagonist (Spironolactone) as 
well.    
7.4.2 ACE inhibitors / ARBs    
The majority (55%) of patients were not taking an ACEi or ARB (None of the patients 
were on both the ACEi and ARB together). The frequency of specific ACEi and ARB 
usage is presented in the table below. Table 7.4.2  
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Table 7.4.2 Type and frequency of ACE inhibitors / ARBs in the clinic 
Type of ACEi  / ARBs  Frequency (N= 109) Percent 
Perindopril 
32 29 
Ramipril 
23 21 
Lisinopril 
19 17 
Enalapril 
10 9 
Trandolapril 
1 1 
Losartan 
10 9 
Valsartan 
5 5 
Candesartan 
5 5 
Irbesartan 
3 3 
Olmesartan 
1 1 
Total 
109  
 
7.4.3 Beta blockers  
Eighty three (34%) of the patients were taking a beta blocker on presentation and the 
majority were on Atenolol. Table 7.4.3 
 Table 7.4.3 Patients taking beta blockers 
Type of beta blocker Frequency (n=83) Percent 
Atenolol 64 77 
Bisoprolol 11 13 
Carvedilol 3 4 
Metoprolol 1 1 
Nebivolol 3 4 
Timolol 1 1 
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7.4.4 Other medications 
Digoxin 39 (16%) 
Aspirin 118 (49%) 
Warfarin 38 (16%) 
Calcium channel blockers 83 (34%) 
Statins 90 (37%) 
 
7.5 Medications changed in the clinic 
Only a minority of patients had their treatment changed in the clinic. In 20 (8%) 
patients an ACEi was started, and in another 20 patients, the dose of medication was 
adjusted. The adjustments to medications were mainly for optimising blood pressure 
control. Five patients had their loop diuretics stopped. 
Twenty six (11%) patients were also started on a beta blocker. In the majority of 
patients this was done to optimise heart rate control in atrial fibrillation. Calcium 
channel blockers were started in 6 patients. Warfarin was initiated in 23 (10%) 
patients. Table 7.5.1 
Table 7.5.1 Dose changed in clinic 
 Started Dose change Stopped 
ACE inhibitors 20 (8%) 20 (8%)  
Beta blockers 26 (11%)  2 
Loop diuretics 7 (3%)  5 (2%) 
Aldosterone antagonist 7 (3%)   
Digoxin  5 (2%)   
Warfarin  23 (10%)   
Calcium channel blockers   6(3%) 
 
7.6 Cause of shortness of breath (ascribed in the HF clinic) 
At the time that most of these patients were evaluated, it was not normal practice to 
make a diagnosis of HFpEF. The reviewing clinician therefore attempted to identify a 
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cause for their shortness of breath and / or oedema. Atrial fibrillation, hypertension, 
and left ventricular hypertrophy were the commonest reason ascribed for their 
symptoms. Table 7.6 
Table 7.6 Cause of shortness of breath 
 
 (n = 241) 
HFpEF 30 
Atrial Fibrillation 44 
Obesity  17 
Hypertension  38 
Calcium channel blockers 5 
COPD/ Asthma 9 
Dependent oedema  20 
Old age 4 
LVH 18 
IHD 21 
Other * 9 
No cause ascribed 26 
* Lack of fitness, kyphoscoliosis, and anaemia. 
7.7 Follow up  
After clinic attendance the majority of patients were discharged back to the referring 
doctor. Only 57 (24%) patients were invited back for a further review in the HF clinic. 
Table 7.7 
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Table 7.7 Frequency of follow up visits by patients to the HF clinic 
Number of patients Frequency of visits 
1 19 
2 14 
3 9 
4 7 
5 3 
7 2 
11 1 
13 1 
15 1 
 
7.7.1 Other procedures performed 
Other procedures and investigations were requested as appropriate to help manage 
the patients. Table 7.7.1 
Table 7.7.1 Other procedures and tests requested  
Tests Frequency 
DCCV 3 
ETT 4 
PFT 1 
24 hr monitor 2 
PPM 1 
(DCCV= DC cardioversion; ETT= exercise tolerance test; PFT= pulmonary function 
test; PPM= permanent pacemaker implantation)  
7.8 First admission to hospital  
Following the HF clinic appointment, the first episode of admission to the hospital was 
recorded. One hundred and fifty eight (65%) of the patients had least one admission 
to the hospital during the follow up period and 83 (35%) had no admissions.  
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The median time to first admission following the clinic appointment was 29.4 months 
(127.90 weeks). Of the 158 patients, 134 (85%) were managed by general 
physicians, 17 (11%) by the cardiologists, and the remainder were looked after by 
other specialists. Table 7.8.1 & 2 
7.8.1 Presenting complaints on admission   
 Frequency (n = 158) 
Shortness of breath 36 
Chest pain 24 
Fall 15 
Collapse 21 
Stroke 8 
Cancer 2 
Confusion 10 
Diarrhoea 8 
Generally unwell 11 
Acute renal failure 2 
Cardiac arrest 1 
Other 20 
 
7.8.2 Patient characteristics on admission  
Males 50 (32%) 
Females 108 (68%) 
Age (mean) years 79 
Mean systolic BP 140 mmHg 
Mean diastolic BP 73 mmHg 
Mean heart rate 82/min 
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Patients who were admitted to the hospital had a significantly lower mean systolic and 
diastolic BP as compared to their BP at the time of the clinic assessment. The mean 
heart rate, on the other hand was significantly higher on admission as compared with 
the time of the initial clinic assessment. The lower mean BP on admission could have 
a number of explanations, including a consequence of the cause of admission or the 
effect of drug modification since the initial clinic visit. Table 7.8.2.a & b   
Table 7.8.2a [Blood pressure (BP) and Heart rate (HR) (Paired Samples T test)] 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 BP (systolic) on 
admission 140 155 28.9 2.3 
BP (systolic) in clinic 
153 155 21.3 1.7 
Pair 2 BP (diastolic) on 
admission 73 157 14.3 1.1 
BP (diastolic) in 
clinic 83 157 13.1 1.0 
Pair 3 HR on admission 
82 158 19.4 1.5 
HR in clinic 
77 158 18.6 1.4 
 
Table 7.8.2b [Blood pressure (BP) and Heart rate (HR) (Paired Samples Test)] on 
admission and clinic 
 
Paired Differences 
t df P 
Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% CI of the 
Difference 
Lower Upper 
Pair 1 
Systolic BP (admis) 
- Systolic BP (clinic) 
-12.9 32.8 2.6 -18.1 -7.6 -4.8 154 .01 
Pair 2 
Diastolic BP (admis) 
- Diastolic BP (clinic) 
-9.5 18.3 1.4 -12.4 -6.6 -6.5 156 .01 
Pair 3 
HR admission 
- HR in clinic 
5.6 23.2 1.8 2.0 9.3 3.0 157 .00 
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7.8.3 Clinical examination findings on admission 
Of the one hundred and fifty eight patients who had an admission to hospital, 70 
(44%) had swollen ankles, 27 (17%) had raised JVP, 63 (43%) were in NYHA class 3-
4, and 10 (4%) presented with increased weight. Chart 7.8.3 
Chart 7.8.3 
 
7.8.4 ECG and Chest X-ray on admission  
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On admission 17 patients had a normal chest X-ray. Of the 113 patients who had 
cardiomegaly, 20 also had concomitant pulmonary oedema. Eleven patients had 
other findings and 18 patients did not have a chest X-ray done on admission. 
7.8.5 Blood tests 
As compared to the clinic, bloods tests on admission showed a significant increase in 
urea and creatinine level. At admission, 36 (23%) patients had a significant rise (≥ 
50% increase) in creatinine values, 65 (41%) had significantly (> 8 mmol/l) elevated 
urea levels, 11 (7%) had hyperkalemia (potassium ≥ 6mmol/l), and 30 (19%) of 
patients had hyponatremia (sodium < 135mmol/l) as compared to the clinic 
assessment values. Table 7.8.5a  
Table 7.8.5a Blood test results on admission 
 
Sodium 
(mmol/l) 
Potassium 
(mmol/l) 
Urea 
(mmol/l) 
Creatinine 
(µmol/l) 
Mean 138 4.3 12 138 
Median 139 4.2 9 105 
Std. Deviation 4.5 0.7 10 96 
Minimum 123 3 3 7 
Maximum 149 8 70 691 
 
A paired samples 2 tail test showed a significant difference in the mean value of blood 
results at the time of clinical review and at the time of the first hospital admission. 
Only the mean value for sodium was significantly lower at the time of admission 
whereas the mean values were significantly higher for potassium, urea, and 
creatinine. Table 7.8.5b & c 
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Table 7.8.5b Blood tests on admission and in clinic (Paired samples statistics) 
 Mean N Std. Deviation 
Std. Error of 
Mean 
Pair 1 
Sodium (admission) 138 158 4.5 0.4 
sodium (clinic) 140 158 3.3 0.3 
Pair 2 
Potassium admission 4.3 158 0.7 0.1 
Potassium in clinic 4.2 158 0.1 0.1 
Pair 3 
Urea on admission 12 158 10 1 
Urea in clinic 8 158 3.2 0.3 
Pair 4 
Creatinine  admission 138 158 96 8 
Creatinine in clinic 114 158 64 5 
 
Table 7.8.5c Blood tests on admission and in the clinic (Paired samples t test) 
 
Paired Differences 
t df p 
Mean Std. Dev 
Std. 
Error 
Mean 
95% CI of the 
Difference 
Lower Upper 
Pair 1 
Sodium (admis) 
 – sodium (clinic) 
-1.9 4.6 0.4 -2.6 -1.2 -5.2 157 .01 
Pair 2 
Potassium (admis) 
 - Potassium (clinic) 
1 0.7 0.1 -.1 0.2 1.8 157 .07 
Pair 3 
Urea (admission) 
 - Urea (clinic) 
4.4 10 0.8 2.9 5.9 5.8 157 .01 
Pair 4 
Creatinine (admis) 
 - Creatinine (clinic) 
24 86 7 10.5 37.5 3.5 157 .01 
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7.9 Medications on admission 
Table 7.9 Medications on admission 
Medications Frequency [n=158] 
ACEi / ARBs 92 (58%) 
Beta blockers 58 (37%) 
Diuretics 113 (76%) 
Aldosterone antagonist 16 (10%) 
Digoxin 34 (26%) 
 
7.9.1 Medications changed in hospital 
 Only a minority of the patients had any alteration to their medications in the hospital. 
An ACEi was started in 5, and stopped in 13 patients. A beta blocker was started in 4, 
and stopped in 3 patients. Diuretics dosage was reduced (including discontinued) in 
10 patients and increased in 2. Only 2 patients had spironolactone and digoxin 
started. 
7.10 Frequency of admission to hospital  
Admission to the hospital for any reason is a marker of a sicker and higher risk 
population. These patients are likely to fare worse than the comparative group not 
managed as inpatients. 
We studied the HFpEF patients who were admitted to the hospital for any reason. The 
first episode of admission for any reason was studied in detail. For subsequent 
admissions frequency data was only collected for the total number of admissions and 
the total number of days spent as an inpatient. Table 7.10  
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Table 7.10 Duration and number of inpatient episodes 
 
First admission 
(total days) 
Total number of 
admissions 
(per patient) 
Total inpatient stay 
(days) 
Admitted 158   
Not admitted 83   
Mean 12 2 26. 
Median 6 2 17 
Mode 2 1 2 
Std. Deviation 15 2 25 
Minimum 1 0 1 
Maximum 90 9 123 
Sum 1856 367 4164 
 
One hundred and fifty eight (66%) patients were admitted during the follow up period. 
Sixty seven (42%) patients had a single episode, and 91 (58%) patients had more 
than one episode of admission. Patients spent an average of 11.75 days as inpatients 
on their first admission. On an average patients had 2.32 episodes of admission. The 
cumulative sum of all days spent in the hospital for any reason was 4164. Thus on 
average each patient spent 26.35 days in hospital.  
7.11 Other co-morbidities developed 
Over the follow up period patients also developed significant other co-morbidities. 
Cancer (n = 26), stroke (n = 22), chronic kidney disease (n = 17), and dementia (n = 
15) were the leading new diagnoses made. Seven patients were diagnosed with 
COPD, 5 of whom had mild and 2 had severe symptoms needing home oxygen. 
Table 7.11 
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Table 7.11 Other co morbidities developed 
 Frequency  Percent  
AF 9 4 
Bleeding 8 3 
Cancer 26 11 
Cardiac arrest 2 1 
CCF 6 3 
CKD 17 7 
COPD 7 3 
Dementia 15 6 
Diabetes 4 2 
Fall 7 3 
IHD 7 3 
Pulmonary fibrosis 1 0.4 
Stroke 22 9 
 
7.12 Exposure to medications 
In a subset analysis, patients who had been exposed to any of the four medications 
were selected. The data for the total duration that patients had been prescribed an 
ACEi / ARB, beta blocker, aldosterone antagonist (spironolactone, eplerenone) and 
digoxin was collected from the hospital case records and general practice records. In 
the final analysis 161 (67%) patients had been prescribed an ACE inhibitor, 122 
(50%) had been prescribed a beta blocker. Table 7.12   
Table 7.12 Duration of medicine exposure 
Medications Number of patients 
Mean duration of 
exposure (months) 
ACEi / ARB 161 (67%) 73 
Beta blockers 121 (50%) 77 
Aldosterone antagonist 29 (12%) 31 
Digoxin 57 (24%) 71 
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The mean duration of exposure was calculated from the actual date of start of the 
prescription to the stop date. Where patients were continuing on the medications at 
the end of the study follow up period, 31/08/2011 was taken as the study stop date. 
7.12.1 Survival analysis for total drug duration  
Univariate and multivariate survival analysis for all-cause mortality using drug duration 
as a co variant was done using a Cox regression model for ACEi / ARBs, beta 
blockers, aldosterone antagonists, and digoxin.  
7.12.2 Univariate analysis for total drug duration  
Table 7.12.2 Univariate analysis for total duration of drug usage 
 B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
ACEi / ARB -.01 .00 27.5 1 .01 .9 .97 .98 
Beta blockers -.11 .03 8.9 1 .00 .8 .83 .96 
Digoxin  -.00 .00 4.3 1 .03 .9 .98 .99 
Aldosterone antagonist -.01 .01 1.8 1 .17 .9 .96 1 
 
In the univariate model ACEi / ARBs, beta blockers, and digoxin were statistically 
significant, as determined by the p value and the 95% CI for the odds ratio.  
The magnitude of this effect is likely to be small as the odds ratio for ACEi / ARBs, 
and digoxin is very close to unity. This would suggest that though the results are 
statistically significant the clinical effect is likely to be small, although it is showing a 
favourable trend. The magnitude of effect for beta blockers is slightly more. Table 
7.12.2  
7.12.3 Multivariate analysis for total drug duration 
In the multivariate analysis of the above when all the four medications were put in the 
model the event rate was too small to give any meaningful information. Subsequently 
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data for both digoxin and aldosterone antagonists were removed from the model for 
the analysis purposes.  
Use of ACEi / ARBs, and beta blockers were significantly related to the all-cause 
mortality. These results suggest that patients taking ACEi / ARBs and beta blockers 
have a favourable prognosis compared with patients who were not taking them. Table 
7.12.3 
Table 7.12.3 Multivariate analysis for drug duration 
       95% CI for OR 
 B SE Wald df p Odds ratio Lower Upper 
Step 1 ACE i total exposure -.01 .05 8.4 1 .00 .98 .97 .99 
Step 2 
ACE i total exposure -.01 .05 7.3 1 .00 .98 .97 .99 
Beta blocker exposure -.11 .05 4.4 1 .03 .89 .80 .99 
 
7.13 Repeat Echocardiogram 
One hundred and five (44%) persons had a repeat echocardiogram during the follow 
up period. Seventy three (70%) of the patients had good LV systolic function with 
either left ventricular hypertrophy (LVH) or an enlarged left atrium (LA). Eighteen 
(17%) of the patients were diagnosed with HFpEF using the E/E’ ratio. A new 
diagnosis of LVSD was made in 12 patients. Of these 8 had mild, 2 had moderate, 
and 2 had severe LVSD. Table 7.13 
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Table 7.13 Repeat echocardiogram findings 
 [n=105] 
Good LV  systolic function 34 
Good LV systolic function with LVH 39 
Heart failure with preserved EF 18 
Mild LV systolic dysfunction 8 
Moderate LV systolic dysfunction 2 
Severe LV systolic dysfunction 2 
Severe valve disease 2 
 
7.14 Mortality and place of death 
Over the median follow up of 6.9 years there were 118 deaths. The location of each 
patient’s death gives us important information about their management in the last few 
days of their existence. For the present study, the number of patients dying in and out 
of the hospital was similar. Of the 118 patients who died during the follow up period, 
54 (46%) died at home, and 50 (42%) died in the hospital. For 14(12%) patients the 
place of death could not be ascertained. Of all the deaths 2 patients suffered cardiac 
arrest at home and were brought to hospital while 1 person had an in-hospital cardiac 
arrest. 
7.15 All cause mortality  
The factors that predict poor prognosis in HFpEF patients is not entirely clear. In 
clinical practice the poor prognostic factors for this group have been extrapolated from 
the studies done with LVSD patients. For the present study prognostic factors for 
HFpEF were examined using Cox regression analysis. 
7.15.1 Univariate analysis  
Cox univariate analysis was performed to identify risk factors as predictors of poor 
outcome in the HFpEF group. Table 7.15.1 
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Table 7.15.1 Univariate analysis for all-cause mortality 
   B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
Age .06 .01 21.2 1       .01 1 1 1.1 
Gender  -.22 .19 1.4 1 .24 0.7 0.5 1.2 
Smoker  .09 .09 .87 1 .35 1 0.9 1.3 
Hypertension  -.55 .22 6.2 1 .01 0.5 0.4 0.8 
AF .39 .18 4.3 1 .03 1.4 1 2 
Diabetes  .28 .21 1.8 1 .17 1.3 0.9 2 
IHD -.00 .20 .00 1 .99 0.9 0.6 1.5 
MI .14 .25 .32 1 .57 1.1 0.7 1.9 
COPD .54 .37 2.2 1 .14 1.7 0.8 3.5 
Stroke  .52 .42 1.5 1 .21 1.6 0.7 3.9 
NYHA  .63 .17 14.2 1 .01 1.8 1.3 2.6 
Hospital 
admission 
1.13 .25 21.1 1 .01 3.0 1.9 5 
 
Using this model age, hypertension, atrial fibrillation, NYHA class, and admission to 
hospital were the risk factors that were significant predictors of poor outcome. 
(Hospitalisation was defined as patients admitted once during follow up).   
7.15.2 Multivariate analysis 
With multivariate analysis age, hypertension, admission to the hospital, and NYHA 
class continued to be significant predictors of poor prognosis, while atrial fibrillation 
was not significant. Table 7.15.2 
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Table 7.15.2 Multivariate analysis for all-cause mortality 
 B SE Wald df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
Age .04 .01 12 1 .01 1 1 1.1 
Hypertension -.51 .23 5 1 .02 0.6 0.4 0.9 
Atrial Fibrillation .08 .19 0.2 1 .7 1 0.8 1.6 
Admission to 
hospital  .85 .25 11 1 .01 2. 1.4 3.9 
NYHA class .58 .17 12 1 .01 1.8 1.3 2.5 
 
Graph 7.15.2a Survival function for admission to hospital 
 
7.15.3 Cox forward conditional regression analysis  
Variables found to be significant in multivariate analysis were further assessed using 
Cox proportional hazard forward conditional regression analysis. Age, hypertension, 
admission to hospital, and NYHA class continued to be significantly related to 
survival.  Table 7.15.3 
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Table 7.15.3 Cox forward conditional regression analysis for all-cause mortality  
 B SE Wald df p Odds ratio  
95.0% CI for OR 
Lower Upper 
Step 1 Admission  1 .24 20.2 1 .00 3 1.8 5 
Step 2 Age 0.05 .01 13.5 1 .00 1 1 1 
Admission  0.9 .25 13.4 1 .00 2.5 1.5 4 
Step 3 Age 0.05 .01 13.7 1 .00 1.0 1 1 
Admission  0.8 .25 11.3 1 .01 2.3 1.4 4 
NYHA class   13 3 .05    
Step 4 Age 0.05 .01 13 1 .00 1.05 1 1.1 
Hypertension  -0.52 .22 5.3 1 .02 .6 0.4 1 
Admission  0.84 .25 11 1 .00 2.3 1.4 3.8 
NYHA class   14 3 .00    
 
Graph 7.15.3 survival function for NYHA class 
 
Patients in NYHA class 3 and 4 had a poorer prognosis than NYHA class 1 and 2. 
Graph 7.15.3 
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7.16 Analysis of survival function using stratification 
The categorical co variants (hypertension, admission to hospital, and NYHA class) 
found to be significant in the forward conditional regression for all-cause mortality 
were analysed for model checking using individual variable stratification. In stratified 
proportional hazards model separate baseline hazards are computed for each level of 
the stratification variable, while regression coefficients for the remaining covariates 
are equal across the strata. 
7.16.1 Hypertension  
Of the 118 events, 92 (78%) patients had a history of hypertension, and 26 (22%) had 
normal blood pressure. Data were censored for 110 hypertensive and 13 normal 
blood pressure patients. When hypertension as a risk factor is factorised, patients 
with a history of hypertension had a better outcome as compared to the patients with 
no history of hypertension. This apparent paradox could possibly be due to the effect 
of medications for hypertension, but was also affected by the large number of 
censored patient data in the hypertensive group. Graph 7.16.1 
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Note: - [Survival function at mean of the covariates shows the survival curves 
adjusted for the covariates in a regression model] 
7.16.2 NYHA class 
Stratification of the data by NYHA classification for model checking showed that there 
were 67 events in NYHA class 2 and 45 events in NYHA class 3. NYHA class 2 had a 
better prognosis than NYHA class 3. Graph 7.16.2 
Graph 7.16.2 Survival function for NYHA class 
 
7.16.3 Admission to the hospital 
Of the 118 patients who died, 98 (83%) had at least one admission to the hospital. 
Admission to the hospital for any reason was a predictor of poor outcome. Graph 
7.16.3 
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Graph 7.16.3 Survival after admission to hospital 
 
 
7.17 Age band analysis   
The raw data suggested a difference in mortality at the higher end of the age range. 
To analyse the affect of age on all-cause mortality, we converted age into a 
categorical variable and divided patients according to the median age in two groups 
(> 79 years and < 80 years). One hundred and thirty eight patients were less than 80 
years old, of which 53 died, and 103 patients were more than 79 years old of whom 
65 died. The higher age group had a worse prognosis. Table7.17 & Graph 7.17a & b 
Table 7.17 Age band analysis 
 
B SE Wald Df P Odds ratio 
95.0% CI for OR 
Lower Upper 
Age band .74 .18 15.9 1 .00 2.1 1.4 3 
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Graph 7.17a Survival function for age band. 
 
Graph 7.17b Kaplan Meier survival curve for age band. 
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7.17.1 Multivariate and regression analysis using age band 
When data were analysed using ageband instead of “age” as a variable in the Cox 
multivariable proportional hazard model, gender, hypertension, ageband, and NYHA 
class were significantly related to poor survival. COPD was not significant. When 
these variables were further analysed using forward stepwise (conditional logistic 
regression) the four variables continued to be significantly related to poor survival. 
Table 7.17.1 
Table 7.17.1 Cox forward conditional regression analysis for age band 
 B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
Step 1 Age band 
.74 .18 15.9 1 .00 2.1 1.4 3 
Step 2 Age band 
.71 .18 14.1 1 .00 2.0 1.4 2.9 
NYHA class 
  14.1 3 .00    
Step 3 Gender  
-.46 .20 5.3 1 .02 .6 .4 .9 
Age band 
.79 .19 17.1 1 .00 2.2 1.5 3.2 
NYHA class 
  15.2 3 .00    
Step 4 Gender  
-.49 .20 5.8 1 .01 .6 .4 .9 
HT 
-.52 .22 5.4 1 .02 .5 .3 .9 
Age band 
.76 .19 15.7 1 .00 2.1 1.4 3.1 
NYHA class 
  16.1 3 .00    
7.17.2 Stratification with age band 
When data were analysed by stratifying ageband, the curves were parallel with no 
substantial difference as compared to when the age variable was used for 
stratification. Table and graph 7.17.2 
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Table 7.17.2 Multivariable analysis with age band as stratification 
 B SE Wald Df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
Gender -0.5 0.2 5.9 1 .01 0.6 0.4 0.9 
Hypertension -0.5 0.2 5 1 .02 0.6 0.4 0.9 
NYHA class   16.2 3 .01    
Graph 7.17.2 survival for age band stratification 
  
When ageband variable data are analysed using stratification for gender, 
hypertension, and NYHA class, the survival curves cross over suggesting non 
significance.  
7.17.3 Ageband and gender interaction 
The possibility of interaction between ageband and gender was explored. When we 
analyse for interaction between ageband and gender variables, ageband continues to 
be statistically significant but gender and ageband*gender interaction are not 
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significant and there is no interaction between ageband and gender. This is a different 
model as it attempts to seek an interaction where there is none. In summary all 
modelling, where appropriate, has legitimately not included ageband and gender 
interaction. Table 7.17.3 
Table 7.17.3 Ageband and gender interaction 
 B SE Wald Df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
Gender  
.50 .27 3.2 1 .07 1.6 1 2.8 
Ageband 
.90 .25 13.4 1 .00 2.4 1.5 4 
Ageband*gender 
-.22 .39 0.31 1 .57 .8 0.4 1.7 
 
7.18 Cause of death  
Patients with HFpEF had more non cardiovascular deaths (57%) than cardiovascular 
(43%) deaths. Heart failure was more common in the cardiovascular category and 
cancer in the non-cardiovascular category. Flow diagram 7.18 
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Flow diagram 7.18 Cause of death 
 
7.19 Prognostic factors for cardiovascular deaths 
7.19.1 Univariate and multivariate risk factor analysis 
In the univariate model for cardiovascular deaths age, gender, atrial fibrillation, 
diabetes, and admission to hospital were associated with a poor outcome. Table 7.19  
In the multivariable analysis age, gender, atrial fibrillation and diabetes continued to 
be significantly associated with poor prognosis. As in the analysis of all-cause 
mortality, females had a better prognosis than the males for the cardiovascular 
deaths. Admission to the hospital was not a significant risk factor for cardiovascular 
deaths. Table 7.19.1  
Total deaths 
118 
Non CVS 
67 (57%) 
Cancer 
25 (37%) 
Chest Infection 
16 (24%) 
Others  
26 (39%) 
CVS 
51 (43%) 
Heart failure 
18 (35%) 
IHD 
16 (31.5%) 
Stroke 
16 (31.5%) 
Abdominal Aortic 
Aneurysm 
1 (2%) 
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Table 7.19 Univariate analysis for cardiovascular deaths 
 B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
Age .07 .02 11 1 .01 1 1 1.1 
Gender  -.72 .28 6.3 1 .01 .48 0.3 0.9 
Hypertension  -.42 .35 1.4 1 .23 .65 0.3 1 
Atrial fibrillation 1.02 .29 12.6 1 .00 2.7 1.6 4.8 
Diabetes  .68 .3 5.2 1 .02 1.9 1.1 3.5 
IHD .54 .28 3.6 1 .05 1.7 .98 3 
MI .45 .34 1.7 1 .18 1.6 0.8 3.1 
COPD -.01 .72 .0 1 .98 1 .23 4 
Stroke .67 .59 1.3 1 .25 2 0.6 6.3 
Admission  1.04 .36 8 1 .00 3 1.4 5.8 
 
Table17.9.1 Multivariate analysis for cardiovascular deaths 
 B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
Age .10 .02 17.4 1 .00 1.1 1 1.1 
Gender  -.97 .35 7.4 1 .00 0.3 .2 .7 
Smoker    1.1 2 .56    
Smoker (1) -.12 1.05 .0 1 .90 0.8 .1 6.9 
Smoker (2) .34 .33 1 1 .30 1.5 .7 2.7 
Hypertension -.41 .37 1.2 1 .27 0.6 .3 1.3 
Atrial fibrillation .78 .32 5.9 1 .01 2.2 1.2 4.1 
Diabetes .85 .34 6.2 1 .01 2.3 1.2 4.5 
IHD .22 .32 .4 1 .48 1.2 .6 2.3 
MI .53 .42 1.6 1 .20 1.7 .7 3.9 
COPD/ asthma -.76 .80 .9 1 .34 .5 .09 2.2 
Stroke  -1.20 .82 2.1 1 .14 .3 .06 1.5 
NYHA class   4.4 3 .21    
Admission  .59 .38 2.3 1 .12 1.8 .8 3.8 
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7.19.2 Forward conditional regression analysis  
Using forward conditional regression analysis for cardiovascular risk factors, age, 
gender, atrial fibrillation, and diabetes were significantly related to poor outcome. Data 
presented in appendix 4 as Table 7.19.2. 
7.20 Stratification for cardiovascular risk factors 
The categorical co variants (gender, diabetes, and atrial fibrillation) found to be 
significant in the forward conditional regression analysis for cardiovascular mortality 
were analysed for model checking using individual variable stratification. 
7.20.1 Gender  
When data are stratified according to gender, of the 51 cardiovascular deaths there 
were 25 male deaths with 39 censored, and 26 female deaths with 131 censored. The 
survival curves are parallel until up to five years of follow up, when as with the all-
cause mortality stratification, there is drop in male survival. Graph 7.20.1 
Graph 7.20.1 Survival function for gender stratification 
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7.20.2 Diabetes  
Of the 51 patients with cardiovascular deaths 18 had diabetes. Patients with diabetes 
had a poorer outcome. Graph 7.20.2 
Graph 7.20.2 Stratification for diabetes  
 
7.20.3 Atrial fibrillation   
Survival function shows that the curves diverge early on, thus suggesting that patients 
who had atrial fibrillation were more likely to die of cardiovascular cause. Graph 
7.20.3 
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Graph 7.20.3 Survival function for atrial fibrillation 
 
7.21 Conclusions and discussion 
7.21.1 Descriptive analysis  
 In our study HFpEF patients were more likely to be females, and to have 
hypertension and atrial fibrillation as risk factors. These findings are consistent 
with other published studies in the literature (117, 225).  
 At the clinic appointment, patients had symptoms for 6 months on average, 
and most commonly had NYHA class 2 symptoms.  
 Cardiomegaly and atrial fibrillation were the commonest findings on the chest 
X-ray and ECG respectively.  
 Though the mean values of blood test results for serum urea, creatinine, 
sodium, potassium and haemoglobin were within the normal limits, abnormal 
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results, above the normal range for urea and creatinine were present in for 4 
and 31 percent patients respectively. Serum sodium <135 mmols/l in 4% and 
potassium ≥ 6 mmols/l in 1% of the patients was also present. 
 At the clinic appointment 45% of the patients were already on an ACE inhibitor 
/ ARB and 34% on a beta blocker. Following the clinic appointment another 
8% were started on an ACEi / ARBs and 11% on a beta blocker.  
 In the absence of a firm diagnosis, the commonest reasons ascribed for 
shortness of breath were atrial fibrillation and hypertension in this group. 
 Only small numbers (24%) were reviewed in the follow up clinic. 
7.21.2 Admission data analysis 
 The majority (65%) of patients had at least one admission to hospital. The 
average time from the clinic appointment to first admission was 29.4 months. 
Patients were mostly admitted with shortness of breath and chest pain. 
 The mean systolic and diastolic blood pressures on admission were 
significantly lower than the clinic readings. This could be due to the effects of 
the medications patients were taking or a marker of general ill health. 
 The blood tests on admission showed a significant increase in urea and 
creatinine level compared to the previous clinic results.   
 On admission 7% of the patients had significant hyperkalemia and 19% had 
significant hyponateremia compared to the results from the clinic. 
 Admission to the hospital was a significant risk factor for all cause mortality but 
not cardiovascular deaths. Patients needing admission to the hospital are 
generally sicker than the general population and have a worse prognosis.   
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 Cancer, stroke, and chronic kidney disease were the leading co-morbidities 
that developed during the follow up period in the HFpEF group. 
 
7.21.3 Drug data analysis 
 There was a trend towards better prognosis for patients who were taking an 
ACEi and beta blockers in the HFpEF group. This was also true for the 
duration they had been taking these medications, with patients who had been 
taking drugs for a longer duration having better outcome. The survival benefit 
of taking an ACEi is at variance with the major randomised clinical trials in 
HFpEF patients (PEP-CHF, CHARM preserved, I-Preserved) which had not 
shown any survival benefit with ACEi / ARBs.  
The possible explanation for the apparent survival benefit of taking an ACEi is 
likely because the sicker patients may not be able to take all the protector 
drugs and thus have a poor outcome. Also unlike the clinical trials ours is a 
real world cohort of patients and thus the populations studied were different 
giving different results.  
The criteria used to enrol patients for the CHARM (115) trial were less 
rigorous. Patients had to be in NYHA class 2-4, with a history of hospitalisation 
for a cardiac cause, and an LVEF >40%. There was no prerequisite for any 
objective evidence of diastolic dysfunction or signs of HF. For PEP-CHF (116) 
study patients were > 70 years old, treated with diuretics for a clinical 
diagnosis of CHF due to LV diastolic dysfunction, hospitalised for a 
cardiovascular cause within 6 months, and able to walk unaided. This study 
excluded a large number of patients who were less than 70 years. Also, the 
clinical diagnosis of HF was only partially supported by patient characteristics 
and the patients with mild symptoms could have had other conditions than HF. 
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While in the I-PRESERVE (117) study many of the patients may not have had 
HF. Also the blood pressure lowering effect of the ACEi / ABR’s could be 
responsible for the beneficial effect seen. 
 Similar to the SENIORS (118) trial our cohort of patients who were taking beta 
blockers showed improved outcome for all cause mortality. 
7.21.4 All-cause mortality data analysis 
 Co variants age, hypertension, NYHA class, and admission to hospital were 
significantly related to poor outcome in all-cause mortality.  
 Though the number of females in the HFpEF group was significantly more, the 
all-cause mortality was not significantly different between males and females. 
 When data were analysed using age as a categorical variable by banding, 
those patients who are older than 80 years had a poorer prognosis as 
compared with those less than 80 year old. 
 There was no statistical interaction demonstrated between ageband and 
gender when these were analysed separately. 
7.21.5 Cardiovascular mortality data analysis 
 In our study HFpEF patients had more non cardiovascular deaths than 
cardiovascular deaths. This result is in contrast to the data from the 
prospective trial but consistent with other population based cohort studies. In 
the I-PRESERVE (117) trial 70% of patients had cardiovascular deaths. In the 
population based study of Henkel and colleagues (127) 49% had a non 
cardiovascular death. The reasons for this could be the retrospective cohort 
study design, which unlike the prospective trials, includes patients with other 
serious illnesses and co morbidities which also affect survival. 
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 Cancer (37%), followed by chest infection (24%), was the leading cause of 
non cardiovascular deaths in this group. These results are similar to data from 
other trials. Henkel et al (127) found cancer (23%) and pulmonary disease 
(29%) as the leading cause of non cardiovascular deaths.  
 Heart failure was the leading cause of cardiovascular mortality, followed by 
equal numbers of stroke and deaths secondary to ischemic heart disease.  
 Age, gender, atrial fibrillation, and diabetes were predictors of a poor outcome 
for cardiovascular deaths. Those in the younger age group and females had a 
better outcome as compared to older patients and males.  Advanced age, 
male sex, and diabetes mellitus have been found to be predictors of a poor 
outcome in other studies (127, 240). 
 In conclusion HFpEF patients were more likely to be females, older, and had a 
poor overall survival with more non cardiovascular deaths than cardiovascular 
deaths. In patients who were taking ACEi /ARBs and beta blockers there was 
a trend towards improved survival. 
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Chapter 8 
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Left ventricular systolic dysfunction (LVSD) - Results  
Left ventricular systolic dysfunction was diagnosed in 270 (26%) of the 1041 patients.  
Case notes for two patients were not available for review and the analysis is done 
using the data for 268 patients.  
8.1 Demographics  
Mean Age, years (range) 74 (60) 
Males 164 (61%) 
Females 104 (39%) 
Hypertension 114 (43%) 
Atrial fibrillation 66 (25%) 
Diabetes 42 (16%) 
History of IHD/MI 140 (52%) 
COPD 58 (22%) 
Stroke  34 (13%) 
 
8.1.1 Smoking history 
Smoking is a strong risk factor for cardiovascular disease. Patients who were 
diagnosed to have LVSD were most commonly ex-smokers 136 (51%), while 83 
(31%) patients had never smoked, and 49 (18%) were current smokers.  
8.2 Descriptive analysis of clinical features  
8.2.1 Referral symptoms  
Patients had been symptomatic for an average of 5.46 months (median and mode 3 
months, with maximum of 60 months) before they were referred to the HF clinic. 
Shortness of breath and swelling of ankles were the two most common reasons for 
referral to the HF clinic. Table 8.2.1   
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Table 8.2.1 Referral reason 
Shortness of breath 262 (98%) 
Swelling of ankles 190 (71%) 
Orthopnoea 120 (45%) 
Paroxysmal nocturnal dyspnoea 70 (26%) 
Fatigue 64 (24%) 
Palpitations 25 (9%) 
 
8.2.2 NYHA class  
The majority of patients were in NYHA class 3. Table 8.2.2 
Table 8.2.2 NYHA classification in clinic 
 Frequency Percent 
NYHA class 1 4 2 
NYHA class 2 117 44 
NYHA class 3 134 50 
NYHA class 4 13 4 
Total 268 100 
 
8.2.3 Clinical examination  
At the time of referral by the general practitioner 191 (71%) patients had swollen 
ankles, but when reviewed in the HF clinic, only 90 (34%) patients had oedema. This 
may be because the majority of these patients were started on a diuretic by their GP 
prior to their appointment in the HF clinic. 
At the clinic appointment 115 (43%) patients had a raised JVP; other clinical findings 
are presented in the table below. Table 8.3.3 
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Table 8.2.3 Clinical examination findings 
Swelling of ankles 90 (34%) 
Raised JVP 115 (43%) 
Systolic murmur 138 (52%) 
Diastolic murmur 11 (4%) 
Lung crepitation 84 (31%) 
Dull bases on chest examination 16 (6%) 
Wheeze  24 (9%) 
 
8.2.4 Blood pressure and heart rate  
All except one patient had their blood pressure and heart rate recorded at the HF 
clinic review. Table 8.2.4  
Table 8.2.4 Blood pressure and heart rate in the clinic  
 Systolic BP Diastolic BP Heart rate 
Total readings 267 268 268 
Missing 1 0 0 
Mean value (mmHg) 141.5 78.6 82.5 
Median value (mmHg) 140 80 80 
Mode (mmHg) 140 80 80 
Std. Deviation 23.7 13.2 20.4 
Minimum (mmHg) 78 50 34 
Maximum (mmHg) 240 140 160 
 
8.2.5 ECG findings 
Only 27 (10%) of the patients had a normal ECG. Some patients had more than one 
abnormality present on ECG. Table 8.2.5 
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Table 8.2.5 ECG findings 
Normal ECG 27 (10%) 
LAD 26 (10%) 
LBBB 66 (25%) 
LVH 38 (14%) 
Atrial fibrillation 70 (26%) 
Heart block 27 (9%) 
T wave changes 55 (21%) 
Previous MI 31 (12%) 
RBBB 16 (6%) 
 
Most of the patients with heart block had 1st degree heart block (prolonged PR 
interval). Two patients had trifasicular block and 2 were in complete heart block. 
(These were referred for permanent pacemaker implantation). 
8.2.6 Chest X- ray 
All patients had a chest X - ray at the time of clinical appointment. This was reviewed 
and reported by the physician in the HF clinic. The chest X - rays were also formally 
reported independently by the radiologist unaware of the results of the 
echocardiogram, the clinical history, or the clinical findings. 
Only a minority (20%) of the patients had a chest X - ray reported as normal. 
Cardiomegaly (68%) was the most common finding followed by upper lobe venous 
diversion (29%), both suggestive of fluid overload. A small number of patients had 
pulmonary oedema (25%). Table 8.2.6   
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Table 8.2.6 Result of chest X- ray 
Normal  54 (20%) 
Cardiomegaly  181 (68%) 
Upper lobe diversion  77 (29%) 
Pulmonary oedema 66 (25%) 
Pleural effusion 34 (13%) 
COPD changes  20 (7%) 
 
8.2.7 Echocardiography  
The echocardiogram remains the cornerstone of diagnosing HF. One hundred and 
three (38%) patients had severe systolic dysfunction, 90 (34%) had moderate and 75 
(28%) had mild LV systolic dysfunction on their echocardiogram. Some patients also 
had valvular heart disease like mitral regurgitation (MR), tricuspid regurgitation (TR), 
Aortic regurgitation (AR) and aortic stenosis (AS). Table 8.2.7 
Table 8.2.7 Other findings on Echocardiography 
E/A reversal  37 (14%) 
LVH 63 (24%) 
Moderate MR  106 (40%) 
Severe MR 29 (11%) 
Moderate TR 41 (15%) 
Severe TR 15 (6%) 
Moderate AR 24 (9%) 
Moderate AS 3 (1%) 
Severe AS 4 (2%) 
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8.2.8 Blood tests in the clinic  
Blood results for all but one patient were available from the clinic. Table 8.2.8   
Table 8.2.8 Blood tests in the clinic 
 
Sodium 
(mmol/L) 
Potassium
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Cholesterol 
(mmol/L) 
Hb 
(mg/dl) 
Mcv 
(Fl) 
Number   267 267 267 267 196 265 264 
Missing value 1 1 1 1 72 3 4 
Mean 139 4.3 8 111 4.8 13 89 
Median 140 4.2 7 104 4.6 13 90 
Mode 141 4 7 110 5 14 90 
Std. 
Deviation 
3.6 0.4 3.6 40.2 1.3 1.7 8.1 
Minimum 127 3 2 46 2 7 5 
Maximum 148 5 26 422 10 19 104 
 
8.2.9 Medications   
At the time of the clinic appointment a high proportion of patients (85%) were taking 
loop diuretics. Some patients were taking an ACEi (55%) and a beta blocker (27%). 
60% patients were taking aspirin. Table 8.2.9 
Table 8.2.9 Medications at clinic review 
ACEi / ARBs 148 (55%) 
Beta blockers 72 (27%) 
Diuretics 228 (85%) 
Aldosterone antagonist  19 (7%) 
Digoxin 42 (16%) 
Aspirin 162 (60%) 
Warfarin 35 (13%) 
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8.2.10 Other medications in the clinic 
Table 8.2.10 Other medications  
Statins 80 (30%) 
Calcium channel blockers 46 (17%) 
Inhalers 41(15%) 
Nitrates 18 (8%) 
Clopidogrel 9 (3%) 
Alpha blockers 10 (4%) 
 
8.2.11 Changes made to medication 
At the clinic appointment the patient’s current treatment was reviewed by the 
physician and changes made to optimise their medical therapy as per the clinical 
guidelines. Chart 8.2.11 
Chart 8.2.11 Medication started in clinic 
. 
8.2.12 Evidence based medical therapy prescribed in the clinic  
Following the first clinic review a high proportion of the patients were prescribed 
evidence based medical therapy as per clinical guidelines. After the clinic review an 
ACEi or ARB was prescribed to additional 39% patients and a beta blocker to 
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additional 31% of the patients. A diuretic was added in 12% of the patients. Thus high 
proportions of patients were on evidence based treatment at the end of clinic 
assessment. Chart 8.2.12     
Chart 8.2.12 Medications prescribed in the clinic 
 
Some patients were started on evidence based treatment later in the titration clinic.  
8.2.13 Cause of LVSD 
Patients were not routinely investigated for the cause of HF. From the history, 
physical examination, and investigations 49 patients were thought to have HF due to 
ischemia, and 13 were diagnosed with cardiomyopathy. 
8.2.14 Follow up in the clinic  
Two hundred and seventeen (81%) of the patients had one or more follow up visits to 
the HF clinic. The average number of visits made was 5.3 (median 4, range 31). The 
follow up visits were to the titration clinic led by the HF specialist nurse. Patients are 
assessed for symptom control and side effects. All had a physical examination and 
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weight was checked. Doses of ACEi /ARBs, and beta blockers were titrated to the 
maximum tolerated and once patients were on optimal medical therapy (OMT) they 
were discharged back to their general practitioners.  
8.3 Admission to hospital 
Seventy percent of the patient had at least one admission to hospital. Table 8.3 
Table 8.3 Admission to hospital  
 Frequency Percent 
Not admitted 79 30 
Admitted 189 70 
Total 268 100 
 
8.3.1 Time to first admission  
On average patients were admitted 21 months after the clinic appointment. Three 
patients were quite symptomatic with shortness of breath needing admission form the 
clinic. Table 8.3.1 
Table 8.3.1 Time to first admission from clinic review 
Admitted (n) 189 
Not admitted  79 
Mean  (months) 21.1 
Median (months) 15.5 
Std. Deviation (months) 21 
Minimum (months) 0.0 
Maximum (months) 84.7 
 
8.3.2 Reason for admission  
The most common reason for admission was breathlessness (32%), attributed to 
decompensated HF. Twenty one patients (11%) presented with symptoms of chest 
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pain and myocardial infarction. Seven patients presented with bleeding. Unlike the 
HFpEF group no patient was admitted with a diagnosis of cancer. Table 8.3.2 
Table 8.3.2 Reason for admission 
Shortness of breath 61 (32%) 
Chest pain 21 (11%) 
Fall / Fracture 13 (7%) 
Collapse 25 (13%) 
Stroke 14 (7%) 
Cancer 0 
Confusion  1 
Diarrhoea 5 (3%) 
Bleeding 7 (4%) 
Acute renal failure 1 
Cardiac arrest 2 
Other 41 (22%) 
 
Most patients admitted to the hospital were managed on the medical wards and 
looked after by general medical specialists. One hundred and thirty (69%) patients 
were under the care of general medical specialists. Forty (21%) patients were looked 
after by a cardiologist, and 19 (10%) were admitted under the surgical specialists.   
8.3.3 Systolic and diastolic blood pressure 
All patients had blood pressure checked on admission. Data for systolic BP was not 
available for 2 patients and the diastolic blood pressure was not available for 1 
patient. Heart rate was recorded in all patients. Table 8.3.3 
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Table 8.3.3 Systolic and diastolic blood pressure 
 
Systolic BP 
(mmHg) 
Diastolic BP 
(mmHg) 
Heart rate (per 
minute) 
Data available for 187 188 188 
Missing data 2 1 0 
Mean 128 70 79 
Median 128 70 80 
Std. Deviation 29 15 19 
Minimum 54 32 33 
Maximum 210 130 140 
 
8.3.4 Comparison of clinic and admission blood pressures 
The mean systolic and diastolic blood pressures were significantly lower at the first 
admission as compared to the readings at the first clinic appointment. The low BP 
might simply be as a consequence of the reason for admission or due to the fact that 
more patients had their treatment for HF optimised with an ACEi and a beta blocker. 
However the mean heart rate was not significantly different before and after 
admission. Table 8.3.4 a & b 
Table 8.3.4a Blood pressure & Heart rate change [Paired Samples Statistics]. 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
 
Systolic  BP in clinic 140 186 23.2 1.7 
Systolic  BP on  
admission 
128 186 28.5 2.1 
Pair 2 
Diastolic BP in clinic 77 188 12.5 0.9 
Diastolic  BP on 
admission 
70 188 15.1 1 
Pair 3 
HR in clinic 82 188 20.4 1.5 
HR on admission 80 188 18.6 1.4 
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Table 8.3.4b Blood pressure and HR (Paired Difference) 
 Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% CI of the 
Difference t df p 
Lower Upper 
Pair 1 
Systolic BP clinic 
– Systolic BP 
admission 
12 30.3 2.2 7.9 16.7 5.5 185 .00 
Pair 2 
Diastolic  BP clinic 
–Diastolic BP 
admission 
6.6 16.8 1.2 4.2 9.1 5.5 187 .00 
Pair 3 
HR clinic - 
HR admission 2.2 24.3 1.8 -1.3 5.6 1.2 187 .22 
 
8.3.5 Clinical characteristics 
Shortness of breath was the presenting complaint in 61 (32%) of the patients. Twenty 
three (9%) had increased weight. JVP was raised in 37 (14%) of the patients and 64 
(24%) had swollen ankles. One hundred and ten (41%), patients had NYHA class 
assessed and the majority were in NYHA class 3. Table 8.3.5 
Table 8.3.5 NYHA class on admission 
NYHA class I 5 (5%) 
NYHA class II 26 (23%) 
NYHA class III 44 (40%) 
NYHA class IV 35 (32%) 
 
 8.3.6 Blood tests on admission  
Blood tests at the time of admission showed that mean values for serum sodium and 
potassium were within the normal range whereas the mean value for serum urea and 
creatinine were out of range and higher than the values at the time of clinic 
appointment. Table 8.3.6 
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Table 8.3.6 Admission blood tests  
 
 
Sodium 
   (mmols/L) 
Potassium 
   (mmols/L) 
Urea 
(µmols/L) 
Creatinine 
(mmols/L) 
Haemoglobin 
(gm/dl) 
Results 
 available 
188 187 188 187 188 
Missing data 1 2 1 2 1 
Mean 137 4.4 13.9 156 12.6 
Median 138 4.3 10.2 123 12.6 
Mode 137a 4a 6 98a 14 
Std. 
Deviation 
4.8 .7 10.7 101 2.1 
Minimum 114 3 3 35 6 
Maximum 149 8 71 708 18 
a= Multiple modes exist. The smallest value is shown. 
8.3.7 Comparison of the clinic and admission blood tests 
Using a paired sample t-test the mean values of the blood results at the time of the 
clinic appointment and at the time of admission were compared. Only the mean value 
for serum sodium was lower at the time of first admission than the clinic value, 
whereas the mean values for other blood tests like serum potassium, urea, and 
creatinine had gone up. The change in the mean values was also statistically 
significant for all the four blood tests (Table 9.3.7a & b). The higher mean value was 
likely to have been from a combination of use of medications but also a marker of a 
sicker cohort of the population needing hospital admission. The lower mean value for 
sodium at the time of admission is likely caused by the use of diuretics and as a 
consequence of fluid overload. Table 8.3.7a & b 
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Table 8.3.7a Blood tests clinic and on admission (Paired Samples Statistics) 
 Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 
Na+ on admission 137 187 4.8 0.3 
Na+ in clinic 138 187 3.6 0.2 
Pair 2 
K+-on admission 4.4 186 0.7 .05 
K+ in clinic 4.3 186 0.4 .03 
Pair 3 
Urea-on admission 14 187 10 .7 
Urea in clinic 8 187 3.8 .3 
Pair 4 
Creatinine 
admission 
156 186 101 7.4 
Creatinine in clinic 114 186 44 3.2 
 
Table 8.3.7b Blood tests in clinic and on admission (Paired Samples Test) 
 
Paired Differences 
t df p 
Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% CI of the  
Difference 
Lower Upper 
Pair 1 
Na+ admission – 
Na+ in clinic 
-1.3 5 0.4 -2 -0.6 -3.5 186 .00 
Pair 2 
K+ admission – 
K+ clinic 
0.1 0.7 .05 .03 0.3 2.6 185 .00 
Pair 3 
Urea  admission – Urea 
clinic 
5.6 9.5 0.7 4.3 7 8.1 186 .00 
Pair 4 
Creatinine admission  - 
Creatinine clinic 
41.7 87.7 6 29 54 6.5 185 .00 
 
On admission hyponatremia (sodium <135 mmol/l) was present in 21%, and 
hyperkalemia (potassium >6mmol/l) was present in 4% of the patients. An elevated 
level of urea (>10mmol/l) and an increase in creatinine (>50% from baseline) was 
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present in 55% and 31% of the patients respectively. Seven percent of the patients 
had a haemoglobin value of <10 gm/dl on admission. 
8.3.8 Other investigations on admission to hospital 
An ECG result on admission was available in 178 patients. Table 8.3.8 
Table 8.3.8 ECG findings on admission  
Normal  80 
Atrial fibrillation 63 
LBBB 10 
T wave changes 5 
Heart block 6 
Paced rhythm 7 
RBBB 4 
Cardiac arrest 2 
Not available  11 
 
Chest X-ray findings on admission 
Normal  59 (22%) 
Cardiomegaly  65 (24%) 
Pulmonary oedema 40 (15%) 
Consolidation  9 
Pleural effusion 12 
Cancer 1 
Not available  3 
 
8.3.9 Medications on admission 
On admission to the hospital 156 (83%) patients were taking an ACEi / ARBs, while 
91 (48%) were taking a beta blocker. The majority of the patients 166 (88%) were on 
diuretics, while 33 (17%) and 34 (17%) were on spironolactone and digoxin 
respectively. 
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8.3.10 Change in medication doses 
Twenty six (12%) patients had their ACEi stopped and 4 had the ACE inhibitor dose 
reduced during their hospital admission. Twenty two (12%) patients had their beta 
blockers stopped. The reason for discontinuing the beta blocker was recorded only in 
a minority of patients. Acute shortness of breath and bradycardia was the reason in 3 
patients each, whilst in 2 patients they were stopped due to hypotension. Seven 
patients had their dose of diuretics increased on admission and 8 had it stopped. 
Spironolactone was stopped in 7 patients. The reason for stopping the diuretics could 
be the worsening of the serum urea, creatinine and potassium values on the blood 
results. 
8.3.11 Length of stay in hospital  
One hundred patients had more than one admission to the hospital. On average, 
patients with LVSD had 2.2 admissions to the hospital. Patients also spent a mean of 
24 days as an in-patient. Table 8.3.11 
Table 8.3.11 Total stay in hospital 
 [Number admitted = 189, Number not admitted =79] 
 
First admission 
[total days] 
Total Admissions 
[per patient] 
Total days in Hospital 
[per patient] 
Mean 9.5 2.2 22.2 
Median 5 2 14 
Mode 2 1 1 
Std. Deviation 11.5 2.3 24 
Minimum 0 0 1 
Maximum 75 12 138 
Sum 1786 423 4202 
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8.3.12 Co-morbidities developed during follow-up 
Table 8.3.12 Co – morbidities developed during follow-up 
Atrial fibrillation 8 
Fall /collapse 12 
Acute renal failure 15 
Stroke  17 
Cancer  23 
COPD 8 
Dementia 9 
 
8.4 Optimal medical therapy (OMT) and duration of use  
Two hundred fifty six (96%) of the 268 patients in the LVSD group were prescribed an 
ACE inhibitor with an average duration of use 63 months. Two hundred patients 
(75%) had been prescribed a beta blocker with an average duration of use of 59 
months. Sixty five (24%) patients were prescribed an aldosterone antagonist and they 
were taking it for an average of 25 months. Seventy (26%) patients were prescribed 
digoxin with an average duration of use of 43 months. Table 8.4    
Table 8.4 Optimal medical therapy and duration of medications prescribed 
 ACEi / ARBs 
Beta 
blockers 
Digoxin Spironolactone 
Patients prescribed (n) 256 (96%) 200 (75%) 70 (26%) 65 (24%) 
Not prescribed 12 68 198 203 
Mean duration (months) 63 59 43 25 
Median duration (months) 63 53 40 15 
Std. deviation (months) 43 45 38 24 
Min duration (months) 0.2 0.1 1.7 0.3 
Max duration (months) 223 307 152 86 
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8.5 Univariate analysis of duration of drug use 
In univariate analyses the duration of use for all the four medications was associated 
with a better prognosis. Table 8.5 
Table 8.5 Univariate analysis for duration of drug use 
 B SE Wald df p 
Odds 
ratio 
95.0% CI for OR) 
Lower Upper 
ACEi -.02 .002 57.8 1 .00 .98 .97 .99 
Beta blockers -.02 .003 59.5 1 .00 .97 .97 .99 
Spironolactone  -.03 .008 17.1 1 .00 .96 .95 .98 
Digoxin  -.02 .005 9.8 1 .00 .98 .97 .99 
8.6 Multivariate analysis of duration of drug use 
When all the four medications were analysed using a multivariate model the event 
rate was only 11 and none of the medications were significantly related to survival. 
When forward conditional regression analysis was done with all the four medications 
only spironolactone was statistically significant. (Table 8.6a) These data need to be 
interpreted cautiously as the event rate is small. 
Table 8.6a Multivariate analysis of duration of drug use 
 B SE Wald df p. 
Odds 
ratio 
95% CI for OR 
Lower Upper 
Spironolactone -.04 .01 6.1 1 .01 .96 .94 .99 
If only ACEis and beta blockers were in the equation then both were significantly 
related to survival. Table 8.6b 
Table 8.6b Forward conditional regression analysis for duration of drug use  
 B SE Wald df P 
Odds 
ratio 
95% CI for OR 
Lower Upper 
Step 1 Beta blockers -.02 .003 57.8 1 .00 .97 .97 .98 
Step 2 
Ace inhibitor -.00 .003 4.1 1 .04 .99 .98 1 
Beta blockers -.01 .003 32.8 1 .00 .98 .97 .98 
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8.7 Survival analysis for all-cause mortality  
8.7.1 Place of death  
After a median follow up period of 7.07 years the all-cause mortality was 163 (60%). 
Of these 105 (64%) were males and 58 (36%) were females Of the 163 patients who 
died 62 (38%) died at home and 81 (50%) died in the hospital. Data for 20 (12%) 
patients were not available.  
8.7.2 Univariate and multivariate survival analysis   
In the univariate analysis using the Cox proportional hazards regression model age, 
Smoker (current), atrial fibrillation, ischemic heart disease, COPD, stroke, admission, 
and NYHA class were significantly related to all-cause mortality. Table 8.7.2a 
Table 8.7.2a Univariate survival analysis of all-cause mortality risk factors 
 B SE Wald df P 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
Age .04 .00 28 1 .00 1.0 1 1.1 
Gender -24 .16 2.1 1 .14 0.7 0.5 1.1 
Smoker .24 .09 6.9 1 .00 1.2 1.1 1.5 
Hypertension .01 .15 .005 1 .94 1 0.7 1.3 
Atrial fibrillation .47 .17 7.5 1 .00 1.6 1.1 2.3 
Diabetes -.38 .23 2.1 1 .14 0.7 0.4 1.1 
IHD .32 .15 3.9 1 .05 1.3 1 1.9 
MI .13 .15 .7 1 .38 1.14 .8 1.5 
COPD/Asthma -.18 .09 4.1 1 .04 .83 .6 .9 
Stroke -.26 .10 6.3 1 .01 .76 .6 .9 
NYHA class .50 .12 15.1 1 .00 1.6 1.2 2.1 
Admission .92 .21 19.3 1 .00 2.5 1.7 3.8 
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In the multivariate analysis only age, ex-smokers, NYHA class, and admission to 
hospital were the significant risk factors. Atrial fibrillation, ischemic heart disease, 
COPD, and stroke were no longer significant. Table 8.7.2b  
Table 8.7.2b Multivariate survival analysis for all-cause mortality 
 B SE Wald df p Odds ratio  
95.0% CI for OR 
Lower Upper 
Age  .04 .00 15.9 1 .00 1. 1 1.05 
Sex  -.18 .18 1 1 .32 .8 .6 1.2 
Smoker    6.7 2 .03    
Smoker (currant ) .42 .26 2.5 1 .11 1.5 .9 2.5 
Smoker (Ex) .48 .18 6.5 1 .01 1.6 1 2.3 
Hypertension -.12 .16 0.4 1 .48 .9 .6 1.2 
Atrial Fibrillation .15 .19 0.6 1 .42 1.2 .8 1.7 
Diabetes mellitus -.21 .25 0.6 1 .41 .8 .5 1.3 
IHD .29 .28 1.0 1 .31 1.3 .8 2.3 
MI -.33 .27 1.4 1 .23 .7 .4 1.2 
COPD / Asthma .17 .19 0.7 1 .39 1.1 .8 1.7 
Stroke  .34 .22 2.2 1 .13 1.4 .9 2.2 
NYHA class   9.4 3 .02    
Admission  .7 .2 11.4 1 .00 2 1 3 
 
8.7.3 Forward conditional regression analysis  
Using forward conditional regression analysis, age, ex-smokers, and admission to 
hospital for any cause were significant risk factors related to survival. NYHA class 
was significant overall. Gender was not significantly associated to survival (Data 
presented in Appendix 4 -Table 8.7.3)    
8.8 All-cause mortality stratification for model checking   
The categorical variables (smoking status, and NYHA class) found to be significant in 
the forward conditional regression analysis were analysed for model checking using 
stratification.  
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8.8.1 NYHA class  
NYHA class 1 had small event rate. NYHA class 2 patients had a better prognosis 
than  NYHA class 3 and 4 patients. Table and graph 8.8.1 
Table and graph 8.8.1 NYHA class stratum variable 
Stratum Strata label Event Censored Censored Percent 
1 NYHA class 1 1 1 50% 
2 NYHA class 2 63 54 46% 
3 NYHA class 3 89 45 34% 
4 NYHA class 4 10 3 23% 
Total  163 103 39% 
Graph 8.8.1 NYHA class stratification 
 
8.8.2 Smoking status  
Patients who were current smokers had a poorer outcome than people who were 
either ex-smokers or who had never smoked. However, the numbers at the end of the 
survival curves were small. Table and graph 8.8.2 
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Table and graph 8.8.2 Smoking status as stratum variable 
Stratum Strata label Event Censored Censored Percent 
0 Never smoked 45 38 45.8% 
1 Current smoker 26 23 46.9% 
2 Ex-smoker 92 44 32.4% 
Total  163 105 39.2% 
 
Graph 8.8.2 Smoking status and survival  
 
8.8.3 Admission to hospital  
Of the 163 patients who died in the LVSD group, 136 had at least one admission to 
the hospital. When data are analysed by stratification for hospitalisation survival 
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curves diverge suggesting a better survival in patients with no admissions. Graph 
8.8.3 
Graph 8.8.3 Admission to hospital stratification 
 
 
8.9 Age band and gender analysis 
We arbitrarily divided patients in to two age bands (≤ 79 vs. ≥ 79) with gender.  When 
analysed together, ageband was significantly related to survival while gender only just 
reached statistical significance. There was no significant interaction between ageband 
and gender. Table 8.9a & b 
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Table 8.9a Age banding 
  Frequency (n = 268) 
Gender 
1=Male 164 
2=Female 104 
Ageband 
1= LT 80 years 198 
2=MT 79 years 70 
 
Table 8.9b Ageband and gender interaction 
 B SE Wald df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
Age band .66 .2 9.0 1 .00 1.9 1.2 3 
Gender  -.40 .2 3.6 1 .06 .6 .4 1 
Age band*gender .17 .3 .2 1 .6 1.2 .6 2.3 
 
 
8.10 Cause of death 
Of the 163 deaths, a high proportion 113 (69%) was attributable to cardiovascular 
causes. 72 (63%) of these were males and 41 (37%) were females. Flow chart 8.10 
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Flow chart 8.10 Cause of death 
 
 
 
8.11 Survival analysis for death from cardiovascular cause  
In the univariate analysis of the risk factors associated with poor prognosis for 
cardiovascular deaths, age, atrial fibrillation, diabetes, ischemic heart disease, NYHA 
class and admission to hospital were significantly associated with poor survival. Table 
8.11 
 
 
Total mortality 
163 
 
Cardiovascular 
113 (69%) 
Heart Failure 
54 (48%) 
 
IHD 
33 (30%) 
 
Stroke 
16 (15%) 
 
Other 
8 (7%) 
 
Non cardiovascular 
 50 (31%) 
Cancer 
24 (48%) 
 
Pneumonia 
14 (28%) 
 
Other 
12 (24%) 
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Table 8.11 Univariate survival analysis for death from cardiovascular cause 
 B SE Wald df 
 
p 
Odds ratio 
95% CI for OR 
Lower Upper 
Age .05 .01 23 1 .00 1.0 1.0 1.1 
Gender -.20 .19 1 1 .30 .8 .5 1.1 
Hypertension -.04 .19 .05 1 .81 .9 .6 1.3 
Atrial fibrillation .41 .21 3.8 1 .05 1.5 .9 2.2 
Diabetes Mellitus -.62 .31 3.8 1 .05 .5 .2 .9 
IHD .42 .19 4.7 1 .02 1.5 1.0 2.2 
MI .30 .18 2.5 1 .11 1.3 .9 1.9 
COPD -.06 .11 .3 1 .55 .9 .7 1.1 
Stroke -.20 .13 2.3 1 .12 .8 .6 1.0 
NYHA .52 .15 11.6 1 .00 1.6 1.3 2.3 
Admission  .83 .24 11.5 1 .00 2.3 1.4 3.7 
 
8.11.1 Multivariate survival analysis  
Age, NYHA class and admission to hospital, were significant risk factors. Gender was 
not significant. Graphs 8.10.1a & b [Additional data presented as Table 8.10.1 in 
appendix 4] 
Graph 8.11.1a Survival function for gender 
 
173 
 
Graph 8.11.1b Survival function for hospital admission 
 
8.11.2 Forward conditional logistic regression 
With Cox forward conditional logistic regression analysis, age, NYHA class and 
admission to the hospital continued to be significant predictors of poor survival. (Table 
8.11.2)  
Table 8.11.2 Forward conditional logistic regression  
 B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
Step 1 Age .05 .01 23.7 1 .00 1.0 1.0 1.1 
Step 2 
Age .04 .01 19.3 1 .00 1.0 1.0 1.1 
NYHA class .46 .15 9 1 .00 1.6 1 2 
Step 3 
Age .04 .01 18.5 1 .00 1.0 1.0 1.1 
NYHA class .42 .15 8 1 .00 1.5 1 2 
Admission .66 .25 6 1 .01 1.9 1.2 3.1 
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8.11.3 Stratification analysis  
Model checking was done using stratification for categorical variable NYHA class. The 
event rates in NYHA class 1 were small. For NYHA class 2 and 3 the curves diverge 
suggesting that NYHA class 2 had better prognosis then NYHA class 3 and 4. Graph 
8.11.3a 
Graph 8.11.3a Stratification for NYHA class 
 
When data were stratified for admission to hospital, the survival curves initially 
diverge but then crossover. This suggests that initially patients not hospitalised have a 
poor outcome but after about 30 months patients who are hospitalised do worse. This 
data suggests presence of non-proportional hazards in this model and thus the need 
for cautious interpretation. Graph 8.11.3b 
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Graph 8.11.3b Stratification for admission to hospital 
 
 
8.12 Conclusion and discussion   
8.12.1 Descriptive analysis  
 Of all the patients referred to the heart failure clinic a quarter (26%) were 
diagnosed with LVSD on the basis of their echocardiogram. This result is 
consistent with other published studies from hospital based HF services. Shah 
et al (180) reported that a third (31%) of the patients referred to an open 
access HF service had LVSD, whilst in a report by Fox et al (155)  only 26% of 
all referrals to the rapid access HF clinic were diagnosed with LVSD.  
 Although the number of females referred to our HF clinic was more than the 
males (600 vs. 431), they were less likely to be diagnosed with LVSD (104 vs. 
164). These findings are similar to reports from other studies (123, 157, 180) 
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and likely to represent the difficulty in diagnosing HF in the community and 
more so in the female population.  
 Shortness of breath was the commonest (98%) reason for referral with 50% 
having NYHA class 3 symptoms. On clinical examination raised JVP was 
present in 43% patients while 34% had swollen ankles. 
 Atrial fibrillation was the commonest (26%) finding on the ECG followed by 
LBBB (25%). 
 Cardiomegaly (68%) followed by upper lobe diversion (29%) and pulmonary 
oedema (25%) were the commonest findings on chest x-ray examination. 
 Apart from diagnosing systolic dysfunction the one stop diagnostic HF clinic 
also picked up significant valvular lesions. Moderate mitral regurgitation (MR) 
was present in 40%, and severe MR in 11%. Severe aortic stenosis was 
present in 7% of the patients.    
 When first seen at the one stop clinic, a high proportion of patients (85%) were 
taking a diuretic, 55% were also on a ACEi / ARB, and 27% were on a beta 
blocker. 60% of the patients were taking aspirin. In data published by Shah et 
al (180) from an open access HF clinic, the majority (57%) of the patients were 
taking a diuretic. In their study the number of patients taking an ACE inhibitor 
(21%) and a beta blocker (10%) was small. Higher figures in our study likely 
represent an increasing awareness of the evidence based clinical guidelines 
within the medical fraternity over a period of time (241), as the survey by Shah 
et al was conducted a few years prior to the DROPSY.    
 After the first appointment in the HF clinic an additional 40% of the patients 
were started on an ACEi / ARB, and 31% of the patients were started on a 
beta blocker de novo.    
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 The majority (81%) of the patients were referred to the titration clinic. The 
average number of visits per patient to this clinic was 5.3 (range 31). 
 During the study follow up period, 70% of the patients had at least one 
admission to the hospital. The majority (32%) were admitted with 
breathlessness. Similar figures have been reported in the 2010 national HF 
audit (242), where 28% of the patients were admitted with breathlessness and 
40% with reduced exercise capacity.  
 At the time of the admission a high proportion of the patients were on diuretics 
(88%), and taking an ACEi (86%).  
 The mean value for blood tests (serum urea and creatinine) were higher at the 
time of admission compared to the clinic results. Hyponatremia was present in 
21%, and hyperkalemia in 4% of the patients. An elevated level of urea and 
creatinine was present in 55% and 31% of the patients respectively. Seven 
percent of the patients had a haemoglobin value of <10 gm/dl on admission. 
 The mean time to admission from the clinic appointment was 21.1 months with 
a median of 15.5 months. On average patients had 2.2 admissions and spent 
24 days as inpatient. 
 A new diagnosis of cancer was made in 23 patients, and stroke was 
diagnosed in 17 patients. 
8.12.2 Medication usage  
 The HF clinic helped patients to be started on evidence based medical 
treatment and the majority were on optimal medical therapy. At the end of the 
follow up period ACEi / ARBs were prescribed in 96%, and beta blockers in 
75% of the patients. These figures are better than those reported in other 
contemporary published surveys. In the Euro Heart Failure Survey programme 
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(241) only 62% patients were on an ACEi, and 37% on  a beta blocker. In the 
national HF audit 2010 (242) about 85% of the patients were prescribed an 
ACEi and 60% were prescribed a beta blocker. The higher rate of prescription 
for evidence based therapy in our study could be due to the specialist HF 
service that has a dedicated nurse led titration clinic to follow up these 
patients. The number of patients prescribed an aldosterone antagonist in our 
study is lower (24%) than that achieved nationally (36%) (242). This probably 
represents the effect of a smaller evidence base for these agents compared to 
ACEi / ARBs, and beta blockers (242). 
  In univariate analyses for duration of medication use all four drugs (ACEi / 
ARBs, beta blockers, digoxin, and aldosterone antagonist) were related to a 
better outcome. This could be due to the fact that the sicker patients were not 
taking these medications. 
 The longer duration of use for ACEi / ARBs, and beta blockers analysed using 
the multivariate model was associated with a better outcome. This beneficial 
effect of the persistent use of ACEi / ARBs, and beta blockers in patients with 
LVSD was also seen by Lapointe et al  in a survey of HF patients (129).  
8.12.3 Survival analysis for all cause mortality 
 In our study more LVSD patients died in the hospital than at home. This is also 
true nationally where mortality statistics from the office for national statistics 
(ONS) showed that in 2010 of all the deaths in England,  only 21% took place 
at home (243). 
 Independent predictors of all-cause mortality assessed with the Cox 
proportional hazard model were age, ex smokers, atrial fibrillation, ischemic 
heart disease, COPD, stroke, NYHA class, and admission to hospital for any 
cause. Gender was not a predictor of poor survival. 
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 Analysing these risk factors in the multivariate analysis model only age, ex 
smokers, and NYHA class and admission to hospital were significant. These 
factors are similar to those in the published literature. Pocock et al (244) 
reported age, diabetes, higher NYHA class, male sex, among others as 
predictors of poor outcome.         
 When age band is analysed as a categorical variable with gender, there was 
no interaction between the two and older age was a risk factor for poor 
outcome.   
8.12.4 Survival analysis for cardiovascular mortality 
 LVSD patients were more likely to die of cardiovascular deaths. Almost half 
the patients died of HF followed by ischemic heart disease and stroke. These 
results are similar to those reported by other authors. In the 
Echocardiographic Heart of England screening study (ECHOES) (126) 
patients with HF and LVSD were more likely to die of heart failure followed by 
IHD.  In a report by Henkel et al (127) the leading cause of death in  LVSD 
patients was coronary heart disease.  
 Risk factors for cardiovascular deaths in the univariate model were age, atrial 
fibrillation, diabetes, ischemic heart disease, and admission to hospital. In the 
multivariate model, age, and admission to hospital were the only two markers 
of increased risk. 
 In conclusion the LVSD group had more males, more had NYHA class 3 
symptoms, and were likely to be prescribed evidence based treatment, though 
they continued to have a high mortality mainly due to cardiovascular causes.  
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The “Other” (OT) group 
Of the 1041 patients who were referred to the one stop HF clinic 528 patients did not 
fulfil the inclusion criteria for HFpEF in this study nor did they have LVSD on their 
echocardiogram. This group of patients were labelled as the non HF group or the 
“Other” group. A unique study number was assigned to this group for the purposes of 
identification. This number started with the initials “OT” signifying “Other” group.  
Data using the unique study number were collected in an anonymised format on a 
separate Microsoft 2007 Excel sheet and then transferred to the SPSS 19 software 
spreadsheet for the purposes of analysis. 
The primary source of data collection for this group was the clinic letter following the 
appointment at the HF clinic.  As such the data collected for this group was for 
demographics, risk factors, findings of clinical examinations, results of tests, 
presenting medications, any changes made to medications, and outcomes in terms of 
cause of shortness of breath.  
The mortality data for this group, as for LVSD and HFpEF groups, were obtained from 
the medical research and information service (MRIS). 
The data were analysed with SPSS 19 soft ware. Patient characteristics and risk 
factors were analysed using descriptive statistics and Cox regression analysis was 
used for univariate and multivariate risk factor assessment in survival analysis.  
Of the 528 patients in this group no data were available for 6 patients and they were 
not included in the final analysis. 
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9.1 Demographics and past medical history 
Total number of patients  522 
Mean age, years (range)  75 (61) 
Male  183 (35%) 
Female 339 (65%) 
Ischemic heart disease 138 (26%) 
Hypertension 253 (49%) 
Atrial Fibrillation  73 (14%) 
Myocardial infarction 42 (8%) 
Diabetes mellitus  63 (12%) 
COPD 144 (28%) 
 
9.2 Smoking status  
Smoking data were available for 509 patients. The majority 255 (49%) had never 
smoked, 196 (38%) were ex smokers, and only 58 (11%) were current smokers.  
9.3 Echocardiographic findings  
Echocardiograms were performed for all patients as part of clinical assessment. LV 
systolic function was normal in all patients. Valve lesions on the echocardiogram are 
presented below. (Chart 9.3) 
 
Moderate  
MR, 70 
Severe MR, 6 
Moderate AS, 23 
Moderate AR, 19 
Mitral stenosis, 4 
Valvular heart lesions 
Moderate  MR
Severe MR
Moderate AS
Moderate AR
Mitral stenosis
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9.4 ECG and Chest x-ray findings  
Three hundred and twenty one (62%) patients had a normal ECG, while in the 
remaining 201 (38%) of the patients the ECG was reported as abnormal. The data for 
the type of abnormality on the ECG was not recorded.  
Similarly in 359 (69%) patients the chest X - ray was reported as normal and in 159 
(31%) the chest X - ray was reported as abnormal. Individual findings of the chest x-
ray were not recorded.  
9.5 Medications on presentation  
At the time of review in the clinic 293 (56%) patients were taking a loop diuretic. A 
small proportion of patients were also taking a thiazide diuretic. One hundred and 
seventy nine (34%) patients were on an ACE inhibitor and a quarter of them were 
taking a beta blocker. Table 9.5  
Table 9.5 Medication on presentation 
Type of medication Frequency (N = 522) 
ACE inhibitors 179 (34%) 
Angiotensin Receptor Blockers 42 (8%) 
Bendroflumethiazide 77 (15%) 
Furosemide  293 (56%) 
Beta blockers 130 (25%) 
Spironolactone  29 (6%) 
Digoxin  43 (8%) 
 
9.6 Cause of shortness of breath 
These patients when reviewed in the HF clinic had an echocardiogram that showed 
good left ventricular systolic function. This group of patients did not fulfil the inclusion 
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criteria for the HFpEF group so their symptoms of shortness of breath were 
apparently not due to heart failure.  
After their clinic appointment patients were ascribed a possible cause for their 
symptoms of shortness of breath. Table 9.6  
Table 9.6 Cause of shortness of breath 
Conditions Frequency (n  = 522) 
COPD 102 (20%) 
Drug induced 23 (4%) 
Atrial Fibrillation 34 (6%) 
IHD 52 (10%) 
Obesity  27 (5%) 
Anxiety  4 (1%) 
Hypertension  48 (9%) 
Cancer  2 (0.5%) 
Lack of fitness 5 (1%) 
Anaemia  5 (1%) 
Peripheral vascular disease 22(4%) 
Valvular heart disease 40 (8%) 
Diastolic dysfunction 10 (2%) 
Left ventricular hypertrophy 30 (6%) 
Patient denied shortness of breath 36 (7%) 
No cause found 82 (16%) 
 
Chronic obstructive airways disease (COPD) was ascribed as the commonest cause 
of shortness of breath in 20% of the patients. This was followed by 82 patients where 
no cause could be ascribed for their symptoms. Thirty six (7%) patients denied any 
symptoms when seen in the clinic. Ischemic heart disease and hypertension were 
thought to be the cause for the symptoms in 10% of the patients. 
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9.7 Mortality  
From 01 Feb 2002 to 31 Aug 2011 (mean follow up period of 6.81 years) 213 (41%) 
patients of 522 in this cohort died. Of these 88 (41%) were males and 125 (59%) were 
females. The survival time from the clinic appointment was calculated in months. 
Table 9.7 
Table 9.7 Survival time (months) from clinic review 
Mean  40 
Median 38 
Std. Deviation 26 
Minimum 0.07 
Maximum 95 
Percentiles 25 20 
 
50 38 
75 60 
 
9.7.1 Cause of death  
The cause of death as put on the death certificate for these patients was analysed.  
Cause of death was classified according to the World Health Organisation’s 
international classification of disease (ICD-10).(245) 
The three leading cause of deaths were  
 Cardiovascular disease (CVS) 
 Chest infection/ Chronic obstructive airways disease (COPD) 
 Cancer 
Of the 213 deaths, 81(38%) patients died of cardiovascular (CVS) disease. Further 
classification for the CVS disease showed that 25 (12%) of these patients had HF as 
the underlying cause of death on their death certificates.  
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Flow chart 9.7.1 Cause of death 
 
Twenty five patients who died of HF had normal LV systolic function on 
echocardiography and also did not fulfil the inclusion criteria for HFpEF. So why did 
they die of HF? It’s possible that these patients had underlying risk factors and 
developed cardiovascular disease at some time in future, resulting in death due to 
HF. 
9.7.2 All-cause mortality survival analysis  
The Cox proportional hazard model was used to assess co variants related to poor 
survival. Age was the only variable associated with a poor prognosis in the univariate 
model. While in the multivariate analysis none of the co variants were significantly 
related to poor survival. Table 9.7.2a & b 
 
 
CVS 
81  
HF  25 
Stroke  22 
IHD 23 
Others 11 
COPD  
49 
Cancer  
51 
Others   
32 
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Table 9.7.2a Univariate analysis for all-cause mortality 
 B SE Wald df P Odds ratio 
95% CI for OR 
Lower Upper 
Age 
.02 .01 4.2 1 .03 1 1.0 1.03 
Gender 
.02 .14 .0 1 .85 1 .7 1.3 
IHD 
-.17 .16 1.1 1 .28 .8 .6 1.1 
AF 
.19 .17 1.2 1 .27 1.2 .9 1.7 
MI 
-.09 .27 .1 1 .73 .9 .5 1.5 
HT 
.17 .13 1.5 1 .22 1.1 .9 1.5 
DM 
.12 .24 .2 1 .61 1.1 .7 1.8 
COPD 
-.06 .15 .2 1 .65 .9 .7 1.2 
Non smoker 
-.22 .14 2.4 1 .12 .8 .6 1 
Ex-smoker 
.22 .14 2.3 1 .12 1.2 .9 1.6 
Current smoker 
-.16 .23 .5 1 .47 .8 .5 1.3 
 
Table 9.7.2b Multivariate analysis for all-cause mortality 
 B SE Wald Df p Odds ratio 
95% CI for OR 
Lower Upper 
Age 
.01 .01 2.5 1 .11 1.0 .9 1 
Gender 
.01 .15 .01 1 .93 1.0 .7 1.3 
IHD 
-.24 .17 1.7 1 .19 .7 .5 1.1 
AF 
.10 .18 .31 1 .57 1.1 .7 1.6 
MI 
-.22 .29 .5 1 .45 .8 .4 1.4 
HT 
.21 .15 1.9 1 .16 1.2 .9 1.7 
DM 
.07 .26 .07 1 .79 1 .6 1.8 
COPD 
.00 .17 .00 1 .98 1 .7 1.4 
Non 
Smoker 
-.70 .37 3.5 1 .06 .5 .2 1 
Ex-smoker 
-.45 .38 1.4 1 .23 .6 .3 1.3 
Current 
smoker 
-.72 .45 2.6 1 .1 .5 .2 1.2 
 
 
188 
 
Graph 9.7.3 Survival function for gender 
 
No further survival analysis was carried out as none of the risk factors were predictors 
of poor outcome. 
9.8 Discussion and conclusion 
Limited data were collected for the non-heart failure “Other” group. Any conclusions 
drawn are only confined to the descriptive analysis. 
 The average age of patients was 74 years and females were 65% of the 
cohort. 
  The majority (49%) of the population had never smoked. 
  A diuretic had been prescribed to 56% of the patients. 
  The commonest cause of shortness of breath ascribed in clinical practice to 
this cohort was COPD. 
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  During the mean follow up of 6.81 years, there were 213 (41%) deaths. 
  The mean survival time from the time of the clinic appointment to death was 
40 months. 
 Death was attributed to cardiovascular disease in 81 (38%) patients. Of these 
HF was the leading cause followed by stroke and ischemic heart disease. 
These figures are similar to the data from the ONS  (243) where  
cardiovascular disease remain the leading cause of deaths in the UK 
population nationally.  
 The high number (12%) of patients who had HF as cause of death would 
suggest that diagnosing HF in the clinical practice remains a challenge.  
 Though these patients had been reassured from the HF point they still had 
high mortality. This raises questions as to the accuracy of the diagnosis. It is 
possible that more detailed assessment of the cardiac function, including 
newer echo techniques and cardiac magnetic resonance imaging may have 
demonstrated abnormalities not apparent on the original scan. Also it is 
possible that the HF clinic was too narrowly focused on heart failure 
management and not on the overall cardiovascular risks or the management 
of other conditions. 
  Age was the only risk factor predictor for poor survival in univariate analysis.  
In the multivariate model none of the variables were significant predictors of a 
poor outcome. 
  In conclusion, these patients had been reassured from the heart failure point 
of view, but continued to have a high mortality with cardiovascular disease 
being the leading cause of mortality. Diagnosing HF in the real world remains 
a challenge as a significant number of patients died of HF.   
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Chapter 10 
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Comparative analysis of LVSD and HFpEF patients  
Baseline characteristics of the two groups show that in the HFpEF group patients 
were older and more likely to be females. More had hypertension, and atrial 
fibrillation. Whereas in the LVSD group more had ischemic heart disease and stroke. 
Diabetes was not different in the two groups. Table 10   
Table 10: Baseline characteristics of LVSD and HFpEF groups  
 LVSD HFpEF p value 
Total number of patients 268 241  
Average age years (range) 74 (60) 78 (52) .01 
Males 164 (61%) 84 (35%) 00 
Females 104 (39%) 157 (65%) 00 
Hypertension  114 (43%) 202 (84%) .01 
Atrial fibrillation 66 (25%) 86 (36%) .01 
Ischemic heart disease 140 (52%) 101 (42%) .01 
Diabetes  42 (16%) 55 (23%) .40 
Stroke  34 (13%) 10 (4%) .01 
ACE inhibitors 148 (55%) 109(45%) .02 
Beta blockers 72 (27%) 83 (34%) .06 
 
10.1 Referral symptoms 
For both LVSD and HFpEF groups shortness of breath was the leading reason for 
referral to the HF clinic. The LVSD group was likely to have more patients with 
orthopnoea, paroxysmal nocturnal dyspnoea (PND), fatigue and palpitations, whereas 
HFpEF patients were more likely to complain of swollen ankles at the time of referral. 
Table 10.1 
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Table 10.1 Referral symptoms 
 LVSD HFpEF 
Shortness of breath (SOB) 262 (98%) 231(96%) 
Swelling of the ankles (SOA) 190 (71%) 188 (78%) 
Orthopnoea  120 (45%) 47(20%) 
Paroxysmal nocturnal 
dyspnoea (PND) 
70 (26%) 13 (5%) 
Fatigue 64 (24%) 7(3%) 
Palpitations 25 (9%) 7(3%) 
 
10.1.1 New York Heart Association (NYHA) class 
More patients in the LVSD group had NYHA class 3 symptoms compared to the 
HFpEF group, more of whom had NYHA class 2 symptoms. Table 10.1.1 
Table 10.1.1 NYHA classification in the clinic 
 NYHA class 1 NYHA class 2 NYHA class 3 NYHA class 4 
LVSD, n (%) 4(1) 117 (44) 134 (50) 13 (5) 
HFpEF, n (%) 6 (3) 157 (65) 75 (31) 3 (1) 
 
10.1.2 Blood pressure and heart rate  
The mean systolic and diastolic blood pressure measurements in the HF clinic in the 
HFpEF group were significantly higher than the LVSD group while heart rate was 
significantly higher in the LVSD group. Table 10.1.2a [Data for independent t-test 
presented in appendix 4 as Table 10.1.2b] 
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Table 10.1.2a Blood pressure and heart rate in clinic 
 
1=LVSD. 
2=HFpEF 
Number Mean Std. Deviation Std. Error Mean 
Systolic BP 
(mmHg) 
1 267 142 23.6 1.4 
2 239 154 21.7 1.4 
Diastolic BP 
(mmHg) 
1 268 77 13.2 .8 
2 239 84 13.4 .8 
Heart Rate  
(per minute) 
1 268 83 20.4 1.2 
2 240 76 17.5 1.1 
 
10.1.3 Jugular Venous Pressure  
Raised jugular venous pressure (JVP) is a marker of increased right heart pressure, 
usually due to volume overload. Patients with LVSD were more likely to have raised 
JVP (43%) than the HFpEF patients (27%). Table 10.1.3 
Table 10.1.3 JVP comparison 
 LVSD HFpEF 
 Frequency % Frequency % 
Normal 156 57 214 89 
Raised  115 43 27 11 
Total 241 100.0 241 100.0 
 
10.1.4 Clinical Findings 
Seventy eight percent patients in the HFpEF group and 71% in the LVSD group were 
referred because of swollen ankles (this could be a consequence of calcium channel 
blockers, which were more often prescribed to HFpEF patients), though only a 
minority had ankle oedema at the clinic appointment. Table 10.1.4 
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Table 10.1.4 Clinical Findings  
 LVSD HFpEF 
Swelling of ankles 90 (34%) 102 (42%) 
Systolic murmur 138 (52%) 78 (32%) 
Diastolic murmur 11 (4%) 7 (3%) 
Lung crepitation 84 (31%) 30 (12%) 
Dull bases on chest examination 16 (6%) 3 (1%) 
Wheeze  24 (9%) 7 (3%) 
 
10.1.5 Chest X-ray findings  
Ninety percent of the patients in the HFpEF group had cardiomegaly (cardio-thoracic 
ratio >0.5), while pulmonary oedema, and upper lobe diversion, were more common 
in the LVSD group. Table 10.1.5 
Table 10.1.5 Chest X-ray findings  
Chest X-ray 
 
LVSD HFpEF 
Normal  54 (20%) 18 (8%) 
Cardiomegaly 181 (68%) 217 (90%) 
Upper lobe diversion 77 (29%) 61(25%) 
Pulmonary oedema 66 (25%) 12 (5%) 
Pleural effusion  34 (13%) 9 (4%) 
Other findings 20 (7%) 1 
 
10.1.6 Echocardiogram findings 
Whilst patients in the LVSD group had systolic dysfunction patients in the HFpEF 
group were more likely to have left ventricular hypertrophy and E/A reversal on their 
echocardiogram as markers of impaired filling and impaired relaxation. Table 10.1.6 
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Table 10.1.6 Echocardiographic findings  
 LVSD HFpEF 
E/A reversal  37 (14%) 86 (36%) 
LVH 63 (24%) 136 (56%) 
Moderate MR  106 (40%) 52 (21%) 
Severe MR 29 (11%) 0 
Moderate TR 41 (15%) 27 (11%) 
Severe TR 15 (6%) 0 
Moderate AR 24 (9%) 0 
Moderate AS 3 (1%) 0 
Severe AS 4 (2%) 0 
 
10.1.7 ECG findings 
In the HFpEF group patients were more likely to have either a normal ECG or atrial 
fibrillation. In the LVSD group patients had more left bundle branch block (LBBB) 
pattern and ischemic changes on their ECG. This would be consistent with the 
findings that the commonest cause of LVSD is ischemic heart disease. Table 10.1.7 
Table 10.1.7 ECG findings 
 
LVSD (n = 268) HFpEF (n = 241) 
Normal  
27 (10%) 71 (30%) 
Left axis deviation 
26 (10%) 11 (5%) 
Left bundle branch block 
66 (25%) 15 (6%) 
Left ventricular hypertrophy 
38 (14%) 34 (14%) 
Bradycardia  
25 (9%) 11 (5%) 
Atrial fibrillation 
70 (26%) 87 (36%) 
Right bundle branch block 
16 (6%) 14 (6%) 
Ischemic changes 
55 (21%) 12 (5%) 
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10.2 Blood test results  
In both LVSD and the HFpEF groups, the mean values of the blood tests checked in 
the clinic were similar. Analysing the results using student t test did not show any 
statistical difference between the observed means (Table 10.2). [Additional data 
analysis are presented in appendix 4 as Table 10.2a & b]  
Table 10.2 Blood test results in the clinic 
 LVSD (mean) HFpEF (mean) 
Sodium (mmol/l) 140 140 
Potassium (mmol/l) 4.3 4.2 
Urea (mmol/l) 8 7 
Creatinine (µmol/l) 111 109 
Cholesterol (mg/l) 4.8 5 
Haemoglobin (mg/dl) 13 13 
MCV (fl) 87 90 
 
10.3 Medications on presentation  
The LVSD group was more likely to be on an ACEi / ARB and aspirin, whilst more 
HFpEF patients were on a beta blocker, calcium channel blocker, and a statin. Table 
10.3 
Table 10.3 Medications on presentation 
 LVSD HFpEF 
ACEi / ARBs 148 (55%) 109 (45%) 
Beta blockers 72 (27%) 83 (34%) 
Diuretics  228 (85%) 192 (80%) 
Digoxin  42 (16%) 39 (16%) 
Aspirin  162 (60%) 118 (49%) 
Warfarin  35 (13%) 38 (16%) 
Calcium channel blockers 46 (16%) 83 (34%) 
Statins  80 (30%) 90 (37%) 
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10.3.1 Medications started in the clinic 
Patients in the LVSD group were more likely to be started on an ACEi / ARB, beta 
blocker, loop diuretic and an aldosterone antagonist. The HFpEF group were mostly 
discharged back to their primary care physicians for further management and usually 
did not have any intervention initiated in the HF clinic. Table 10.3.1 
Table 10.3.1 Medications started in the clinic 
 LVSD HFpEF 
ACE i / ARBs 105 (39%) 20 (8%) 
Beta blockers 84 (31%) 26 (11%) 
Loop diuretics 31 (12%) 7 (3%) 
Aldosterone antagonist 24 (9%) 7 (3%) 
Digoxin  14 (5%) 5 (2%) 
Warfarin  23 (9%) 23 (10%) 
 
10.3.2 Follow up in HF titration clinic 
Two hundred seventeen (81%) patients with LVSD, made 5.29 visits on average to 
the HF clinic, while in the HFpEF group 57 (24%) patients made 1.19 visits to the HF 
clinic [p = 0.001]. Table 10.3.2 
Table 10.3.2 Follow up in the HF titration clinic 
 
Followed up Not followed up 
LVSD (n=268) 
217 (81%) 51 (19%) 
HFpEF (n=241) 
 57 (24%) 184 (76%) 
 
10.4 Admission  
The number of patients admitted to the hospital was not statistically different in the 
two groups [p = 0.23]. Chart 10.4 
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Chart 10.4 Hospital admission 
 
10.4.1 Time to admission  
From the time of clinic appointment to first admission the mean duration (months) was 
longer for HFpEF group [29.41 months], compared to [21.13 months] for the LVSD 
group. Three patients from the LVSD group were particularly unwell and were 
admitted to the hospital from the HF clinic on the same day. Box plot chart & table 
10.4.1 
Table 10.4.1 Time to admission  
 LVSD (months) HFpEF (months) 
Mean  21 [95%CI 17.98 - 24.29] 29 [ 95%CI 25.97 - 32.87] 
Median  15.5 23 
Std. Deviation  21 23 
Minimum duration 0.0 0.03 
Maximum duration 85 100 
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Chart 10.4.1 Box and plot chart for time to first admission 
 
Using Student’s independent samples t test to compare the means in the two groups 
the difference in the mean duration of admission from the time of clinic appointment to 
the first admission to the hospital was statistically significant, [p = 0.001, 95% CI -
12.63 – 3.24], suggesting that patients in the LVSD group were more likely to be 
admitted to the hospital sooner compared to the HFpEF group. Table 10.4.1a 
Table 10.4.1a Time to admission (months) - Independent Samples Test 
Levene's Test for Equality of 
Variances 
t-test for Equality of Means 
 F Sig. T df p 
Mean 
Difference 
Std. Error 
Difference 
95% CI of the 
Difference 
Lower Upper 
Equal variances 
assumed 2.8 .09 -3.3 342 .01 -7.9 2.3 -12.6 -3.2 
Equal variances 
not assumed   -3.3 319 .01 -7.9 2.4 -12.6 -3.2 
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10.4.2 Reasons for first admission 
 LVSD (n=189) HFpEF (n=158) 
Shortness of breath 61 (32%) 36 (23%) 
Chest pain 21 (11%) 24 (15%) 
Fall 13 (7%) 15 (9%) 
Collapse 25 (13%) 21 (13%) 
Stroke 14 (7%) 8 (5%) 
Cancer 0 2 
Confusion 1 10 (6%) 
Diarrhoea 5 (3%) 8 (5%) 
Generally unwell 7 (4%) 11 (6%) 
Acute renal failure 1 2 
Cardiac arrest 2 1 
Other 41 (22%) 20 (13%) 
 
While shortness of breath was the commonest cause for admission in both the 
groups, chest pain was the second most common cause in the HFpEF group and 
“collapse” was more common than chest pain in the LVSD group.  Seven percent of 
the patients were admitted with stroke in the LVSD group compared to 5% in the 
HFpEF. More patients in the HFpEF group were admitted with confusion than the 
LVSD group. This could be because the HFpEF group had an older population.    
10.4.3 Blood pressure and heart rate on admission 
The mean systolic but not diastolic blood pressure, for the HFpEF group was 
significantly higher [p = 0.01, 95% CI -19 to - 6.7] than the LVSD group. This would 
most likely be due to higher baseline blood pressure in the HFpEF group. Table 
10.4.3a [Additional data analysis for t-test is presented in appendix 4 as table 10.4.3b]  
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Table 10.4.3a Blood pressure and heart rate comparison on admission 
1 = LVSD. 2 = HFpEF N Mean Std. Deviation 
Std. Error 
Mean 
Systolic BP on 
admission 
1 187 128 28.5 2.1 
2 156 140 28.8 2.3 
Diastolic BP on 
admission 
1 188 70 15.1 1.1 
2 158 73 14.3 1.1 
HR on admission 
1 188 79 18.6 1.3 
2 158 82 19.4 1.5 
 
10.4.4 Clinical findings on admission 
Table 10.4.4 JVP and swelling of ankles 
 LVSD HFpEF 
JVP raised 37 (14%) 27 (11%) 
SOA 64 (24%) 70 (29%) 
 
10.4.5 Blood tests on admission  
The mean values of sodium, potassium, urea, creatinine, and haemoglobin on 
admission were similar in both the groups and using independent samples t - test, 
there was no statistical difference in the two groups. (Table 10.4.5) 
Table 10.4.5 Blood tests on admission 
 
LVSD HFpEF p [95% CI] 
Sodium (mean) 137 138      0.51 [-1.32 - 0.66] 
Potassium (mean) 4.4 4.4      0.69 [-0.12 - 0.19] 
Urea (mean) 14 12      0.16 [-0.38 – 3.9] 
Creatinine (mean) 102 138 0.55 [-153.6 - 81.9] 
Haemoglobin (mean 12.6 12.3      0.12 [-0.09 - 0.07] 
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10.4.6 NYHA class on admission 
Not all patients on admission had their NYHA class assessed or recorded in the 
admission notes. In the LVSD group 110 patients had NYHA assessed, while in the 
HFpEF group only 94 of the patients admitted had the NYHA class recorded in their 
notes. The majority of patients who had their NYHA class recorded in both groups 
were in class 3. Significantly more patients in the LVSD group presented with NYHA 
class 4 symptoms than the HFpEF group [p = 0.001] Table 10.4.6 
Table 10.4.6 NYHA class on admission 
 LVSD (n = 110) HFpEF (n = 94) 
NYHA class 1 5 (5%) 1 (1%) 
NYHA class 2 26 (23%) 30 (32%) 
NYHA class 3 44 (40%) 49 (52%) 
NYHA class 4 35 (32%) 14 (15%) 
 
10.4.7 ECG on admission 
 LVSD (n = 189) HFpEF (n = 158) 
Normal  80 (42%) 50 (32%) 
Atrial fibrillation 63 (33%) 73 (46%) 
LBBB 10 (5%) 5 (3%) 
Ischemic 5 (3%) 3 (2%) 
Heart block 7 (4%) 1 
RBBB 4 (2%) 1 
Paced  7 (4%) 3 (2%) 
Cardiac arrest 2 (1%) 0 
Not available 11 (6%) 22 (14%) 
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10.4.8 Medications on admission 
Patients in the LVSD group were more likely to be on an ACEi / ARB and a beta 
blocker when admitted to hospital. Table 10.4.8 
Table 10.4.8 Medication on admission 
 
LVSD (n = 189) HFpEF  (n = 158) 
ACE inhibitors 
158 (83%) 98 (58%) 
Beta blockers 
91 (48%) 58 (37%) 
Diuretics 
166 (88%) 113 (76%) 
Digoxin  
34 (17%) 34 (26%) 
Aldosterone antagonist 
33 (17%) 16 (10%) 
 
10.5 First admission 
Though the mean number of days spent in the hospital on first admission was greater 
in the HFpEF group this was not statistically significant. [p = 0.13: 95% CI = -5.061 to 
0.647]. Table 10.5 
Table 10.5 First admission [Total days in hospital] 
 LVSD (n = 189) HFpEF (n = 158) 
Mean 9.4 12 
Median 5 6 
Mode 2 2 
Std. Deviation 11.5 14.9 
Minimum 0 1 
Maximum 75 90 
Sum 1786 1856 
 
10.5.1 Total number of admissions 
The number of admissions per patient in both the groups was not statistically different 
[p = 0.11: 95% CI = -0.29 to 0.52]. Table 10.5.1 
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Table 10.5.1 Number of admissions per patient 
 LVSD (n = 189) HFpEF (n = 158) 
Mean 2.2 2.3 
Median 2 2 
Mode 1 1 
Std deviation 2.4 1.6 
Minimum 0 0 
Maximum 12 9 
Sum   423 367 
 
10.5.2 Total days as inpatient  
The mean number of all days spent in the hospital by the HFpEF group was more 
than but not statistically different from the LVSD group. [p = 0.119: 95% CI= -9.308 to 
1.065]. Table 10.5.2 
Table 10.5.2 Total days as inpatient (per patient) 
 LVSD (n = 189) HFpEF (n = 158) 
Mean 22.2 26.4 
Median 14 17 
Mode 1 2 
Std deviation 23.8 25.1 
Minimum 1 1 
Maximum 138 123 
Sum 4202 4164 
 
10.6 Exposure to medications 
Duration of use of ACEi / ARBs, beta blockers, aldosterone antagonist, and digoxin 
was analysed for the LVSD and HFpEF patients, using univariate analysis with a Cox 
proportional hazard model.  
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10.6.1 ACE inhibitors / ARBs  
The mean duration of use of ACEi / ARBs in LVSD group was 51.23 months 
compared to 56.16 months in the HFpEF group. When these data were analysed 
using the univariate analysis, all-cause mortality was significantly lower in the HFpEF 
group compared to the LVSD group. Table 10.6.1a and b, chart 10.6.1 
Table 10.6.1a Stratum status for ACEi / ARB use 
Stratum Event Censored 
Censored 
(percent) 
1 (LVSD) 153 103 40.2% 
2 (HFpEF) 71 90 55.9% 
Total 224 193 46.3% 
 
Table 10.6.1b Univariate analysis for duration of ACEi / ARB use 
 B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
ACE  inhibitor / ARB 
exposure duration 
(months) 
-.01 .00 85.3 1  .00 .98 .97 .98 
 
Chart 10.6.1 Survival function for duration of ACEi / ARB use    
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10.6.2 Beta blockers 
The mean duration of use of beta blockers in the LVSD group was 42.78 months 
compared to 63.96 months in the HFpEF group. Univariate analysis for all-cause 
mortality with beta blockers favoured a better outcome for the HFpEF group. Table 
10.6.2a and b, Chart 10.6.2 
Table 10.6.2a Stratum status for duration of beta blocker use  
Stratum Event Censored Censored (Percent) 
1 (LVSD) 110 90 45.0% 
2 (HFpEF) 50 71 58.7% 
Total 160 161 50.2% 
 
 
Table 10.6.2b Stratum status for duration of beta blocker use 
Beta blocker 
(duration)  
B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
-.01 .00 60.2 1   .01 .9 .9 1 
Chart 10.6.2 Survival function for duration of beta blocker use  
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10.6.3 Aldosterone antagonist  
On average LVSD patients were taking an aldosterone antagonist for 17.33 months 
and the HFpEF patients for 27.92 months. When the aldosterone antagonists use 
data were analysed the survival curves converge towards the end suggesting 
presence of non-proportional hazards. Table 10.6.3a and b, chart 10.6.3 
Table 10.6.3a Stratum status for aldosterone antagonist use  
Stratum Event Censored Censored (%) 
       1(LVSD) 47 23 33 
       2 (HFpEF) 16 13 45 
Total 63 36 36 
 
Table 10.6.3b Stratum status for aldosterone antagonist  
Aldosterone 
antagonist 
duration 
B SE Wald df p Odds ratio 
95% CI for OR 
Lower Upper 
-.03 .00 18.6 1   .01 .97 .95 .98 
 
Chart 10.6.3 Survival function for duration of aldosterone antagonist 
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10.6.4 Digoxin  
As with aldosterone antagonist usage the survival curves converge at the end 
suggesting non proportional hazards. Table 10.6.4a and b, chart 10.6.4 
Table 10.6.4 Stratum Status for digoxin  
Stratum Event Censored Censored (%) 
1(LVSD) 49 16 25 
2 (HFpEF) 39 18 32 
Total 88 34 28 
 
Table 10.6.4 Stratum status for digoxin 
Digoxin (duration use)  
B SE Wald df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
-.01 .00 13.4 1 .01 .98 .98 .99 
 
Chart 10.6.4 Survival function for digoxin use duration 
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10.7 All cause mortality   
When all-cause mortality was analysed using a Cox proportional hazard model for 
adjusted data, HFpEF group had a better survival compared to LVSD group. Table 
10.7 & chart 10.7a & b 
Table 10.7 Stratum Status for all-cause mortality 
Stratum Event Censored Censored (percent) 
1(LVSD) 163 105 39.2% 
2 (HFpEF) 118 123 51.0% 
Total 281 228 44.8% 
 
Chart 10.7a Survival function for all cause mortality 
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Chart 10.7b Kaplan Meier all cause mortality survival curve
 
10.8 Cardiovascular mortality  
Cardiovascular deaths were significantly more common in the LVSD group as 
compared to the HFpEF group. Table 10.8a, b & c, chart 10.8 
Table 10.8a Cause of death 
 
Cardiovascular 
deaths 
Non cardiovascular 
deaths 
LVSD (n=163) 113 (69%) 50 (31%) 
HFpEF (n=118) 51 (43%) 67 (57%) 
 
Table 10.8b Univariate analysis for cardiovascular mortality in LVSD and HFpEF 
groups 
LVSD & 
HFpEF  
groups 
B SE Wald df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
-.82 .16 23.8 1 .01 .44 .31 .61 
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Table 10.8c Stratum for cardiovascular mortality 
Stratum Event Censored Censored (percent) 
1 (LVSD) 113 155 57.8% 
2 (HFpEF) 51 190 78.8% 
Total 164 345 67.8% 
 
Chart 10.8 Cardiovascular mortality in LVSD and HFpEF 
 
 
 
10.9 Other co morbidities developed   
Stroke and cancer were the commonest co morbidities developed. Table 10.9 
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Table 10.9 Co morbidities developed in LVSD and HFpEF groups 
 LVSD, n (%) HFpEF, n (%) 
AF 8 (3) 9 (4) 
Cancer 23 (9) 26 (11) 
CKD 16 (6) 17 (7) 
COPD 10 (4) 7 (3) 
Dementia 9 (3) 15 (6) 
Diabetes 1 (1) 4 (2) 
Fall 12 (4) 7 (3) 
Stroke 17 (6) 22 (9) 
 
10.10 Place of death  
 
More patients died at hospital in the LVSD group while more patients died at home in 
the HFpEF group. 
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10.11 Conclusions and discussion  
10.11.1 HF Clinic review analysis 
 Of all the three groups HFpEF patients were the oldest. 
 Overall more females were referred to the one stop HF clinic than males.  
 Females were more likely to be diagnosed with HFpEF 
 LVSD patients were more likely to have NYHA class 3 symptoms and have 
raised JVP, while HFpEF patients were slightly more likely to have complained 
of swollen ankles. 
  Blood pressure was significantly higher in the HFpEF patients, while heart 
rate was significantly higher in the LVSD group. 
 Cardiomegaly on the chest X-ray was more common in the HFpEF patients 
while the LVSD group were more likely to have pulmonary oedema. 
  The ECG in the HFpEF group was more likely to be normal or have atrial 
fibrillation, while the LVSD group had more LBBB on the ECG. 
 LVH and E/A ratio reversal were more likely in the HFpEF patients.  
 Blood test results were not significantly different in the two groups. 
 At the clinic appointment the average values of blood tests (serum sodium, 
potassium, urea, creatinine, and haemoglobin) were similar in both the groups. 
 At the clinic appointment more LVSD patients were on an ACEi /ARB, and 
aspirin, while more HFpEF patients were on a beta blocker. A large number of 
patients in both groups had been prescribed a diuretic.  
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  After the clinic appointment the LVSD patients were more likely to be started 
on an ACEi / ARB, a beta blocker, an aldosterone antagonist, and a diuretic 
while warfarin was more commonly prescribed in the HFpEF group. 
 HFpEF patients more likely to be discharged from the specialist HF clinic.  
10.11.2 Admission to hospital data analysis 
 The number of patients admitted to the hospital was not significantly different 
in the two groups. 
 The duration to first admission following the clinic appointment was 
significantly longer for the HFpEF patients. Shortness of breath was the 
leading cause for admission in both groups. The shorter duration to admission 
in the LVSD group is likely due to the higher NYHA class in these patients with 
a higher probability to develop decompensated symptoms precipitating an 
admission.   
 Results for blood tests were not significantly different in the two groups on 
admission. 
 The admission ECG was more likely to be normal in the LVSD group, while 
HFpEF patients were more likely to have atrial fibrillation. 
 A raised JVP was more likely in the LVSD group on admission while swelling 
of the ankles was more likely to be present in the HFpEF group. 
 At the time of admission more HFpEF patients had NYHA class 3 symptoms 
while more LVSD patients had NYHA class 4 symptoms.  
 At admission more LVSD patients were taking an ACEi /ARB, and a beta 
blocker. 
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 Although the total number of admissions per patient was similar in both the 
groups, HFpEF patients spent a significantly longer time as inpatients. The 
reasons for this are not clear and this study has not looked into the details of 
individual episodes of admission. The longer duration of hospital stay by 
HFpEF patients would suggest that these patients are equally, if not more 
unwell than the LVSD patients (with more complex co-morbidities) and 
needing more resources to look after them. 
10.11.3 Mortality 
 Patients with HFpEF, who were prescribed an ACEi /ARB, had a better 
survival rate than patients with LVSD on an ACEi / ARB, and similarly for 
those prescribed a beta blocker.  The reason why patients in the HFpEF group 
had a better prognosis with an ACEi / ARB and a beta blocker is difficult to 
explain. There is no published literature available where the use of these 
medications has been compared in the two groups.  
 LVSD patients were more likely to die of cardiovascular causes while HFpEF 
patients had more non cardiovascular deaths. LVSD patients were more likely 
to die at the hospital while HFpEF patients were more likely to die at home. 
 The HFpEF group had more patients diagnosed with cancer and stroke. 
 In conclusion both LVSD and HFpEF patients had poor prognosis but different 
causes of death. While LVSD patients were more likely to die of 
cardiovascular deaths, HFpEF patients died of non-cardiovascular causes.   
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Heart rate and survival  
There is a growing body of evidence from the epidemiological and experimental 
studies of a strong association between elevated heart rate (HR) and increased 
cardiovascular risk (246). Also there have been experimental and observational 
studies suggesting that increased HR is associated with a worse prognosis in HFpEF 
patients and better HR control could be a therapeutic target (118, 247, 248). 
We analysed the role of base line HR on survival in the LVSD and HFpEF groups. 
When HR was analysed as a continuous variable the impact on survival was non- 
significant.  
11.1 LVSD group 
For the LVSD group the median heart was 80 beats per minute (b.p.m). patients were 
stratified in to two groups. (Group 1 = HR 0-80 b.p.m and Group 2 = HR 81-160 
b.p.m) When data were analysed for all-cause mortality median HR of more than 80 
b.p.m was not a significant predictor of poor survival. Table 11.1a 
Table 11.1a Median HR analysis for all-cause mortality in LVSD group 
LVSD B SE Wald df P Odds ratio 
95.0% CI for OR 
Lower Upper 
Median HR   .20 .15 1.7 1 .18 1.2 .9 1.6 
 
For cardiovascular deaths and hospitalisation in the LVSD group, the median HR was 
not significant risk factor. Thus the data for the LVSD group were not analysed any 
further. Table 11.1b 
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Table 11.1b Median HR analysis for cardiovascular deaths and hospitalisation 
LVSD B SE Wald df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
CVS deaths .07 .18 .15 1 .69 1.1 .7 1.5 
Hospitalisation  .21 .16 2.07 1 .14 1.2 .2 1.6 
 
11.2 HFpEF group 
The median HR for the HFpEF patients at the time of the clinic review was 77 b.p.m. 
Using the median HR as a cut off value, the HFpEF patients were stratified in to two 
groups: group 1 (HR 1 – 77), and group 2 (HR 78 – 150) b.p.m. There were 132 
patients with HR ≤ 76 b.p.m and 108 with HR ≥ 77 b.p.m. Higher baseline HR (>78 
b.p.m) was a marker of higher all-cause mortality in the HFpEF group.  
Table 11.2 Median HR analysis for all-cause mortality in HFpEF group  
HFpEF B SE Wald df P 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
Median HR  .35 .18 3.7 1 .05 1.4 .9 2 
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 Graph 11.2 Heart rate banding and survival 
 
11.3 Heart rate and beta blockers 
HFpEF patients who had a higher base line HR (≥ 78 b.p.m), and were taking a beta 
blocker had significantly better outcome. Table and Graph 11.3 
Table 11.3 Patients taking beta blockers 
Taking Beta 
blockers 
B SE Wald df p Odds ratio 
95% CI for OR 
Lower Upper 
-.38 .19 4 1 .04 .68 .5 .9 
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Graph 11.3 Survival function for beta blockers and median HR ≥ 78 b.p.m 
 
Median HR banding at baseline, before the initiation of a beta blocker, was not 
significantly related to all-cause mortality in the HFpEF group. Table 11.3a  
Table 11.3a Survival analysis before beta blocker initiation 
Before initiating 
beta blockers 
B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
-.09 .20 .1 1 .66 .91 .6 1.3 
 
Use of ACE inhibitors was not significantly related to survival with median HR banding 
[odds ratio 0.70; p = 0.06: 95% .48 – 1.01]. 
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11.4 Conclusion and Discussion  
In our study an elevated baseline HR in the HFpEF patients is an independent 
predictor of all-cause mortality, with a trend to increased hospitalisation. HFpEF 
patients who were taking a beta blocker had a significantly better outcome. 
Under physiological conditions increase in heart rate (HR) results in increased 
relaxation and reduced diastolic filling pressure in the ventricle. In HFpEF patients 
increased HR impairs ventricle filling pressure and delays relaxation. Also the late 
atrial contribution to ventricular filling reduces with increased HR (249, 250). 
Selby et al (251) have carried out experimental work using LV biopsy samples during 
coronary bypass surgery. They have shown that in patients with normal EF and 
increased LV mass there is a tachycardia induced incomplete relaxation of the 
myocardium.  
In patients with LVSD a resting heart rate of > 60 b.p.m has been recognised as a 
predictor of poor outcome (105, 252). Similarly the role of beta blockers to reduce 
death and rehospitalisation in patients with LVSD is well established (248, 253) and 
recommended in the clinical guidelines (24).     
No treatment has yet been shown to reduce morbidity and mortality in patients with 
HFpEF and there are no large scale trials that have investigated the role of resting HR 
in HFpEF patients.  
In the SENIORS trial (254) in a subgroup analysis of patients with a baseline HR ≤ 80 
and > 80 b.p.m, the primary outcome of all-cause mortality or cardiovascular 
hospitalisation was not different in the two groups. This result is unlike our study 
where a resting HR of ≥ 78 b.p.m was associated with poor survival. The reasons for 
this most likely include the different selection criteria used in the two studies. The 
inclusion criteria in the SENIORS trial were age > 70 years and an EF of ≥ 35% while 
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for our study the inclusion criteria  were age  >18 years and an EF ≥ 40%. Though, 
similar to our study, in the SENIORS trial use of beta blockers significantly reduced 
the cardiovascular death and hospitalisation in HF patients regardless of the EF, age, 
or gender. 
There are few studies that have examined the role of beta blockers in providing 
protection to HFpEF patients. Smith et al (255) examined the association between 
use of beta blockers and frequent hospitalisation in HFpEF patients. They showed 
that use of beta blockers was associated with a decreased risk of hospitalisation for 
patients with HFpEF and coronary heart disease.   
Two studies (256, 257), with less than 30 patients each have shown that the HR 
lowering calcium channel blocker verapamil may improve exercise capacity and 
symptoms in HFpEF patients.   
In conclusion, for HFpEF patients in our study, an elevated HR at baseline was an 
independent predictor of all-cause mortality. The use of beta-blockers in those with a 
higher baseline HR was associated with a significantly better outcome. These data 
suggest a potential therapeutic target in HFpEF patients.   
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Discussion and conclusions 
 Heart failure is a common condition that is responsible for significant morbidity and 
mortality (1). The incidence and prevelance of HF is increasing (258). 
The importance of the systolic function for pumping blood around the body and its 
impairment causing symptoms of HF has been well recognised. In the past four 
decades research has mainly focused on impaired systolic function leading to an 
improved appreciation of the pathophysiology of heart failure (HF) and its 
management.  Thus there is now a strong evidence base for managing patients with 
left ventricular systolic dysfunction (LVSD).  
Equally, in the last two decades there has been an increasing appreciation that 
patietns who present with signs and symptoms of HF did not always have impaired 
systolic function as an explanation for their symptoms. 
This prompted researchers to look at the filling and relaxation properties of the left 
ventricle to explain the symptoms. Thus the concept of “diastolic” heart failure or heart 
failure with normal or preserved ejection fraction (HFpEF) came about (259).  
Over a period of time it has become clear that by focusing all our attention on the 
systolic dysfunction of the heart, an almost equal number of patients with signs and 
symptoms of heart failure, but with mildly reduced or preserved systolic function, may 
have been falsely reassured.  
Once it had been recognised that a cohort of patients with signs and symptoms of 
heart failure had HFpEF, there was an attempt to extrapolate evidence from studies 
done in patients with LVSD and apply it to the HFpEF population, on the assumption 
that both these groups were part of the same pathophysiological process. Major trials 
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using ACEi / ARBs or beta blockers did not show any mortality benefit in HFpEF 
patients (115-117, 229, 230).  
A complete gamut of questions still remains unanswered about the HFpEF patients. 
What are their clinical characteristics?  What risk factors do they have? How are they 
managed in real life? Why and how often are they admitted to the hospital? What 
other co morbidities do they develop? Where do they die and what do these patients 
die from? 
The Darlington Retrospective Out Patient Study (DROPSY) has tried to answer some 
these questions. 
12.1 Main findings of the study 
Our research is highlighted by two factors. First it was a pragmatic real life study 
based on patients referred in an unrestricted manner to the HF clinic. Secondly, 
notwithstanding issues of compliance, some 96% of the patients with LVSD were on 
evidence based therapy, specifically an ACEi. Thus our results, when compared to 
other studies, which are mainly based on clinical trials, have real life validity in a 
clinical setting.   
The DROPSY study has shown that patients who were referred to the HF clinic had 
overall poor survival, as has been shown in other studies. 
 In the LVSD group 163 (60%) of the 268 patients who were seen in the HF clinic died 
during the median follow up of 7 years. These figures suggest a continuing high 
mortality in the LVSD patients, despite the majority of these patients being on optimal 
medical therapy (an ACEi, a beta blocker and an aldosterone antagonist). The 
reasons for this high mortality are not clear. The published literature for mortality in 
the LVSD group has similar figures. Henkel et all (127) in 2008 from the Olmsted 
County community HF based cohort reported a 5 year survival of only 40%. Mehta et 
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al (260) in 2009 reported all-cause mortality of 14% at 6 months after a new diagnosis 
of HF in the UK population. Patients who are admitted to hospital have an even worse 
prognosis. The national heart failure audit in 2010 reported that 32% of patients died 
within a year of admission.   
In the LVSD group, of the 113 patients who died of cardiovascular causes, 54 (48%) 
died due to HF. These results are similar to those reported by other authors. In the 
Echocardiographic Heart of England screening study (ECHOES) (126) patients with 
HF and LVSD were more likely to die of HF followed by IHD.  In a report by Henkel et 
al (127) the leading cause of death in  LVSD patients was coronary heart disease. A 
more recent meta analysis [Meta-analysis Global Group in Chronic Heart Failure 
(MAGGIC)] by Doughty et al (135) compared survival in patients with HFpEF and 
those with LVSD using individual patient data. They included 31 studies comprising 
41972 patients. LVSD was present in 31625 patients and they had a higher risk of 
cardiovascular death [hazard ratio 0.55: 95% CI: 0.49 - 0.61]. 
There have been some reports that have looked at the long term trend in HF 
mortality. Sutcliffe et al (261) analysed trends in community mortality for HF patients 
in England and Wales from 1950 to 2003. They reported that HF deaths rose by a 
factor of four between 1950 and 1974, and then fell by a quarter by 2003. A similar 
trend has been reported from Scotland by Murdoch et al (262). In another community 
based cohort from the Olmsted County, Roger et al (263) found that the 5 year age- 
adjusted survival was 43% in 1979-1984 vs. 52% in 1996-2000.  
These reports suggest that HF patients saw a steady improvement in survival over 
the last four decades which coincides with more and more patients being managed in 
accordance with the evidence based guidelines. The improved survival especially in 
the community based cohorts could also be due to early detection and treatment of 
HF, improved survival and decline in cardiovascular disease and improved control of 
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hypertension (264). In the UK this has probably been aided by the health policy 
initiative of rewarding GP practices through the Quality and Outcomes Framework 
(QOF) (265).  
Recent data on mortality of patients with LVSD suggest that the benefit provided by 
the current treatment options have reached a plateau. In a recent paper Loh et al 
(266) analysed three 6 year eras 1993-98, 1999-2004, and 2005-10. According to the 
authors, although the overall mortality for all patients at the three year follow up point 
fell from 36.4% in the first era to 31.5% in the third era, the mortality still remains high. 
Despite an improvement of care and outcomes for HF patients, the overall mortality 
and morbidity remains high. Thus, there is an urgent need for further research to 
develop and investigate new modalities of treatment for these patients.    
The mortality in the HFpEF group was comparable (50% vs. 60%) to the LVSD group. 
There were 118 (50%) deaths during the follow up period. Various published studies 
have produced conflicting results for mortality in HFpEF studies. Cleland et al in the 
PEP-CHF (116) trial, reported 12.8% deaths after a mean follow up of 26 months, 
whereas a literature based meta analysis by Somaratne et al (134) reported a 32% 
mortality after a mean follow up of  47 months. The national HF audit 2010 (242) 
reported that the prognosis in patients with HFpEF was as poor as patients with 
LVSD. 
In our study HFpEF patients had more non cardiovascular deaths than cardiovascular 
deaths. This result is in contrast to the data from the prospective trials but consistent 
with other population based cohort studies. In the I-PRESERVE (117) trial 70% of 
patients had cardiovascular deaths. Similar results were reported by Chan et al (267). 
While in a community based cohort Henkel et al (127) reported that HFpEF patients 
had a higher (49%) rate of non-cardiovascular deaths. The conflicting results from 
various studies are likely due to study design, sample size, and how the cause of 
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death has been ascertained. The DROPSY cohort, unlike the prospective trials, 
included patients with other serious illnesses and co morbidities which also affect 
survival. 
Compared to the LVSD cohort, the five year survival of patients with HFpEF in our 
study was only marginally better, 50% vs. 40%. Studies that have compared the 
mortality in patients with HFpEF and LVSD have generally reported either similar or 
slightly better survival in the HFpEF patients. Few studies have reported a higher 
mortality for HFpEF patients. One of the earlier studies by Vasan et al  (268) reported 
an annual mortality of 18.9% in the HFpEF group vs. 8.7% in the LVSD group. The 
sample size of this study was small, which may have affected the result. Most of the 
other studies have reported a better survival for the HFpEF group. Owan et al (132) 
studied all consecutive patients hospitalised with decompensated HF and found the 
survival rate was higher in the HFpEF patients than among the LVSD patients, with 
mortality rates at one year of 29% vs. 32% and 65% and 68% at five years 
respectively. Lenzen et al (133) in the Euro Heart Failure survey, during a 12 week 
follow up, reported a higher incidence of all-cause mortality in the LVSD group (12%) 
vs. the HFpEF group (10%).  Bhatia et al (131) reported no significant difference in 
the 30 day and 1 year mortality in patients with HFpEF and LVSD 5% vs.7% and 22% 
vs. 26% respectively.  
Thus HFpEF patients have a slightly better five year survival but overall the mortality 
remains high. In the absence of any evidence based treatment for this group this is 
unlikely to improve. For the present, better management of the major risk factors like 
hypertension, diabetes, atrial fibrillation, ischemic heart disease is the only approach 
available. 
In our study HFpEF patients who were taking ACEi /ARBs and beta blockers had a 
better survival. DROPSY was not randomised so the group taking and not taking any 
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particular drug will differ in other ways and our data need to be interpreted with 
caution. The Heart Failure Society (269) recommends, that an ACEi should be 
considered in all patients with HFpEF who have symptoms of atherosclerotic 
cardiovascular disease or diabetes.    
Using univariate and multivariate analysis, the confounding variables can be explored. 
This has been explored in chapters 7 and 11. Age ≥ 80 years, hypertension, atrial 
fibrillation, NYHA class, and admission to hospital were significant predictors of a poor 
outcome in HFpEF patients.  
In our study a median resting heart rate of 78 / min or more in the HFpEF patients 
was an independent predictor of a poor outcome. An elevated HR has been 
recognised as a major predictor of cardiovascular morbidity and mortality (246).  
In the HFpEF patients there is a dearth of published data about the role of increased 
resting heart rate on morbidity and mortality. There is some evidence that increased 
resting heart rate induces relaxation abnormalities in the normal myocardium. Donald 
et al (251), in an experimental study, observed that there was incomplete relaxation 
even at lower heart rates in those with left ventricular hypertrophy compared with 
those with normal muscle mass. There is also some evidence that selective HR 
reduction with Ivabradine in patients with HFpEF leads to changes in hemodynamic 
parameters demonstrating unloading of the Left ventricle (270) and improved function 
and exercise capacity (271). Targeting the resting heart rate may be a potential new 
treatment option in HFpEF patients that could improve symptoms and survival. 
In the third “Other” group there were 213 (41%) deaths. The majority of patients, 81 
(38%), died of cardiovascular causes. The leading cardiovascular cause of death was 
HF, followed by stroke and ischemic heart disease. These figures are similar to the 
data from the ONS  (243) where cardiovascular disease remains  the leading cause of 
deaths in the UK population nationally.  
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The reasons for the high proportion (12%) of HF deaths in our third “Other” group of 
patients are not clear. There could be two plausible explanations for the high 
proportion of HF deaths. The first reason may be due to the fact that data for this 
cohort of patients were only collected from the HF clinic appointment letter with no 
further input from the case records. It is possible that some of the patients who had 
underlying cardiovascular risk factors (diabetes, hypertension, coronary artery 
disease, obesity, peripheral vascular disease, family history of cardiomyopathy, 
history of exposure to cardiac toxins, arrhythmia, sleep disordered breathing) 
subsequently developed HF. It can be argued that patients who have risk factors for 
HF require aggressive management of modifiable risk factors. These patients may 
have undetected abnormalities of cardiac structure and function and depending on 
their risk factors may warrant invasive or non-invasive evaluation to ascertain their 
cardiac structure and function.  
The second plausible reason could be that these patients in spite of a normal 
echocardiogram and no clinical evidence of HF really had HF but were missed by the 
present diagnostic algorithm used in clinical practice.   
This raises the question as to whether different diagnostic approaches might be 
beneficial in these patients. Could this be by using different echocardiographic 
parameters, using markers like B-type natriuretic peptide (BNP) / N-terminal pro-BNP 
or a detailed analysis of cardiac structure and function using MRI scan as well? 
B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-pro 
BNP) have been widely available for some time (272) but there is wide variation in the 
recommended cut off values in clinical guidelines (22, 269). Despite 
recommendations that natriuretic peptides should be a part of the diagnostic pathway 
for HF they remain underutilised in clinical practise (273). For our study BNP/ NT-pro 
BNP test was done from Feb 2002- June 2004 in the HF clinic as part of a different 
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research project. Subsequently patients seen in the HF clinic after June 2004 did not 
have BNP/NT-pro BNP levels measured and as such BNP and NT-pro BNP has not 
been used in the analysis of this study.  
The role of echocardiography is central in the assessment of the management of the 
HF patients. For the present, two dimensional echocardiography remains the 
preferred modality to diagnose HF (269). It provides a good general assessment of 
LV systolic function but can be limited due to both inter and intra operator variability, 
poor acoustic windows and the need for geometric assumptions in quantifying LV 
systolic function (274).  Recently newer techniques have been developed. These 
include micro bubble contrast which result in improved left ventricular definition and 
thus improved assessment of the LV volumes, wall motion and ejection fraction (275). 
3D echocardiography allows real time imaging with accurate and reproducible 
regional and global LV assessment. 
 Strain and strain rate imaging measure actual deformation of the LV and can 
differentiate between active (fibre shortening or lengthening) and passive (translation 
or tethering) movement of myocardial segments and to quantify dyssynchrony (276, 
277). Speckle tracking involves the detection of multiple unique patterns of 
echocardiographic pixel intensity that can be tracked throughout the cardiac cycle 
(276). 
Imaging, by providing more precise, sensitive, and reproducible information of the LV 
function will help eliminate some of the limitations at present. 
Cardiac MRI on the other hand is potentially the ideal technique to assess myocardial 
anatomy, regional and global function, and viability. It reveals the underlying cause of 
HF, can monitor disease progression and treatment effect, and also provide 
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prognostic information (227, 274). At the present moment cardiac MRI scan is not 
widely available and more of less used as a research tool.  
Thus, for the present, diagnosing HF in clinical practice remains a challenge and 
there is an urgent need to improve the diagnostic and investigative algorithms.  
12.2 Limitations of the study 
This was a retrospective cohort study design. There are both advantages and 
disadvantages to this design. The main advantages are that less time is required to 
conduct the study as the disease or outcome has already occurred, it lets you 
simultaneously look at multiple outcomes, it is a useful means of an initial study to 
establish associations, is less likely to lose patients to follow up, and can answer 
questions that may not be answered through other study designs. 
The main disadvantages of the retrospective study design are issues around data 
quality (as it relies on the data that has been recorded), there is no control group, and 
selection bias. 
The data were collected from the case notes of the patients. Accuracy of the data 
depended upon the details recorded in the case notes. It is possible that some of the 
information recorded in the notes was not up to date or accurate. Every effort was 
made to make sure that the data collected were as representative as possible. The 
majority of the data collected (e.g. blood tests, chest X - ray reports) were also double 
checked from the hospital information system thus minimising the chance of error. 
Data were collected by the researcher solely, but to minimise the chance of any 
systemic reproduction of error in data collection, double data entry was done for 10% 
of the data by a research nurse. Only small discrepancies in data values were found 
with no systematic errors.         
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This study did not recruit any patients and had no patient contact. Though the two 
groups (LVSD and HFpEF) have been compared in the analysis the results should be 
interpreted with caution, as data have been collected retrospectively and no 
intervention was performed. 
Medications prescribed to the patient may or may not be taken and compliance has 
been an issue both in the trials and real life (278). For this study the data on 
medications was collected from the patient prescriptions. This form of data collection 
assumes that the patients have been taking their medications as per the prescription, 
but there is no way to verify this.  
12.3 Implications of the research 
A pragmatic and practical case definition was used for identification of patients in the 
HFpEF group. The results of this study have raised some important points. The 
HFpEF patients have equally high five year mortality and admission rates as the 
LVSD cohort to the hospital but likely to spend significantly more days as inpatient. 
The use of ACEis and beta blockers was associated with a lower mortality in the 
HFpEF group.  This result is contrary to the major trials (115-117, 279) that showed 
marginal or no benefit of ACE inhibitor or beta blocker usage. This should inform 
further research including randomised controlled studies to answer some of the 
questions. 
12.4 Reflections 
When I undertook the work to look at the heart failure patients referred to the one stop 
HF clinic at Darlington Memorial Hospital, I had very basic experience of research 
work.  
It was a sharp learning curve. The initial steps were to get the project registered with 
various organisations and obtain ethical approval. The issue of obtaining patient 
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consent was the main focus of the ethical discussions and guidance was needed from 
different organisations. The issue of obtaining patient data from GP practices was 
also the main focus of the ethical discussion. The main issue with data collection was 
getting patient notes. Some of the notes had to be requested repeatedly and there 
were some that we did not manage to find. 
Data were collected on a Microsoft Excel sheet. When data were transferred from one 
sheet to another or from one computer to another the dates sometimes changed. I 
discovered that this was because the way date is calculated by Excel is set up in two 
different ways. This had implications for the data collection as we had to go back and 
recheck the dates for patients. This took considerable time. Transferring data from the 
Excel sheet to the SPPS 19 for analysis also changed the date function and created 
similar issues. 
12.5 Future work 
This was a retrospective cohort work that used a practical definition for identifying 
patients with HFpEF. There is still uncertainty regarding the proper diagnosis and 
management of the HFpEF patient. 
We used a pragmatic and practical definition for defining the HFpEF patients. 
Following from this work further research should be possible to look in greater detail 
at these patients and compare interventions such as ACEi /ARBs, beta blockers, or to 
explore newer treatment modalities. 
12.6 Conclusions 
Despite the numerous randomised controlled trials that have shown survival benefit 
with ACEi /ARBs and beta blockers in patients with LVSD, the mortality in this group 
in real life remains high with most deaths due to cardiovascular disease.  
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HFpEF patients have an equally high mortality, spend a long time in hospital and are 
more likely to die of non-cardiovascular causes. Despite the lack of evidence from 
large randomised controlled trials, use of ACEi / ARBs, and beta blockers in our study 
was associated with a lower death rate in HFpEF patients. This needs further 
investigation. Resting heart rate appears to be a marker of poor outcome in the 
HFpEF patients and could be a new therapeutic target that should be investigated 
further. 
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 Research and Development Department 
Darlington Memorial Hospital 
Pierremont Unit 
Hollyhurst Road 
Darlington  
DL3 6HX 
 
Tel: 01325 743458 / 743768 
All studies are subject to the requirements of the DoH’s Research Governance Framework 2005 Second Edition and 
subsequent amendments.  If you have not read this document, or are unfamiliar with its contents you are strongly advised 
to refer to it before commencing with any research or data collection.  You may not commence data collection until you 
have written formal authorisation from the Chair of the Research Review Board and an appropriate ethics committee. 
 
 
1
st
 December 2009 
 
 
Ethics Committee 
 
 
Dear Ethics Chair 
 
Re: Outcome in patients with heart failure & treated as per guidelines. 
 
R & D Ref: MED-097-2009 
 
Please find enclosed the above titled study for Ethics Review as evidence of IRAS Question 
A54.  This project has been through the Trust’s peer review process and has been given 
provisional approval by the Trust’s Research Review Board.  We have enclosed copies of 
correspondence for your information. 
 
If you have any further queries please contact the R&D Office. 
 
Yours sincerely 
 
 
 
 
Dr Y Yiannakou 
Chair – Research Review Board 
 
 
Enc. 
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Research and Development Department 
Darlington Memorial Hospital 
Pierremont Unit 
Hollyhurst Road 
Darlington  
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Tel: 01325 743458 / 743768 
All studies are subject to the requirements of the DoH’s Research Governance Framework 
2005 Second Edition and subsequent amendments.  If you have not read this document, 
or are unfamiliar with its contents you are strongly advised to refer to it before 
commencing with any research or data collection.  You may not commence data collection 
until you have written formal authorisation from the Chair of the Research Review Board 
and an appropriate ethics committee. 
 
 
Private & Confidential 
 
1st December 2009 
 
Dr Rajender Singh 
Senior Trust Fellow 
Darlington Memorial Hospital 
 
 
Dear Dr Singh  
 
Re: Outcome in patients with heart failure & treated as per guidelines. 
 
R & D Ref: Med-097-2009 
 
Thank you for your submission for research governance approval to undertake the 
above study.  The application has been reviewed and I write to inform you of the 
decision.   
 
The documents reviewed where: 
 
Document Type Version Dated Date 
Received 
R&D Form 2.0 - 01/12/09 
Draft proposal 2 15/11/09 16/11/09 
GP Info leaflet 2 15/11/09 16/11/09 
 
Your study can now be submitted to an ethics committee for ethical review.   
 I have enclosed a letter of Trust R&D Support to be submitted along with this 
letter and correspondence from the Research Review Board to the REC reviewing 
your study as evidence for IRAS question A54.   
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 The North East Central Allocation telephone number is 0191 4283305, you 
can either submit to the next available meeting in the North East or choose CDTV 
REC 1.   
 As the Trust is the sponsor for your study (QA64). Lynne Williams, Research 
& Development Manager will have to sign your IRAS form QD2. This can be done 
electronically through IRAS. (Please see attached guidance.) 
 Once the Ethics Committee have given your study a favourable ethical 
opinion, please forward a copy of the letter and copies of amended documents in 
response to the REC request to the R&D Office at the above address, so that, Trust 
R&D approval is given to the correct version your study.  
 The study must not be started until you have obtained both Ethics and Trust 
R&D approval letters. 
 
 
 
If you require any further advice please do not hesitate to contact either myself or 
Joanne Stephenson. 
 
 
Yours sincerely  
 
 
 
Dr Y Yiannakou 
Research Review Board Chair 
 
cc. Dr Jerry Murphy 
Consultant Cardiologist 
Darlington Memorial Hospital 
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Appendix 4 
Table 7.19.2 HFpEF forward conditional regression analysis for cardiovascular 
mortality  
 B SE Wald df p Odds ratio 
95.0% CI for OR 
Lower Upper 
Step 1 Atrial Fibrillation 1.02 .28 12.5 1 .00 2.7 1.5 4.8 
Step 2 
Age .06 .02 8.2 1 .00 1.0 1.0 1.1 
Atrial Fibrillation .88 .29 9.3 1 .00 2.4 1.3 4.3 
Step 3 
Age .07 .02 12.3 1 .00 1.0 1.0 1.1 
Gender -.97 .29 10.7 1 .00 .3 .2 .6 
Atrial fibrillation .86 .28 8.9 1 .00 2.3 1.3 4.1 
Step 4 
Age .09 .02 15.2 1 .00 1.0 1.0 1.1 
Gender -.89 .30 8.8 1 .00 .4 .2 .7 
Atrial Fibrillation .80 .28 7.8 1 .00 2.2 1.2 3.9 
Diabetes M .85 .31 7.3 1 .00 2.3 1.2 4.3 
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Table 8.7.3 LVSD forward conditional regression analysis for all cause mortality 
 B SE Wald df p Odds ratio  
95.0% CI for OR 
Lower Upper 
Step 1 Age  .04 .01 28.0 1 .00 1.0 1.0 1.0 
Step 2 Age .04 .01 21.7 1 .00 1.0 1.0 1.0 
Admission .79 .21 13.9 1 .00 2.2 1.4 3.3 
Step 3 Age .03 .01 20.9 1 .00 1.0 1.0 1.0 
NYHA class   10.8 3 .01    
NYHA class(1) -1.42 1.0 1.8 1 .17 .2 .0 1.8 
NYHA class(2) -.57 .34 2.8 1 .09 .5 .2 1.1 
NYHA class(3) -.08 .33 .05 1 .81 .9 .4 1.7 
Admission .76 .21 12.8 1 .00 2.1 1.4 3.2 
Step 4 Age  .04 .01 21.0 1 .00 1.0 1.0 1.0 
smoker   7.8 2 .01    
Smoker (currant) .44 .25 2.9 1 .08 1.5 .9 2.5 
Smoker (ex) .51 .18 7.6 1 .00 1.6 1.1 2.3 
NYHA class   10.9 3 .01    
NYHA class(1) -1.54 1.05 2.1 1 .14 .2 .02 1.6 
NYHA class(2) -.53 .34 2.4 1 .11 .5 .2 1.1 
NYHA class(3) -.03 .33 .01 1 .90 .9 .4 1.8 
Admission .77 .21 13.2 1 .00 2.1 1.4 3.3 
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Table 8.10.1 Multivariate survival analysis of cardiovascular risk factors 
 B SE Wald df p 
Odds 
ratio 
95.0% CI for OR 
Lower Upper 
Age  .04 .01 14.1 1 .00 1.0 1.0 1.0 
Gender  -.19 .21 .77 1 .37 .8 .5 1.2 
Smoker    3.34 2 .18    
Smoker (currant) .12 .33 .14 1 .70 1.1 .5 2.1 
Smoker (ex) .38 .21 3.17 1 .07 1.4 .9 2.2 
Hypertension -.17 .20 .72 1 .39 .8 .5 1.2 
Atrial fibrillation .01 .23 .00 1 .96 1.0 .6 1.5 
Diabetes -.45 .32 1.89 1 .16 .6 .3 1.2 
Ischemic heart 
disease 
.16 .35 .20 1 .64 1.1 .5 2.3 
Myocardial infarction -.02 .34 .0 1 .95 .9 .4 1.9 
COPD/ Asthma -.05 .25 .09 1 .76 .9 .5 1.5 
Stroke  .22 .28 .66 1 .41 1.2 .7 2.1 
NYHA class   9.14 3 .02    
NYHA class(1) .64 1.02 .39 1 .52 1.9 .2 14.2 
NYHA class(2) 1.25 1.02 1.50 1 .22 3.5 .4 25.9 
NYHA class(3) 1.22 1.11 1.21 1 .27 3.4 .3 30.1 
Admission .63 .25 6.10 1 .01 1.8 1.1 3.1 
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Table 10.1.2b  Blood pressure and heart rate in clinic [Independent Samples t Test] 
 
Levene's Test for 
Equality of Variances 
T-test for Equality of Means 
F Sig. t df p 
Mean 
Difference 
Std. Error 
Difference 
95% CI of the Difference 
Lower Upper 
Systolic 
BP 
Equal variances 
assumed 
.05 .81 -6.05 504 00 -12.2 2.0 -16.2 -8.2 
Equal variances 
not assumed 
  -6.08 503.7 00 -12.2 2.0 -16.2 -8.3 
Diastolic 
BP 
Equal variances 
assumed 
.00 .95 -4.38 505       00 -5.1 1.1 -7.5 -2.8 
Equal variances 
not assumed 
  -4.37 497.2 00 -5.1 1.1 -7.5 -2.8 
Heart 
Rate 
Equal variances 
assumed 
2.87 .09 3.84 506 00 6.5 1.6 3.1 9.8 
Equal variances 
not assumed 
  3.87 505.2 00 6.5 1.6 3.2 9.8 
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Table 10.2a Blood tests in clinic comparative analysis data 
Group Statistics 
 1=LVSD. 
2=HFpEF N Mean Std. Deviation 
Std. Error 
Mean 
Sodium   
1 268 140 3.3 .20 
2 241 140 3.3 .21 
Potassium    
1 267 4.2 .5 .03 
2 241 4.3 .5 .03 
Urea  
1 267 8 3.5 .22 
2 241 7.6 3.0 .19 
Creatinine  
1 267 111 40.1 2.49 
2 241 109 55.0 3.56 
Hb 
1 265 13 1.7 .10 
2 236 13 1.5 .10 
MCV 
1 264 90 6.1 .38 
2 237 90 6.0 .39 
Cholesterol  
1 196 4.8 1.3 .09 
2 157 5.1 1.7 .13 
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Table 10.2b Blood tests in the clinic -Independent Samples Test  
 
Levene's Test for Equality of 
Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% CI of the difference 
Lower Upper 
Sodium   
Equal variances 
assumed 
.00 .92 .11 507 .91 .03 .30 -.55 .62 
Equal variances not 
assumed 
  .11 500 .91 .03 .30 -.55 .62 
Potassium   
Equal variances 
assumed 
.23 .62 -.13 506 .89 -.06 .04 -.10 .08 
Equal variances not 
assumed 
  -.13 495 .89 -.00 .04 -.10 .08 
Urea  
Equal variances 
assumed 
5.22 .02 1.34 506 .17 .40 .30 -.18 .99 
Equal variances not 
assumed 
  1.35 504 .17 .40 .29 -.18 .99 
Creatinine e 
Equal variances 
assumed 
.07 .78 .57 506 .56 2.42 4.28 -5.94 10.78 
Equal variances not 
assumed 
  .56 435 .57 2.42 4.31 -6.05 10.9 
Hb 
Equal variances 
assumed 
3.28 .07 1.03 499 .29 .15 .14 -.13 .44 
Equal variances not 
assumed 
  1.04 498 .29 .15 .14 -.13 .44 
MCV 
Equal variances 
assumed 
1.15 .28 -.58 499 .55 -.31 .54 -1.37 .75 
Equal variances not 
assumed 
  -.58 495 .55 -.32 .54 -1.39 .75 
Cholesterol    
Equal variances 
assumed 
2.08 .15 -1.86 351 .07 -.28 .16 -.60 .02 
Equal variances not 
assumed 
  -1.75 286 .08 -.28 .16 -.61 .03 
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Table 10.4.3b Independent samples t - test for equality of means of blood pressure 
and heart rate on admission to hospital 
 
Levene's Test for Equality of Variances t-test for Equality of Means 
 F Sig. t Df p 
Mean 
Differen
ce 
Std. 
Error 
Differen
ce 
95% CI of the 
Difference 
Lower Upper 
Systolic BP on 
admission 
Equal variances 
assumed 
.31 .57 -4.1 341 .00 -12.8 3.1 -19 -6.7 
Equal variances not 
assumed 
  -4.1 328 .00 -12.8 3.1 -19 -6.7 
Diastolic  BP 
on admission 
Equal variances 
assumed 
.11 .73 -1.8 344 .06 -2.9 1.5 -6 .2 
Equal variances not 
assumed 
  -1.8 338 .068 -2.9 1.5 -6 .2 
HR on 
admission 
Equal variances 
assumed 
.00 .95 -1.3 344 .17 -2.8 2.0 -6 1.2 
Equal variances not 
assumed 
  -1.3 328 .17 -2.8 2.0 -6 1.2 
 
